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PHYTOCOMPLEXITY: IMPLICATIONS FOR DEVELOPMENT OF NOVEL
ANTICANCER THERAPEUTICS USING DIETARY AGENTS

by

SUSHMA REDDY GUNDALA

Under the Direction of RITU ANEJA

ABSTRACT
Chemotherapy, employing single-molecule or multidrug concoctions inspired by the
diverse repository of plant chemicals, has been the mainstay of cancer treatment for years.
However, isolating single molecules has proven to be expensive along with limited therapeutic
window and toxicity. On the other hand, whole foods, while preserving the natural complex
balance between their constituent phytochemicals and being non-toxic, have proven to impart
better disease-fighting efficacies, thus leading to an increased focus on dietary interventions to
both treat and prevent cancer. Owing to the complex interactions between their constituent
phytochemicals, several dietary agents have been investigated for their therapeutic and
preventive efficacies. However, due to lack of emphasis on confounding factors like

bioavailability, absorption, metabolism, and excretion, essentially driven by phytocomplexity,
incorporation of whole foods in therapeutic regimen has not been successful. This thesis
exemplifies the need to investigate factors associated with the limitations in the current approach
with respect to dietary agents. Bioactivity-guided fractionation of sweet potato greens extract
(SPGE) led to the identification of ~100-fold more potent fraction in vitro. However, this
efficacy could not be translated in vivo. We also studied whole ginger extract (GE) for its in vitro
and in vivo prostate tumor growth-inhibitory and apoptosis-inducing effects. In addition, GE
proved to be more efficacious as compared to its individual most-active constituents owing to the
differences in their pharmacokinetic (PK) and bioavailability measurements. Hence, these studies
emphasize the crucial role of synergistic/additive interactions among the constituents of whole
foods in successful translation of their therapeutic benefits. Another factor that seeks further
attention is the unique cellular mechanisms engaged by these phytochemicals to confer their
remarkable effects. Phenolic compounds, the most-abundant of all phytochemicals, are well
known for their antioxidant properties and act via reactive oxygen species (ROS)-mediated
mechanisms. We however assert the underappreciated xenohormetic prooxidant role of
phenolics, where cancer cell death is caused by induction of intolerable levels of ROS. We
demonstrated that a Piper betel constituent, hydroxychavicol (HC), mediates cytotoxicity via
ROS-induced DNA-damage. This thesis thus provides compelling grounds for future preclinical
studies to validate their potential usefulness for cancer management.
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1

INTRODUCTION

Background and Significance1
At least since the 4th century BC, cancer has maliciously loomed in mankind. It has been
the leading cause of death over the past two decades affecting various populations worldwide at
alarming rates (Parkin et al., 2005). Despite the continuing attempts in search of a cure for cancer
to alleviate its appalling outcomes, the war against this deadly neoplasm is growing stronger day
by day. Surgery, radiation, chemotherapy, immunotherapy, laser therapy, etc., modalities of the
current day have met with limited success. Chemotherapy, employing single-molecule or
multidrug concoctions aiming at various targets, is the most sought after treatment for cancer
today. It involves pharmaceutical compositions of various purified compounds identified from
the endless repository of plant chemicals.

However, this approach of isolating the active

ingredients from plant resources so far has had a restricted control over this aggressive
malignancy. On the other hand, whole foods, which preserve the natural balance between their
constituent phytochemicals as bestowed by Mother Nature, have proven to impart better diseasefighting efficacies, thus leading to an increased focus on dietary interventions to both treat and
prevent cancer. This thesis focuses on engaging the benefits of phytocomplexity in our
persevering pursuit of the war against cancer.

1

Parts of this chapter have been published verbatim in Carcinogenesis 2014 as

Enterohepatic re-circulation of bioactive ginger phytochemicals is associated with enhanced
tumor growth-inhibitory activity of ginger extract and Cancer Prev. Res. (Phila). 2014 as Piper
betel leaf: A reservoir of potential xenohormetic nutraceuticals with cancer-fighting properties.

2
1.1

Dietary Phytochemicals and Cancer
Cancer develops in various phases starting from initiation, as triggered by environmental

carcinogens, radiation etc., and progressing to develop into a malignant state via the promotion
and progression phases, which are relatively protracted processes (Mann et al., 2005). Thus
cancer proliferates uncontrollably and ultimately invades the surrounding tissues, spreading to
distant organs resulting in metastases. Modulation of this disease progression by interfering with
various drugs and chemicals has been the focus of current-day chemotherapy. Although this kind
of intervention is often associated with toxic side effects, it has been the most sought-after
approach. Furthermore, the concept of chemoprevention emerged in the 20th century, which
targets at thwarting the developmental process of cancer using relatively non-toxic chemicals
(Sporn, 1976; Sporn and Suh, 2000; Surh, 2003). Since its inception, researchers worldwide have
been focusing on developing agents that can obstruct each step of carcinogenesis, which also can
be used to treat fully developed cancers. Several such agents including the current-day
chemotherapeutics are obtained or inspired from Nature (Houghton, 1995). Most of these
anticancer agents are widely present in our regular diet including fruits and vegetables.

On the other hand, one-third of the estimated cancer cases in the United States have been
attributed to improper diet, nutrition, obesity and lack of physical activity. These cues linking
nutritional aspects leading to cancer are important to design and develop novel strategies and
therapeutics as our arsenal against cancer (Hanahan and Weinberg, 2000, 2011). Substantial
evidence has revealed that a wholesome diet constituting of fruits, vegetables, whole grains,
cereals, dietary fibers etc., has not only protective and preventive effects against various cancers
but also a lower risk of developing the malignancy (Quideau et al., 2011; Surh, 2003). The vital

3
components of these natural dietary sources are phenolic compounds, anthocyanins, terpenoids,
aromatic acids, alkaloids, glucusonilates etc., collectively known as phytochemicals. Several
researchers have extensively worked on determining the health benefits of these dietary
phytochemicals. Major focus has been aimed at identifying the blocking agents that obstruct the
initiation phase and suppressing agents that retard the promotion and progression phases of the
carcinogenesis process. Some of these dietary phytochemcials include catechins from green tea,
resveratrol from grapes, proanthocyanidins from grape seed extracts, isothiocyanates from
cruciferous vegetables, curcuminoids from turmeric, flavonoids and phenolic compounds from
fruits and vegetables and many others. Most importantly these phytochemicals have been shown
to possess potent tumor growth inhibiting properties while remaining non-toxic towards the
normal cells and tissues. For example, curcumin, a beta diketone purified from turmeric, has
been long known to act as an effective anti-inflammatory agent along with anticancer properties
(Sharma, 1976). It was shown to inhibit the tumor initiation process developed due to BaP and
DMBA (dimethylbenz[α]anthracene), while also inhibiting tumor promotion induced by 12-Otetradecanoylphorbol-13-acetate (TPA) (Singletary and MacDonald, 2000). Sulforaphane (SFN),
a component of cruciferous vegetables, was shown to inhibit gastro-intestinal adenoma
formations in APC 112 Min/+ mice and DNA adduct formation due to polycyclic aromatic
hydrocarbon - benzo[a]pyrene (BaP) and 1, 6-dinitropyrene (Hu et al., 2006). On the other hand,
another cruciferous component, phenylethylisothiocyanate (PEITC), in combination with
curcumin was found to significantly inhibit tumor formation in athymic nude mice implanted
with human prostate xenografts. EGCG (epigallocatechin gallate), the active constituent of green
tea, was also proven to promote apoptosis in human bladder cancer cells while modulating the
PI3K/Akt signaling pathway (Johnson et al., 2010; Raza and John, 2005).

4

All these anticancer dietary phytochemicals were found to have one aspect in common:
non-toxicity towards normal tissues/cells. This differential outcome was observed to be due to
the ability of these phytochemcials to induce apoptosis selectively in the abnormally proliferating
cancer cells by exploiting their higher metabolic activity and inducing detoxifying enzymes,
which in turn makes them non-toxic towards the normal cell population. Extensive research on
chemopreventive mechanisms rendered by active phytochemicals presented us with some crucial
cues. For example, upregulation of phase I and II detoxifying enzymes, quinone reductase (QR),
UDP-glucuronyltransferase (UGT) and glutathione-s-transferase (GST) in particular, by the plant
chemicals like SFN, curcumin, PEITC, EGCG etc., was associated with enhanced elimination of
toxic molecules and carcinogens from the system (Surh, 2003). Hence, prudent modulation of
physiological cascades within the cancer cells by employing dietary phytochemicals presents a
safer route to fight against this malicious disease.
1.2

Whole food extracts vs single agents – significance of phytocomplexity
Extensive research conducted on determining the disease-fighting properties of individual

phytochemicals has also revealed that they must be consumed in large quantities to achieve
physiologically relevant doses in order to exert the respective health benefits. For example, the in
vitro IC50 concentration of 6-gingerol (6G), an active constituent of ginger extract, was found to
be ~88-177 µg/ml in various cell lines (Brahmbhatt et al., 2013; Wang et al., 2003). On the other
hand, an in vivo oral dose of 100 mg/kg bw of 6G yielded blood plasma levels of ~ 2µg/ml 6G
(Zick et al., 2008; Zick et al., 2010). Thus, it requires ~6g/kg bw of 6G to be consumed in order
to achieve equivalent active concentrations of 6G in the blood plasma. Such high doses of
bioactive phytochemicals often result in cellular and organ toxicity. Similar is the case with the
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current chemotherapeutic drugs, which despite their lower effective doses, exert undesirable side
effects, thus categorizing them as toxic drugs.

With the accession of organic chemistry since early 19th century, several drugs, including
morphine, taxol, cocaine, vincristine, vinblastine, codeine, quinine, noscapine, digitoxin etc.,
have been purified and extracted from medicinal plants and herbs (Ji et al., 2009). This idea of
purifying a single agent from a complex natural material has misled us to assume that only one
or few components of a plant are responsible for the efficacy. Ever since, the researchers and
drug industries have invested in designing and producing purified drugs directed towards specific
ligands acting on disease targets. There have been such several successful anticancer agents with
remarkable efficacy. However, in the past few decades, the number of innovative drugs
introduced into the market has declined and a majority of these failed during the final phases of
clinical trials and some even after introduction into the market. The reason behind these debacles
is mainly due to the fact that cancer has a multi-factorial pathogenesis. Targeting a single
molecular player in a specific pathway is no longer suitable to destroy the tumors, as metastasis
and relapse are highly likely outcomes of such therapies. Furthermore, such highly selective
targeted therapies may even have certain unexpected biochemical effects, resulting in toxicity.
Thus, to address these failures, in the recent years, scientists have focused on multi-targeted
therapies employing combination chemotherapy, where two or more chemotherapeutic drugs are
given in a concoction (Azuine and Bhide, 1992; Chou, 2010; Clark et al., 2006; Lansky et al.,
2005; Wagner, 2011; Xiao and Yang, 2008). Still, toxicity issues persist, likely due to the need
for administering varying doses of the each drug in the cocktail such that their respective potent
doses can be achieved in vivo to have an effect against the malignancy.

6

However, Mother Nature has a solution concerning this matter, particularly in the form of
whole foods that have been overlooked for ages. The idea of isolating the “active constituent”
from plant extracts does not take into account the possibility of natural phytochemical cocktails
that may interact among themselves to deliver combined superior health benefits. Several lines of
evidence also indicate that a single constituent isolated from a complex phytochemical mixture
present in whole foods or their extracts may even lose its bioactivity or cause undesirable cancerpromoting effects, as in the case of β-carotene (Omenn et al., 1996). It is also likely that isolating
a single compound from complex foods may not be effective even at high, relatively toxic doses,
whereas combinations of lower, less-toxic doses of each compound may be effective. The natural
balance among various constituent phytochemicals in whole foods or extracts not only presents
lower doses of predefined formulations to impart health benefits, but also the additive and
synergistic interactions among these phytochemicals support multiple roles from preventing
DNA mutations, impeding cell cycle, inhibiting cell proliferation, inducing apoptosis to even
modifying the immune responses compared to their comprising individual components. This
advantage of whole foods could perhaps be because of the natural preservation of a complex
phytochemical mixture in whole foods that can act on multiple targets due to their physiological
consequences, i.e., particularly increasing solubility and absorption of these active ingredients.
This natural setting in whole foods thus delivers desired beneficial effects while eliminating the
possible harmful effects of the individual components. However, the outcomes of these complex
interactions between various constituents of plant-based foods are dictated by several
mechanistic factors such as bioavailability, cellular transport mechanisms, pro-drug activation
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and deactivation of active drug entities and, most importantly, the action of synergistic allies at
multiple target sites.

As defined by Nature, every fruit and vegetable contains a defined ratio of
phytochemicals within them, which are pre-designed to target several sites in the body upon
ingestion. Poor quality of plant material processing, incompetent fractionation processes,
degradation of active constituents and lack of appropriate biological models for testing are some
of the several explanations for the unsuccessful isolations of active constituents from whole
extracts. It is thus important to maintain the balance of phytochemicals and keep their intricate
network intact by employing whole foods instead of single active entities. Furthermore, despite
the innumerable advantages acquired by consuming whole food extracts, they have not gained
much attention to be employed as chemotherapeutic or chemopreventive agents. This could
possibly be due to the lack of understanding of the interactions between plant constituents, in
vivo physiological interactions, and the prospects of these phytochemicals at the target sites.
Hence, a detailed evaluation of the in vivo mechanisms of action and the fate of the constituent
phytochemicals upon consumption of whole foods is required in order to employ whole foods as
therapeutic and preventive agents.
1.3

Synergy: Complex interactions among constituent phytochemicals in whole food
extracts (Gundala et al., 2014)
Disease pathogenesis is a continuous developmental process, which often renders the

disease-inducing pathogens or cells in case of cancer to develop resistance against the effective
drugs or individual phytochemicals. However, whole food extracts have an advantage against
this predicament due to the co-existence of several phytochemicals within them that interact with
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the organism or cells and among each other to ward off the disease. For example, in case of
cancer, the malignant cells are metabolically highly active and these processes involve a variety
of enzymes and receptors containing specific sites that can accommodate the phytochemicals and
drug molecules. However, several constituent plant chemicals of whole foods compete with each
other or interact among themselves to attack these specific sites to impart better efficacy (Liu,
2003, 2004). Further, there might be several mechanisms by which these phytochemicals act in
parallel at the target sites. Furthermore, the complexity of phytochemicals in their natural forms
in plant-based foods precludes a definitive conclusion regarding their mechanisms of action.
However, the existence of synergistic interactions have been long known and linked to the
activity of whole foods.
Epidemiological studies suggest that a high intake of fruits and vegetables is linked to a
reduced cancer risk. Phytochemicals present in fruits and vegetables (e.g., carotenoids,
polyphenolics, anthocyanins, terpenes, alkaloids) are functionally pleiotropic; they possess
multiple intracellular targets, simultaneously affecting different signaling cascades usually
altered in cancer cells with limited toxicity to normal cells, thereby reducing overall cancer risk.
Several reports suggest that the anticancer benefits of fruits and vegetables are due to an additive
or synergistic interplay of the complex mixture of phytochemicals present in them. This
emerging notion further lends support to the premise of concomitantly targeting multiple
pathways. Whole foods have been so far studied to deliver “pharmacodynamic synergy”
(Danielsson et al., 2011), where the constituent phytochemicals act at different target sites to
enhance the overall therapeutic index.
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Such kind of synergy or potentiation is where the effect of the combination of
phytochemicals is greater than the additive sum of effects of individual phytochemicals. For
example, studies of green tea polyphenols have demonstrated that EGCG and at least four other
catechins are necessary for maximum in vivo efficacy, suggesting that synergistic inter-reactivity
or dependency on other components of the whole food is required for optimal activity (Azam et
al., 2004; Johnson et al., 2010; Kinjo et al., 2002; Raza and John, 2005). Similarly, the highest
antioxidant activity was realized with the combination of polyphenols in pomegranate juice as
opposed to the constituent polyphenols alone. In a comparable investigation of cranberry extract,
enhanced antiproliferative activity was attributed to the synergistic and additive interactions of
its main components, including anthocyanins, proanthocyanidins, and flavanol glycosides
(Ferguson et al., 2004; Kandil et al., 2002; Seeram et al., 2004). Recent findings from our
laboratory also underscore the importance of synergistic interactions among ginger biophenolics
present in GE (Gundala et al., 2014), which may tremendously lower the concentration of the
effective doses while maintaining efficacy. The natural abundance, low cost, and non-toxicity of
this very common spice are strong attributes that favor ginger as a chemopreventive as well as a
potential chemotherapeutic alternative in the treatment of prostate cancer. Such studies thus offer
a plausible explanation as to why clinical trials with pure, single phytochemicals, such as αtocopherol, β-carotene, and vitamin C, have met with limited success (1994; Greenberg et al.,
1994; Liu, 2003; Omenn et al., 1996). It is thus likely that disrupting the natural balance of
phytochemicals as it exists in fruits and vegetables by extracting individual phytochemicals from
the “food matrix” may result in sub-optimal health benefits.
Apart from the pharmacodynamic synergy, phytocomplexity further offers additional
significant in vivo benefits in terms of “pharmacokinetic synergy” (Yang et al., 2014), where the
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constituent phytochemicals of whole foods with less or no activity aid the most-active
constituent phytochemicals to reach the sites of action either by improving bioavailability or by
decreasing metabolism and excretion. Our laboratory is the first to demonstrate that ginger
biophenolics upon oral administration of whole ginger extract exhibit such pharmacokinetic
synergy to enhance the bioavailability of 6-gingerol (6G), 8-gingerol (8G), 10-gingerol (10G)
and 6-shogaol (6S) (Gundala et al., 2014). While improving the bioavailability, pharmacokinetic
synergy might also result in resistance-reversal mechanisms and induction of other
complementary mechanisms including immunomodulation.
1.4

Untapped arena: Pharmacokinetic analysis of whole food extracts
Researchers have been investigating the in vivo fate of drug molecules or single active

constituents of plant origins, while evaluating the kinetics and extent of absorption by measuring
the plasma, urine and/or feces concentrations of drugs and phytochemicals after administration.
Bioavailability, including maximum plasma concentration (Cmax), time taken to reach Cmax
(Tmax), area under the plasma concentration-time curve (AUC), elimination half-life etc.,
parameters are evaluated in order to determine the right dosage to achieve maximum anticancer
benefits. Though the efficacy of several whole food extracts has been determined, such kind of
detailed pharmacokinetic evaluation is limited. The paucity of the pharmacodynamic and
pharmacokinetic data involving whole foods needs to be addressed in order to exploit their health
benefits imparted due to phytocomplexity. This data will further be useful to design and interpret
the intervention studies employing fruits and vegetables.
Bioavailability, metabolism and elimination of active phytochemicals in whole foods can
be greatly affected by other constituent partners. The non-active phytochemicals can enhance the
permeability of the active ones, inhibit efflux pumps required for elimination of drugs in order to
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increase the latter’s mean residence time, modify the ADME (absorption, distribution,
metabolism and excretion) characteristics and even modulate the phase I and II metabolizing
enzymes favoring the metabolism of the active constituents. Recent findings from our laboratory
support the idea of pharmacokinetic synergy, as the bioavailability of active ginger biophenolics
was improved upon administering whole ginger extract, where it is likely that other constituent
partners of GE helped in better absorption of 6G, 8G, 10G and 6S either by competing to get
glucuronidated for elimination or via regulating the phase I and II metabolizing enzymes.
Further studies to determine the nature of interactions and mechanisms by which these
“silent” partners help the active associates to deliver maximum efficacy are crucial in developing
new therapeutic and preventive strategies. This information will further acknowledge the idea of
pharmacokinetic synergy imparted via phytocomplexity in the case of whole foods. Also, this
will open new avenues in the fields of chemotherapy and chemoprevention, where phytotherapy,
the alternate school of thought, will be further appreciated for its safe yet complex mode of
action and cost-effectiveness.
1.5

Xenohormesis: Potential pro-oxidative and/or anti-oxidant cancer-fighting properties
of dietary phytochemicals (Gundala and Aneja, 2014)
Health-promoting phytochemicals, mainly the phenolic compounds merit a special

mention, as they are the most-abundant and primary defense molecules of plants and have
protected them during evolution. In addition, these phenolics have “chemically” contributed to
maintain an ecological equilibrium between plants and other living organisms feeding on them,
including us humans. The magnanimous nature of these compounds can be attributed to the
inherent physicochemical properties packaged within the phenol functional group, which
bestows unto them a versatile phenolic function of acting as an antioxidant as well as a
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prooxidant. Plant foods consisting of such nutraceuticals also offer both chemotherapeutic
(cancer cells) and chemopreventive benefits (pre-malignant cells), albeit through different
mechanisms. Furthermore, an interesting novel paradigm called “xenohormesis”, involving
polyphenols is gaining momentum, which hypothesizes that polyphenols were synthesized by
common ancestors of plants and animals (Howitz and Sinclair, 2008). Despite the evolutionary
divergence of the respective kingdoms, it is intriguing that many crucial mammalian enzymes
and receptors have been conserved which can be regulated and modulated by plant-produced
phytochemicals.

Paramount interest centers on the belief that adverse environmental conditions or stress
induces the synthesis of phytochemicals including polyphenols in plants. Interestingly, when
ingested by humans, these phytochemicals upregulate pathways that provide stress-resistance in
animals. Conceivably, this suggests that humans that consume phytochemicals via plant-based
foods have sensing mechanisms (enzymes/receptors) to perceive these chemical cues and elicit
beneficial responses that enhance the well-being of humans thus imparting overall health
benefits. This phenomenon has been brilliantly termed as “xenohormesis” by Howitz and
Sinclair fairly recently in 2008, wherein xenos, is the Greek word for stranger, and hormesis, the
term for health benefits (Hooper et al., 2010; Howitz and Sinclair, 2008; Lamming et al., 2004;
Surh, 2011). In simplistic terms, it is health benefits conferred by a stranger! In a nutshell,
ingestion of phytochemicals causes the body to be tricked into believing that it is under some
kind of stress, which triggers a system-wide response to combat stress.
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While normally, the presence of a handful of initiated or pre-malignant cells would not be
able to trigger a sufficiently strong signal for the body to perceive and respond to,
phytochemicals may place the system on “high-alert” and stimulate a heightened stress-response
that could effectively eliminate the initiated or pre-malignant cells thus emphasizing the
workings of plant phytochemicals in the chemopreventive context. Once the pre-neoplastic cells
undergo malignant transformation into cancer cells, they can perhaps only be eliminated through
chemotherapeutic strategies, as upon becoming cancerous, as these cells have surpassed their
amenability to chemopreventive measures.

Figure 1.1 Representation of the fate of cancer cells under varying ROS levels
Cancer cells having moderate levels of ROS tend to adapt to the stress conditions and show
enhanced expression of pro-survival molecules. For example, when whole food constituents like
betel leaf nutraceuticals interfere with this situation, causing the moderate ROS levels to increase
over the threshold, the cancer cells can no longer withstand the oxidative stress and thus are
killed via various possible mechanisms (Atsumi et al., 2005; Bhide et al., 1991a; Bhide et al.,
1979; Bhide et al., 1991b; Chang et al., 2007; Chang et al., 2002; Chen et al., 2000; Gibellini,
2010; Kumar, 2010; Lee-Chen et al., 1996; Ma et al., 2013; Nagabhushan et al., 1989; Sakihama
et al., 2002; Trachootham et al., 2009; Verma et al., 2010).
Unlike normal cells, cancer cells owing to their enhanced metabolic activity have
constitutively higher levels of reactive oxygen species (ROS), which spawns a persistent
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prooxidative environment (Schumacker, 2006; Szatrowski and Nathan, 1991; Trachootham et al.,
2009). Nonetheless, cancer cells despite high ROS concentrations, survive by adapting to the
increased oxidative stress by upregulating pro-survival mechanisms and altering their antioxidant
systems (Figure 1.1). Normal cells, however, operate within an “optimal window” to maintain a
redox balance between generation and elimination of free radicals, but also possess a robust
capacity to tolerate a sizeable fluctuation in ROS levels. In contrast, the high basal ROS levels in
cancer cells provide a much narrower window to endure elevations in ROS levels, thus making it
their “Achilles heel”. This “vulnerability” or susceptibility of cancer cells can be exploited by
whole foods containing phenolic entities to selectively kill cancer cells by augmenting ROS
levels beyond the toxic threshold that cancer cells can withstand and thus induce apoptosis
(Figure 1.2). Nevertheless, a “similar-scaled” prooxidant deviation from redox homeostasis is
well tolerated by normal cells (Figure 1.2). This partly explains why plant-based foods with a
concoction of free radical scavenging and generating agents are well-tolerated and non-toxic.
The width of the “therapeutic window” may be evaluated by the redox differences between
normal and tumor cells and may be specific to the nature of the components present in the plantbased food.
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Figure 1.2 Xenohormetic response
The bioactive phenolics of betel leaves may facilitate elimination of initiated cells, thus ensuring
that they do not develop into cancer. By ‘signaling’ that there is some “stress” in the
environment, ingested phytochemicals like betel nutraceuticals are thought to potentiate a
systemic stress-combating response in normal cells, which in turn triggers the up regulation of
endogenous antioxidant enzymes by modulating the nuclear transcription factor erythroid 2p45
(NF-E2)–related factor 2 (Nrf2) expression or the endogenous thiol (GSH) levels. Due to the
systemic activation of this defense system, the initiated cells can be effectively scavenged and
eliminated, presumably by the immune system, which is placed on “high-alert”. On the other
hand in the cancer cells, an opposite effect of further stress induction is observed due to which
apoptosis is induced and/or the endogenous Nrf2 and thiol levels are depleted (Lee-Hilz et al.,
2006; Surh, 2011).
The xenohormetic process thus fills the gaps in knowledge on the cancer preventative
benefits of plant-based phytochemicals in addition to their roles to kill transformed cancer cells.
The xenohormesis phenomenon aids to comprehend the basis of the chemopreventive potential
of phytochemicals or whole foods that prevent carcinogenesis and intervene early on in the
malignant transformation process.
1.6

Summary
The primary focus of my research emphasizes understanding the health benefits imparted
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by dietary phytochemicals. For this we chose to work with in vitro and in vivo prostate cancer
models. Prostate cancer is the second leading cause of death among American men, next to lung
cancer. Though it is a slow-growing cancer, it can be aggressive and even fatal. Given its
hormone-dependency, many prostate cancer patients often respond to hormone ablation therapy.
Yet in most cases, it becomes hormone refractory, which cannot be treated effectively thus
resulting in death. Furthermore, due to its high prevalence in American men, its treatmentassociated morbidity, long latency period, and defined molecular pathogenesis, prostate cancer
serves as a potential target to develop novel chemotherapeutic and chemopreventive strategies.

Dietary interventions seem to be cost-effective and safer options in treating cancer as the
constituent phytochemicals, polyphenols in particular, of dietary agents can deliver maximum
therapeutic benefits via pharmacodynamic and pharmacokinetic synergies. Furthermore, plant
extracts constituting xenohormetic phytochemicals are the new age drugs to be employed and
engaged in the war against cancer. This dissertation compiles the results from investigations
performed in our laboratory involving a variety of plant-based foods with exceptional anticancer
potential, which are as follows: 1) Polyphenol-rich sweet potato greens extract inhibits
proliferation and induces apoptosis in both in vitro and in vivo prostate cancer models. Its
constituent polar phenolic acids synergize to inhibit prostate cancer cell proliferation and in vivo
tumor growth. 2) Benefits of whole ginger extract in prostate cancer, where ginger
phytochemicals exhibit robust synergy to inhibit prostate cancer cell proliferation. They also
undergo enterohepatic re-circulation, which is associated with enhanced tumor growth-inhibitory
activity of ginger extract. 3) The anticancer benefits and bio-guided fractionation of Piper betel
leaf extract, a reservoir of potential xenohormetic nutraceuticals with cancer-fighting properties,
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to identify active constituents for prostate cancer management. Hydroxychavicol, a betel leaf
component, inhibits prostate cancer through an interplay of ROS-driven autophagy and
apoptosis.

2

WHOLE FOOD EXTRACTS PRESENT SUPERLATIVE EFFICACY
COMPARED TO THEIR PURIFIED COUNTERPARTS2

2.1

Abstract
Polyphenolic phytochemicals present in fruits and vegetables indisputably confer

anticancer benefits upon regular consumption. Sweet potato (Ipomoea batatas) leaves or greens,
extensively consumed as a vegetable in Africa and Asia, are an excellent source of dietary
polyphenols such as anthocyanins and phenolic acids. Here, we demonstrated that sweet potato
2

This chapter has been published verbatim in Carcinogenesis 2011 as Polyphenol-rich
sweet potato greens extract inhibits proliferation and induces apoptosis in prostate cancer cells
in vitro and in vivo and Carcinogenesis 2013 as Polar phenolic acid constituents in sweet potato
greens extract synergize to inhibit prostate cancer cell proliferation and in vivo tumor growth.
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greens extract (SPGE) has the maximum polyphenol content compared with several commercial
vegetables including spinach. Further, we demonstrated the growth-inhibitory and apoptosisinducing properties of polyphenol-rich sweet potato greens extract (SPGE) in cell culture and in
vivo prostate cancer xenograft models. Oral administration of 400 mg/kg SPGE remarkably
inhibited growth and progression of prostate tumor xenografts by 69% in nude mice, as shown
by tumor volume measurements and non-invasive real-time bioluminescent imaging. We also
report a bioactivity-guided fractionation of SPGE based upon differential solvent polarity using
chromatographic techniques that led to the identification of a remarkably active polyphenolenriched fraction, F5, which was ~100-fold more potent than the parent extract as shown by IC50
measurements in human prostate cancer cells. HPLC-UV and mass-spectrometric analyses of the
seven SPGE fractions suggested varying abundance of the major phenols, quinic acid (QA),
caffeic acid (CA) its ester, chlorogenic (ChA) acid, and isochlorogenic acids, 4,5-di-CQA, 3,5di-CQA and 3,4-di-CQA, with a distinct composition of the most-active fraction, F5. Subfractionation of F5 resulted in loss of bioactivity, suggesting synergistic interactions among the
constituent phytochemicals. Quantitative analyses revealed a ~2.6 and ~3.6 fold enrichment of
QA and ChA respectively, in F5 and a definitive ratiometric relationship between the
isochlorogenic acids. Daily oral administration of 400 mg/kg bw of F5 inhibited growth and
progression of prostate tumor xenografts by ~75% in nude mice, as evidenced by tumor volume
measurements and non-invasive real-time bioluminescence imaging. These data generate
compelling grounds to further examine the chemopreventive efficacy of the most-active fraction
of sweet potato greens extract, and suggests its potential usefulness as a dietary supplement for
prostate cancer management.

19
2.2

Introduction
Nearly one-third of all cancer deaths in the USA can be prevented through appropriate

dietary modification (Anand et al., 2008; Khan et al., 2008; Kolonel et al., 2004). Regular
consumption of fruits and vegetables (five servings per day) (Williams, 1995) is highly
recommended today in the American and European diet, mainly because the constituent
phytochemicals, in particular, polyphenols, they contain are known to play important roles in
long-term health protection, notably by reducing the risk of chronic and degenerative diseases
including cancer (Crozier et al., 2009; Treutter, 2005). Prostate cancer is particularly amenable to
dietary chemopreventive strategies since it presents a significantly large-window of latency (20–
30 years) and its mean age of diagnosis is ~68 years (Cooke et al., 2005; Kaur et al., 2009;
Veluri et al., 2006; Yang et al., 2001). About 35 plant-based foods identified by the NCI display
effective anticancer properties including garlic, turmeric, cruciferous vegetables (e.g. broccoli,
brussels sprouts, cabbage) and grape seed extracts (Colli and Amling, 2009; Kaur et al., 2009;
Steinkellner et al., 2001; Surh, 2003; Traka et al., 2008). Many fruit and vegetable whole extracts
have also been tested for their efficacy in inhibiting prostate cancer growth (Cooke et al., 2005;
Kaur et al., 2009; Ray et al., 2010; Surh, 2003; Yang et al., 2001). Plant polyphenols, a class of
naturally occurring water-soluble phenolic compounds, are crucial for optimal human health
benefits and are being increasingly recognized owing to their abundance in fruits, vegetables and
derived foodstuffs (Quideau et al., 2011). The conformational flexibility of polyphenols
facilitates complex oligo/polymeric assemblies that enable plants to take advantage of the
remarkably diverse range of biophysicochemical properties exhibited by the phenol functional
group thus making plant polyphenolics as unique and intriguing natural products (Quideau et al.,
2011). No wonder polyphenols have sparked a new appraisal of diverse plant-derived foods and
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beverages such as tea, red wine, coffee, cider, chocolate as well as many other food commodities
derived from fruits, including berries. The ability of phenolics to homolytically release a
hydrogen atom is one of the fundamental processes that underlie the acclaimed health-benefiting
antioxidative property of polyphenolics to act as scavengers of free radicals and reactive
oxidative species that may drive malignant transformation and carcinogenesis (Quideau et al.,
2011).
Nutrition research has long favored a reductionist approach emphasizing single
phytochemical-based health benefits. However, the idea of synergy among constituent
phytochemicals present in whole foods is gaining momentum. Several reports underscore the
benefits of a multi-targeted approach offered by a synergistic mixture of phytochemicals present
in whole foods (Craig, 1999; Dragsted et al., 1993; Liu, 2003; Surh, 2003; Ulbricht and Chao,
2010; Waladkhani and Clemens, 1998). It is becoming recognizable that a whole or partially
purified extract of a plant offers significant advantages over a single isolated ingredient. This can
be most appropriately described as the “herbal shotgun” approach, as opposed to the “silver
bullet” method of conventional medicine (James A. Duke, 2008) and may partially explain the
limited success of clinical trials involving individual phytochemicals such as Vitamin E and
beta-carotene for cancer chemoprevention (Greenberg et al., 1994; Liu, 2004; Tsao et al., 2004).
Nonetheless, these data solidify the notion that health benefits from fruits and vegetables may
not be solely because of the isolated single compounds, but are mainly due to additive and/or
synergistic interactions among components that “partner” together in the concoction at their
relative concentrations. For example, studies with skin-bearing apples have demonstrated strong
antiproliferative activity in human colon and hepatic cancer cells, compared to apples without
skin or its most studied constituent, vitamin C (Wolfe et al., 2003).
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Well-known for their abundance in fruits and vegetables, polyphenols are versatile
molecules containing several hydroxyl groups with multiple aromatic rings. The amphiphilic
phenolic moiety of polyphenols blends the hydrophobic character of its planar aromatic core
with the hydrophilic nature of its polar hydroxy substituent (Quideau et al., 2011). The inherent
bio-physicochemical properties of the phenolic group display a wide repertoire of functional
roles, including plant resistance against microbial pathogens, and protection against solar
radiation. Epidemiological studies suggest an inverse relationship between consumption of
polyphenol-rich foods like cocoa, red wine, tea, fruits, vegetables, etc. and the incidence of
chronic diseases including cancer (Cooke et al., 2005; Kaur et al., 2009; Yang et al., 2001).
Although it is easy to evaluate the protective effect of a single phytochemical, for example, a
single polyphenolic compound, the health benefits of dietary polyphenols are difficult to discern
when numerous phytochemicals including polyphenolics, flavonoids, lignans and tannins are
active and work synergistically. The complexity of polyphenols in foods limits the identification
of definitive compositions of partially purified extracts that display superior efficacy compared
to single-agents or whole foods. Nevertheless, it is likely that a reductionist approach involving
fractionation of a whole extract may result in the increased concentration of bioactive
constituents in a particular sub-fraction, thus enhancing efficacy.
Sweet potato greens (SPG), Ipomoea batatas, a significant source of dietary polyphenols,
are widely consumed as a fresh vegetable in West Africa and Asia, in particular, Taiwan and
China (Mosha and Gaga, 1999). Rich in vitamin B, β-carotene, iron, calcium and zinc, sweet
potato greens (SPG) are highly nutritive and contain as many vitamins, minerals and other
nutrients as spinach (Islam, 2006). SPG are an excellent source of antioxidative polyphenolics,
namely anthocyanins and phenolic acids such as caffeic, monocaffeoylquinic (chlorogenic),
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dicaffeoylquinic and tricaffeoylquinic acids (Huang et al., 2007; Kurata et al., 2007).
Particularly, anthocyanins in SPG have been described to be cyanidin-type rather than peonidintype (Islam et al., 2002a). SPG have been shown radical-scavenging, antimutagenic, antidiabetic,
antibacterial, anti-inflammatory, and anticancer activities (Huang et al., 2007; Islam, 2006). The
chemopreventive action of SPG is suggested by a case–control study in Taiwan reporting that
higher SPG consumption is associated with reduced lung cancer risk (Jin et al., 2007). Although
sporadic studies have reported identification of bioactive polyphenolics and anthocyanin
constituents of SPG (Islam et al., 2002b), there has, heretofore, not been a study that offers a
detailed evaluation of the anticancer potential of sweet potato greens extract (SPGE). To the best
of our knowledge, we are the first to investigate the anticancer attributes of SPGE in vitro and in
vivo and to develop it as a mechanism-based anticancer agent for prostate cancer.
In this chapter, we examine the anticancer effects of SPGE in a panel of prostate cancer
cells by evaluating its effects on cellular proliferation, cell cycle progression and apoptosis. Our
results demonstrate that SPGE causes growth inhibition by inducing a G1 phase arrest followed
by a mitochondrially mediated caspase-dependent intrinsic apoptosis in prostate cancer, PC-3
cells. In vivo studies show that SPGE remarkably inhibits tumor growth of subcutaneously
implanted PC-3 human tumor xenografts in nude mice models without any detectable toxicity.
Also a detailed bioactivity-guided fractionation of SPGE, emphasizing the importance of
synergistic interactions among various bioactive components to confer remarkable in vitro and in
vivo effects in prostate cancer models is reported here.
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2.3
2.3.1

Materials and Methods
Cell culture, antibodies and reagents
Human prostate cancer cell lines (LNCaP, DU145, PC-3, C4-2, C4-2B) were cultured in

RPMI medium (Mediatech, Manassas, VA) with 10% fetal bovine serum. Luciferase-expressing
PC-3 cells (PC3-luc) were from Perkin Elmer (Hopkinton, MA) and were maintained in
modified Eagle’s medium with 10% fetal bovine serum. Antibodies to cyclin D1, cyclin A,
cytochrome c, Bcl2, phospho-Bcl2, cleaved caspase-3 and cleaved poly (adenosine diphosphateribose) polymerase (PARP) were from Cell Signaling (Beverly, MA). BAX, p21, cyclin E, p53
and β-actin were from Santa Cruz Biotechnology (Santa Cruz, CA). Chlorogenic acid (ChA) and
caffeic acid (CA) were from Sigma (St Louis, MO). MTT dye (Thiazolyl blue tetrazolium
bromide, 98% TLC) and dimethyl sulfoxide (DMSO) were from Sigma-Aldrich (St. Louis, MO).
Quinic acid (QA), chlorogenic acid (ChA), caffeic acid (CA), and Folin-Ciocalteau (FC) reagent,
ACS grade methanol, ethyl acetate, hexanes and high-performance liquid chromatography
(HPLC) grade solvents were from Sigma-Aldrich (St. Louis, MO).
2.3.2

Preparation of SPGE and estimation of polyphenolics
Forty-five-day-old sweet potato (I.batatas) greens [Whatley/Loretan, (TU-155) variety]

were obtained from Tuskegee University Agriculture Department. Extracts were prepared by
soaking shade-dried leaves in methanol overnight for three consecutive days. The supernatant
was collected daily and finally concentrated in vacuo (Buchi-Rotavap) followed by freeze drying
to powder using a lyophilizer. SPGE stock solution was prepared by dissolving 200 mg SPGE in
1 ml dimethyl sulfoxide and various concentrations were obtained by appropriate dilutions.
Batch-to-batch variation was evaluated by analysis of total polyphenolic (~6.5/100 g)
(Truong et al., 2007; Yoshimoto et al., 2002) and anthocyanin (~10.8 Color value/g powder)
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(Islam et al., 2002a) contents, which was observed to be consistent across batches of similar age.
Total phenolic content was determined by Folin–Ciocalteu (FC) method using chlorogenic acid
as the standard. Chlorogenic acid (0.5 g) was dissolved in 10 ml ethanol and then diluted to 100
ml with water to make a final concentration of 5 g/L. 50, 100, 250, and 500 mg/L concentrations
of standards and 0.5, 1, 2, 3, 4 and 5 mg/ml concentrations of test extracts were prepared in
distilled water. 20 µl sample of standard or test extract was dissolved in 1.58 ml water, followed
by 100 µl FC reagent. This mixture was mixed thoroughly and incubated no longer than 8 min.
300 µl sodium carbonate solution was added to the above mixture and was incubated for 2 h at
room temperature. A final volume of 2 ml was measured for absorbance at 765 nm and the
results were expressed as milligrams of chlorogenic acid equivalents (ChAE) per gram dry
material (ChAE mg/g). The linear range of the calibration curve was 0.02 to 0.2 mg/ml. All
samples were analyzed in triplicates.
Classical column chromatographic separation was performed on SPGE (3 g) that was
loaded on to a silica gel column, which was run down using hexane: ethyl acetate solvent system
starting with 500 ml of 100% hexane. The fraction was collected in a conical flask and stored at
4oC. This was followed by elution using 500 ml of hexane:ethyl acetate solution (90:10).
Subsequently, a gradient increase in the percentage of ethyl acetate (10% each time) was
incurred in the mobile phase to elute various components of SPGE into different fractions. After
the elution of 50:50 hexane:ethyl acetate fraction, hexane was replaced by 50% methanol to elute
the highly polar components. With an increment of 10% methanol each time (starting from 50:50
methanol:ethyl acetate) the column was finally eluted with 100% methanol to ensure complete
elution of all components. A total of 17 fractions thus obtained were concentrated in vacuo
(Buchi Rotavap) followed by separation on thin layer chromatography (TLC). Based on the
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observed bands, fractions with similar TLC profiles (Rf values) were pooled to finally obtain 7
fractions (F1-F7). All 7 fractions were freeze-dried using a lyophilizer and were stored at -80oC
until tested.
2.3.3

In vitro proliferation assay
Briefly, 5 x 103 cells/well in a 96-well format were treated with gradient concentrations of

SPGE and test fractions dissolved in DMSO (0.1%). The concentrations used were 1, 10, 25, 50,
75, 100 and 250 µg/ml. F5 was further tested at lower concentrations (0.075, 0.1, 0.5, 1, 5 and
10 µg/ml). After 48 h incubation, cells were washed with PBS followed by addition of 5 mg/ml
MTT solution. Cells were then incubated at 37°C in dark for 4 h. The formazan product was
dissolved by adding 100 µl of 100% DMSO after removing the medium from each well. The
absorbance was measured at 570 nm using a Spectra Max Plus multi-well plate reader
(Molecular Devices, Sunnyvale, CA).
2.3.4

Colony survival assay
1000 PC-3 cells were seeded in a 6-well plate and were treated with 10 µg/ml F5 for 24

and 36 h, then washed, and replaced with regular RPMI medium including the controls. After 7
days, each well was washed twice with 1X PBS, and fixed and stained with the clonogenic
reagent for 20 mins followed by rinsing with tap water. The stained colonies in the control and
treated wells were then counted. A colony was arbitrarily defined to consist of at least 50 cells.
2.3.5

Cell cycle analysis, immunofluorescence microscopy and immunoblot analysis
PC-3 cells treated with 250 µg/ml SPGE for 6, 12, 24, 48, and 72 h, were lysed,

centrifuged, washed with ice-cold PBS, fixed in 70% ethanol and stored at 4°C. Pellets were
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collected, washed twice with PBS and stained with propidium iodide in the presence of RNaseA
for 45 min in the dark. Cell cycle profile was analyzed by flow cytometry (Aneja et al., 2010).
PC-3 cells grown on coverslips were treated with 250 µg/ml SPGE for 24 h, and were
then fixed with ice-cold methanol for 10 min. This was followed by blocking with 2% bovine
serum albumin/PBS at 37°C for 1 h. The coverslips were then incubated with Ki67, cleaved
PARP, and cleaved caspase-3 (1:100 dilution) 37°C for 1 h, which were then washed with 2%
bovine serum albumin/PBS for 10 min at room temperature and incubated with 1:500 dilution of
Alexa 488- (Ex:Em::499:519) or 555- (Ex:Em::553:568) conjugated secondary antibodies. The
coverslips were then mounted with Prolong Gold antifade reagent containing 4’,6-diamidino-2phenylindole (Invitrogen) (Karna et al., 2010).
Protein lysates were collected from cells treated with or without 250 µg/ml SPGE and
were resolved by SDS-PAGE, followed by a transfer onto polyvinylidene difluoride membrane
that was incubated with a primary antibody of choice overnight at 4°C. Appropriate secondary
antibody

was

used

followed

by

visualization

of

the

immune-reactive

bands

by

chemiluminescence detection kit (Pierce). β-actin was loading control (Karna et al., 2010).
2.3.6

Determination of mitochondrial transmembrane potential and caspase-3/7 activity and
TUNEL assay
Mitochondrial transmembrane potential was measured flow cytometrically using

5,5’,6,6’-tetrachloro-1,1’,3,3’-tetraethylbenzimidazol-carbocyanine iodide (JC) staining and
caspase-3 activity was measured using a fluorescent substrate (Karna et al., 2010). Annexin-V
and terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL) assay
was performed where SPGE-treated cells were stained with Alexa-Fluor 488-conjugated
Annexin-V using the Vybrant-Apoptosis Assay Kit from Invitrogen as per the manufacturer’s
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protocol. Annexin-positive cells were visualized using confocal microscopy and quantitated flow
cytometrically. DNA strand-breaks were quantified flow cytometrically using the TUNEL assay
(Aneja et al., 2010).
2.3.7

In vivo tumor growth, SPGE and F5 treatment and bioluminescent imaging
Six-week old male nude mice were obtained from NCI (Frederick, MD) and/or Harlan

laboratories (Indianapolis, IN) and 1 x 106 PC-3-luc cells in 100 µl phosphate-buffered saline
were injected subcutaneously in the right flank. When tumors were palpable, mice were
randomly divided into two groups of eight mice each. Control group received vehicle
(phosphate-buffered saline with 0.05% Tween-80, pH 5 7.4) and the treatment group received
400 mg/kg body wt SPGE and F5 daily by oral gavage. Tumor growth was monitored in real
time by bioluminescent imaging of luciferase activity in live mice using the cryogenically cooled
IVIS-imaging system (Perkin Elmer) with the live imaging software. Briefly, mice were
anesthetized with isoflurane, intraperitoneally injected 25 mg/ml luciferin and imaged with a
CCD camera. Integration of 20 s with four binnings of 100 pixels was used for image acquisition
and signal intensity was quantitated as sum of all detected photon counts within the lesion. Mice
from vehicle or SPGE-treated groups were imaged twice a week allowing temporal assessment
of in vivo tumor growth. All animal experiments were performed in compliance with
Institutional Animal Care and Use Committee guidelines.
2.3.8

Histopathologic and immunohistochemical analyses
After 6 weeks of SPGE, F5 or vehicle feeding, mice were euthanized by exposing to CO2

for 2 min. Organs and tumors were either formalin fixed or frozen immediately. Tumor or organ
sections were stained with hematoxylin and eosin, Cleaved caspase-3, cleaved PARP, Ki67 and
TUNEL staining (Aneja et al., 2008; Aneja et al., 2006). Microscopic evaluation was performed
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by a pathologist in a blinded manner. Blood was collected by cardiocentesis in accordance with
our standard IACUC protocol.
2.3.9

Immunoblot analysis and immunofluorescent microscopy
Tumor lysates treated with vehicle and 400 mg/kg bw F5 were subjected to western blot

analysis. Membranes were probed for cleaved caspase-3 and cleaved PARP along with β-actin,
which was used as a loading control. Paraffin-embedded tumor sections from control and F5treated groups were processed and immunostained with apoptotic markers, cleaved caspase-3
and cleaved PARP, and the proliferation marker, Ki67. Fluorescent images were captured using
confocal microscopy. Human prostate cancer, PC-3 cells were treated with 10 µg/ml F5 and cell
lysates were collected at 0, 6, 12, 24, and 48 h. Immunoblot analysis was performed on the F5treated and control samples by probing for cleaved PARP and β-actin to confirm the induction of
apoptosis.
2.3.10 High performance liquid chromatography with UV and mass spectrometric detection
The high performance liquid chromatography (HPLC)-UV separations were achieved on
an HP1100 series Instrument (Agilent Technologies, Wilmington, DE) equipped with a UVphotodiode array detector using an Eclipse plus reversed phase C-18column (3.5 µm, 4.6 x 150
mm). HPLC-UV separation of 7 fractions was achieved on a HP1100 series Instrument (Agilent
Technologies, Wilmington, DE) equipped with a photodiode array detector, using an Agilent
Zorbax reversed phase (SB-C18, 3.0 × 250 mm, 5.0 µm) column. The mobile phase system
consisting of solvent A (0.1% formic acid in water) and solvent B (ACN) was employed to
achieve the separations. The gradient elution was set as follows: starting at 10% B, achieving
20% B at 20 min followed by 60% B over the next 20 min, which was held for an additional 10
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min; reconditioning to 10% B at 51 min and ending the run at 60 min with a flow rate of 0.4
ml/min. 10 µL of each fraction (1.0 mg/ml), dissolved and filtered in 25% ACN, was injected
into the system and the resultant HPLC-UV peaks were detected at 326 nm.
The HPLC-MS analyses were performed in tandem with HPLC-UV using the Agilent
Zorbax reversed phase (SB-C18, 3.0 × 250 mm, 5.0 µm) column interfaced to an Agilent 6400
series Triple quadrupole LC/MS equipped with an electrospray ionization source, operated in
negative-ion mode. The nebulizer and collision gases were nitrogen and helium, respectively,
with the former set at 40 psi. A drying gas temperature of 300oC, drying gas flow rate of 9 L/min
and capillary voltage of -3000V were the spray chamber parameters. The presence of quinic
(QA, m/z = 191, RT: 2.7min), chlorogenic (ChA, m/z = 353, RT: 11.6min) and caffeic (CA, m/z
= 179, RT: 15.5min) acids in the fractions was confirmed using selected ion monitoring (SIM)
and the HPLC retention time (RT) of the same in all the fractions against pure standards.
2.3.11 Sub-fractionation of F5 using analytical HPLC-UV chromatography
The most-active fraction, F5 was further fractionated into 2 sub-fractions based on the
retention time, F5-A (0-25 min) and F5-B (25.1-50 min) using analytical high performance
liquid chromatography. The sub-fractions thus collected were concentrated and lyophilized to
determine the in vitro efficacy by MTT assay.
2.3.12 Experimental design for the combination studies and determination of synergy
The pure standards, QA, ChA and CA, were combined as a mixture to mimic their
respective concentrations as quantitated in F5. This mixture was used at various increasing
gradient concentrations to test its in vitro efficacy against PC-3 cells. Specifically, the
concentrations used were, 0.075, 0.1, 0.5, 1, 5, and 10 µg/ml. The percentage of cell proliferation
was measured by MTT assay.
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2.3.13 Statistical analysis
The mean and standard deviations were calculated for all quantitative experiments using
Microsoft-Excel software. The Student’s t-test was used to determine the differences between
groups with P-values of <0.05 considered as statistically significant.
2.4
2.4.1

Results
SPGE

inhibits

proliferation,

perturbs

cell

cycle

progression,

and

induces

mitochondrially-mediated intrinsic apoptosis in human prostate cancer cells
Given that prostate cancer has a long latency time and is ideal for chemopreventive
intervention by non-toxic dietary extracts, we asked if SPGE inhibited growth of prostate cancer
cells (LNCaP, DU145, PC-3, C4-2 and C4-2B) in a concentration gradient-dependent manner.
SPGE significantly inhibited cellular proliferation of all prostate cancer cells with IC50 values in
the range of 145–315 µg/ml (Figure 2.1A). The order of sensitivity was C42<LNCaP<DU145<C4-2B<PC-3, with C4-2 being the most sensitive and PC-3 the least.
Importantly, the IC50 of SPGE in normal prostate epithelial cells (PrEC and RWPE-1) was
between 1000 and 1250 µg/ml (Figure 2.1B), which was ~5-fold higher than for cancer cells
suggesting that SPGE specifically targets cancer cells while sparing normal cells.
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Figure 2.1 SPGE inhibits growth and reproductive capacity of prostate cancer cells.
(A) Bar graphical representation of IC50 values of SPGE for various prostate cancer cells and (B)
normal prostate epithelial cells. (C) Bar-graph representation and photograph of crystal violetstained surviving colonies from control and SPGE-treated groups. (Di) Fluorescence
micrographs of PC-3 cells stained for Ki67 or 4’, 6-diamidino-2-phenylindole. (Dii) Bar-graph
quantitation of Ki67- positive or 4’,6-diamidino-2-phenylindole-stained cells treated with vehicle
or 250 µg/ml SPGE. Values and error bars represent average and standard deviations,
respectively, of three independent experiments (P <0.05).
Next, we performed a clonogenic or colony formation assay that evaluates the capacity of
a cell to proliferate indefinitely upon drug removal to form a colony or clone (Figure 2.1C). The
most resistant cell line (i.e. highest IC50), PC-3, was selected for clonogenic assay and
subsequent studies to delineate mechanisms of SPGE action. While controls produced several
colonies, only a fraction of SPGE-treated cells retained the ability to form colonies. Figure 2.1C
shows the effect of 250 µg/ml SPGE on the relative clonogenicity of control and SPGE-treated
PC-3 cells. Representative micrographs of colonies in control and SPGE-treated cells shown at
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the apex of bar graphs quantitated to a ~80% reduction in number and size of surviving colonies
upon SPGE treatment (Figure 2.1C). We also examined nuclear Ki67 expression, which
correlates well with growth fraction and found that Ki67 immunostaining was significantly more
intense in control cells compared with 250 µg/ml SPGE-treated cells over 24 h (Figure 2.1Di).
Bar graph quantitation of Ki67-positive cells scored in both control and SPGE-treated cells
showed a ~82% decrease in treated cells (Figure 2.1Dii). Furthermore, 4’,6-diamidino-2phenylindole staining (Figure 2.1Di) indicated a ~5-fold increase in cells with nuclear
fragmentation (Figure 2.1Dii) compared with controls, suggesting SPGE-induced apoptotic cell
death. In addition, trypan blue data showed that SPGE-induced cell death over time (0, 12, 24, 48
and 72 h) at 250 µg/ml in PC-3 cells.
We next asked if SPGE-mediated growth suppression was due to its cell cycle
intervention. To this end, we evaluated the effect of varying dose and time of SPGE exposure on
the cell cycle progression of PC-3 cells. Figure 2.2Ai and 2.2Aii show dose and time courses of
SPGE treatment in a three-dimensional format. SPGE caused cells to accumulate in the G1 phase
at doses ~100 µg/ml over 24 h and at a dose of 250 µg/ml up to 12 h. This was followed by a
dose- and time-dependent increase in sub-G1 population, representing cells with hypodiploid
(~2N) fragmented DNA, a hallmark of apoptosis. The quantitation of sub-G1 population over
varying dose levels and times is shown in Figure 2.2Aiii and 2.2Aiv, respectively. Since SPGE
arrested cell cycle in the G1 phase at low doses and shorter time periods, we examined this acute
effect of SPGE on G1 phase regulators. Immunoblot analysis revealed a decrease in protein
levels of cyclin D1, cyclin A and cyclin E after 24 h of 250 µg/ml SPGE treatment (Figure 2.2B).
An increase in Cip1/p21 levels was evident at 24 h, in agreement with the G1 arrest (Figure
2.2B).
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Figure 2.2 SPGE perturbs cell cycle progression.
(A) SPGE perturbs cell cycle progression by causing a G1-arrest and increases sub-G1 cell
population, indicative of apoptosis. (Ai) Cell cycle progression over dose (0–600 µg/ml) and
(Aii) time (0–72 h) is shown in a three-dimensional format. (Aiii) Bar graphs depicting sub-G1
population of PC-3 cells treated with SPGE over varying doses and (Aiv) time. (P<0.05
compared with controls). (B) Immunoblots of cell lysates treated in absence or presence of 250
µg/ml SPGE for cyclins D1, A, E and p21. The protein levels were determined by quantifying
the pixel values of the protein bands using ImageJ on the immunoblots and normalized to the
measured value at 0 h treatment. Uniform loading was confirmed by β-actin. (Ci) Confocal
micrographs of Annexin-V-positive cells (staining at cellular rim) upon SPGE treatment for 48 h
and (Cii) quantitation of Annexin-V- or TUNEL-positive cells for vehicle and SPGE treatment
over time determined flow cytometrically. (P<0.05 compared with controls).
Although an increase of sub-G1 population upon SPGE treatment indicated fragmented
DNA suggesting apoptosis, we validated apoptosis both qualitatively and quantitatively by
Annexin-V

staining

using

confocal

microscopy

and

flow

cytometry

methods.

Immunofluorescence confocal micrographs showed that SPGE treatment for 48 h at 250 µg/ml
externalized phosphatidylserine to the outer leaflet of the plasma membrane (observed as a rim)
in PC-3 cells, a hallmark of early apoptosis (Figure 2.2Ci). Flow cytometric quantitation
suggested a steady increase in Annexin-positive cells to ~37% at 72 h (Figure 2.2Cii). It is well
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appreciated that altered cellular morphology, including membrane blebbing, formation of
apoptotic bodies, disruption of cytoskeleton, hypercondensation and fragmentation of chromatin
characterize termination of apoptosis. Thus, we next quantified the increase in concentration of
3’-DNA ends due to DNA fragmentation using a flow cytometry-based TUNEL assay. We found
that SPGE-treated cells showed ~42% TUNEL-positive cells (Figure 2.2Cii) at 72 h compared
with controls, suggesting extensive DNA cleavage.
Both extrinsic and intrinsic apoptotic pathways are well recognized as major mechanisms
of cell death in most cellular systems (Fulda and Debatin, 2006). Having identified that SPGE
induced robust apoptosis, we next evaluated whether the apoptosis was caspase driven. Our data
showed that treatment of PC-3 cells with SPGE did not result in caspase-8 activation and
cleavage (data not shown) indicating non-recruitment of the extrinsic apoptotic pathway.
However, SPGE demonstrated a strong time-dependent cleavage of caspase-3 and PARP, as
observed by immunofluorescence and immunoblotting methods (Figure 2.3Ai and 2.3Aii).
Caspase involvement was further confirmed by measuring caspase-3/7 activity using a
fluorescent substrate (Figure 2.3Aiii). Activation of caspase-3/7 without an effect on caspase-8
suggested involvement of the intrinsic pathway. To establish that this was the major mechanism
of SPGE-induced apoptotic death in PC-3 cells, we pretreated cells for 3 h with pan caspase
inhibitor z-vad-fmk followed by a 48 h treatment with 250 µg/ml SPGE treatment. The extent of
apoptosis was then determined by estimating the sub-G1 population flow cytometrically. We
observed that z-vad-fmk pretreatment significantly inhibited SPGE-induced apoptosis by 65%
(P<0.01), suggesting that cell death was primarily caspase mediated.
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Figure 2.3 SPGE activates the intrinsic apoptotic pathway.
(Ai) Immunofluoresence micrographs of vehicle-treated controls and 250 lg/ml SPGE-treated
cells stained for cleaved caspase-3 and PARP. (Aii) Immunoblot analysis of cleaved caspase-3
and cleaved PARP levels in cell lysates from vehicle-treated controls and SPGE treated PC-3
cells. (Aiii) Caspase-3/7 activity assay over time. SPGE alters mitochondrial transmembrane
potential. (P>0.05 compared with controls). (Bi) Histogram profiles and (Bii) quantitation of
cytosolic monomeric JC-1 in unstained, control and SPGE-treated cells that were read flow
cytometrically (P>0.05 compared with controls). SPGE-induced collapse of transmembrane
potential was measured by increased green fluorescence indicated by a right shift in the
fluorescence intensity curve. (Biii) Immunoblot analyses for p-Bcl2, total Bcl2, BAX and
cytosolic cytochrome c. The protein levels were determined by quantifying the pixel values of
the protein bands using ImageJ on the immunoblots and normalized to the measured value at 0 h
treatment or controls.
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We further confirmed intrinsic apoptosis by measuring the collapse of mitochondrial
transmembrane potential (Ψm) and examining release of mitochondrial cytochrome c into the
cytosol (Martinou et al., 2000). The effect of 24 h SPGE treatment on Ψm was observed by
staining with 5,5’,6,6’-tetrachloro- 1,1’,3,3’-tetraethylbenzimidazol-carbocyanine iodide (JC-1),
a cationic dye, which exhibits potential-dependent mitochondrial accumulation (Reers et al.,
1991). An increase in JC-1 monomeric form indicative of Ψm collapse was quantitatively
determined using flow cytometry. As seen in Figure 2.3Bi, 250 µg/ml SPGE-treated cells at 24 h
showed a right shift in the mean-fluorescence intensity of green JC-1 monomers compared with
controls. There was a ~90% increase in the mean-fluorescence intensity of SPGE-treated JC-1stained cells compared with controls (Figure 2.3Bii). Most often, disruption of Ψm accompanies
alterations in expression level of Bcl2 members, in particular, the ratio of antiapoptotic Bcl2 to
proapoptotic BAX. We found that a 24 h 250 µg/ml SPGE treatment increased the levels of
phosphorylated Bcl2 indicating its inactivation, whereas total Bcl2 levels remained unchanged
(Figure 2.3Biii). A significant increase in BAX levels was observed at 24 h of SPGE treatment
(Figure 2.3Biii). In addition, cytosolic cytochrome c was elevated upon a 24 h SPGE exposure
(Figure 2.3Biii). Thus, these data strongly indicated a mitochondrially driven apoptosis upon
SPGE treatment. We further confirmed the extent of contribution of the mitochondrial pathway
toward SPGE-induced apoptosis using cyclosporin A, a mitochondrial permeability transition
pore inhibitor. Our results show that pretreatment of cells with cyclosporin A for 3 h before
SPGE treatment for 24 h resulted in ~38% sub-G1 population compared with ~62% upon SPGE
treatment alone. Our experiments to study the drop in Ψm correlated with our flow cytometry
data, in that we observed a diminution of the number of cells with depolarized mitochondria
when cyclosporin A was added 3 h before SPGE treatment compared with when SPGE was
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administered alone. This is clearly indicative of the protective effect of cyclosporin A. These
results suggest that there is a significant mitochondrial component to the total apoptotic response
of SPGE.
2.4.2

Oral SPGE feeding significantly inhibits PC-3 tumor growth, induction of apoptosis
and is non-toxic
Having identified significant in vitro antiproliferative and proapoptotic activity of SPGE,

we were curious to examine the in vivo efficacy of SPGE to inhibit human prostate tumor
xenografts subcutaneously implanted in athymic nude mice. We employed a PC-3 cell line
stablyexpressing luciferase (PC-3-luc) that allowed real-time visualization and monitoring of
prostate cancer growth non-invasively. Animals in the treatment group were fed daily with 400
mg/kg body wt SPGE by oral gavage for 6 weeks and treatment responses were followed by
bioluminescent imaging in longitudinal studies using the same cohorts of mice (Figure 2.4Ai). In
vehicle-treated control animals, tumors showed unrestricted progression (Figure 2.4Ai and Aii).
In contrast, SPGE feeding showed a time-dependent inhibition of tumor growth over .6 weeks
(Figure 2.4Ai and Aii), though significant retardation was evident as early as 2–3 weeks post
treatment (Figure 2.4Aii). Quantification of relative photon counts revealed a 69%reduction in
tumor volume with a confidence level of P<0.05 (n=8, Figure 2.4Aii) at week 6 compared with
vehicle-treated controls. To assess overall general health and well being of animals during
treatment, body weights were recorded twice a week. SPGE treatment was well tolerated and
mice maintained normal weight gain (Karna et al., 2011b) with no signs of discomfort during the
treatment regimen. To corroborate our bioluminescent imaging data, we also measured tumor
volumes using a vernier caliper. As shown in Figure 2.4Bi, tumor volume measurements
demonstrated that oral SPGE treatment for 6 weeks (42 days) reduced tumor volume by ~75%.
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All animals in the control group were euthanized by day 42 postinoculation due to tumor
overburden, in compliance with Institutional Animal Care and Use Committee guidelines. At the
end point of animal experiments (week 6), the excised tumors (Figure 2.4Bii) were weighed and
a ~65% reduction in tumor weight was observed in SPGE-treated group compared with controls.
We next determined the longevity of surviving mice by monitoring them for general health and
well being for 10 weeks. Kaplan–Meier analysis revealed a significantly increased survival time
with 87.5% animals treated with SPGE surviving until 10 weeks (P<0.05; Figure 2.4C). This was
a significant prolongation of survival compared with controls where median survival time was
only 6 weeks.

Figure 2.4 Dietary feeding of SPGE inhibits human prostate tumor xenograft growth in
nude mice.
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Male nude mice were subcutaneously injected with 106 PC-3-luc cells. (Ai) Bioluminescent
images indicating inhibition of tumor growth over a period of time. (Aii) Graphical
representation of the quantitative photon count from control and SPGE-treated mice for 6 weeks.
(Bi) Tumor growth monitored (by vernier calipers) and presented as tumor volume in cubic
millimeters, over a period of 42 days. (Bii) Photographic images of excised tumors and graphical
representation of tumor weight. (C) Kaplan–Meier survival graphs of SPGE treatment over 10
weeks. (P<0.05, Aii, Bi).
To evaluate the in vivo effect of SPGE feeding on the antiproliferative response
associated with tumor growth inhibition, tumor tissue lysates were analyzed for cyclins
(including cyclins D1, A, E) and cyclindependent kinase inhibitor, p21, using immunoblotting
methods (Figure 2.5A). SPGE treatment caused a decrease in cyclin D1, A and E, which
correlated with our in vitro findings in PC-3 cells (Figure 2.5A). In addition, p21 upregulation
was evident as a potential mechanism of cell cycle inhibition of tumor cells (Figure 2.5A), which
was in accordance with the G1 phase cell cycle arrest observed in vitro. In vivo apoptotic
response of SPGE feeding in PC-3-luc tumor xenografts was evaluated by caspase 3/7-activity
assay and immunoblotting of tumor lysates for cleaved caspase-3 expression. As expected,
cleaved caspase-3 expression (Figure 2.5A) as well as caspase-3/7 activity (Figure 2.5B) was
higher in SPGE-treated tumors compared with controls. We further asked if SPGE caused
regression of xenografted tumors by inhibiting proliferation and triggering apoptosis.
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Figure 2.5 Tumor tissue lysates express high apoptotic and low proliferation markers.
(A) Western blot analysis, (B) Caspase-3/7 activity (P<0.05), (Ci) hematoxylin and eosin, (Cii)
Ki67, (D) cleaved caspase-3 and PARP from control and 400 mg/kg body wt SPGE-treated mice
tumors.
Hematoxylin and eosin-stained tumor sections from SPGE-treated animals revealed large
areas of tumor cell death seen as tumor necrosis adjacent to normal looking healthy cells.
Significant loss of tumorigenic cells in SPGE-treated animals (Figure 2.5Ci, right, arrow) was
consistent with the therapeutic effect of SPGE. However, some viable tumor cells were observed
at the periphery of cell death zones. In contrast, microsections from control tumor tissues
revealed sheets of tumor cells with high-grade pleomorphic nuclei and angiolymphatic invasion
(Figure 2.5Ci, left). Furthermore, Ki67-stained tumor sections from SPGE-fed animals showed
weak immunoreactivity (Figure 2.5Cii) compared with vehicle-fed animals. Tumor sections from
SPGE-treated groups also showed a marked increase in cleaved caspase-3 and PARP staining
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(Figure 2.5D) compared with vehicle-fed controls, suggesting induction of robust apoptosis in
tumors from SPGE-treated mice.
Toxicity, particularly in tissues with actively proliferating cells, remains a major concern
in prostate cancer patients treated either radiotherapeutically or by chemotherapeutic drug
regimes. We found that there were no detectable differences in the histological appearance of
tissues including the gut, liver, spleen, lung, brain, heart, testes and bone marrow from vehicle
and SPGE-treated tumor-bearing mice (Karna et al., 2011b). In addition, colonic crypts from
both mice groups showed comparable nuclear Ki67 staining, suggesting that SPGE did not affect
normal tissues with rapidly proliferating cells. Furthermore, complete blood count (e.g. red blood
cells, white blood cells, lymphocytes, hemoglobin), serum biochemical-profile markers [alanine
transaminase, aspartate transaminase, alkaline phosphatase for hepatic function and creatinine,
blood urea nitrogen and electrolytes including potassium, magnesium, sodium, calcium and
chlorides for renal function] were within the normal range and similar between the control and
SPGE-treated groups (Karna et al., 2011b).
2.4.3

Identification of constituent bioactive phytochemicals via fractionation of SPGE
Given the significant activity of SPGE, we next attempted to examine and identify its

bioactive constituents. To this end, we first performed a simultaneous on-line HPLC–UV and
HPLC–mass spectrometry (MS) comparative detection in both positive and negative ion modes
for SPGE using acetonitrile (ACN):water (H2O) solvent system. The HPLC–UV chromatograms
show the appearance of 11 peaks (Gundala et al., 2013). However, when SPGE passed through
the MS detector after eluting from UV detector, new peaks appeared in both positive and
negative ion modes, which were lacking UV chromophores. Two bioconstituents, ChA and
caffeic acid (CA) with m/z values of 353.0 and 179.0, respectively, have been successfully
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identified in SPGE using tandem-mass spectrometry (MS–MS) technique. The multiple reaction
monitoring comparison for the respective product ions, 191 for ChA and 135 for CA, between
SPGE and a mixture of pure standards confirmed the presence of both caffeic and ChAs in
SPGE. However, two additional peaks were observed to be having the same m/z values as the
product ion of ChA (which was not seen in case of pure standards), thus raising a possibility of
the presence of ChA derivatives, which follow similar fragmentation pattern (353/191).
2.4.4

A moderately polar fraction, F5, enriched of major SPGE phenolics exhibits
remarkable antiproliferative activity in prostate cancer cells
To gain insights into the nature of compounds present in the whole extract, we employed

a “top-down logic” wherein we fractionated the whole extract using classical column
chromatography (Figure 2.6). This led to the sequential separation of sub-fractions from the
complex whole extract based upon their physicochemical characteristics such as polarity and
solubility. To achieve optimal fractionation of SPGE, we employed a mobile phase system that
ranged from the non-polar hexanes to highly polar methanol. The methanolic extract of SPGE
was loaded onto the column and binary solvent combinations were used as the mobile phase.
Finally, passing 100% methanol through the column ensured complete elution of all compounds.
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Figure 2.6 Fractionation of SPGE using column chromatography.
17 fractions were obtained by separating the sweet potato leaf extract with various solvent ratios
using column chromatography as mentioned in the scheme (top-panel).
The 17 fractions thus obtained were subjected to TLC and fractions with comparable Rf
values were pooled together to finally yield 7 fractions (Figure 2.7A). Our next step was to
perform a comparative quantitation of total polyphenolic content of all 7 SPGE fractions. Using
Folin-Ciocalteu method, different fractions showed varying total polyphenolic content (Figure
2.7B). The quantitative comparison revealed that F5 contains ~2-fold higher phenolic content as
compared to SPGE (Figure 2.7B). Given that polyphenolic content has been correlated with
bioactivity, these data prompted us to examine the in vitro efficacy of the various SPGE
fractions.
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Figure 2.7 Fractionation and evaluation of bioactivity of various SPGE fractions.
(A) TLC of 17 SPGE fractions using an ethyl acetate:hexane (2:1) system for fractions 1–8;
dichloromethane:methanol (3:1) for fractions 9–11 and 2:1 dichloromethane:methanol for
fractions 12–17. Fractions with similar Rf profiles were pooled together to finally obtain seven
fractions. Quantitation of total polyphenol content in all SPGE fractions. (B) Quantitation of total
phenolic content of all the SPGE fractions quantified via FC method. SPGE and its fractions
inhibit proliferation of PC-3 prostate cancer cells. (C) Plot of cell survival versus concentrations
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of fractions tested for PC-3 cells. The IC50 values are indicated in the legend of line plot. Cells
were treated for 48 h with increasing gradient concentrations of the seven fractions (F1–F7) and
the parent SPGE. The percentage of cell proliferation was measured by MTT assay. (D)
Determination of IC50 of F5. PC-3 cells were treated with the most active fraction, F5, from four
different batches at increasing concentrations (0.075–10 µg/ml) for 48 h. The percentage cell
proliferation was measured by MTT assay. (E) F5 shows enhanced inhibition of proliferation in
various prostate cancer cells. Bar graphical representation of IC50 values (mentioned above) of
SPGE and F5 tested in DU145, 22Rv1, LNCaP and C4-2 cells. Cells were treated for 48 h with
increasing gradient concentrations of SPGE and F5. The percentage of cell proliferation was
measured by MTT assay. (F) F5 inhibits the clonogenic capacity of prostate cancer cells. Bar
graphical representation and photograph of crystal violet-stained surviving colonies from control
and F5-treated groups. Results shown are means from three independent experiments (*, P<0.05
compared with controls).
Hence, we next determined the half-maximal concentration of growth inhibition (IC50)
for the 7 SPGE fractions in PC-3 cells using the MTT assay. The IC50 values of F1-F7 were in
the range of ~1-200 µg/ml (Figure 2.7C). Indeed the differential total phenolic content and
polarity of various components that define a fraction might underlie the range of antiproliferative
activity displayed by these fractions. Intriguingly, among the 7 fractions, fraction 5 (F5) was the
most active and its IC50 value was initially calculated to be approximately 1 µg/ml (Figure 2.7C).
To precisely determine the IC50 value of F5, we then tested still lower concentrations (0.075, 0.1,
0.5, 1, 5 and 10 µg/ml) of F5 sub-fraction obtained from 4 different batches (F51, F52, F53 and
F54) in PC-3 cells (Figure 2.7D). The IC50 of F5 was found to be within a range of 0.794-1.5
µg/ml (Figure 2.7D), which was ~100 fold more potent compared to the whole SPGE extract
(IC50=100 µg/ml). In addition, F5 exhibited better efficacy in other prostate cancer cell lines
(LNCaP, 22Rv1, DU145 and C4-2) (Figure 2.7E) compared to SPGE suggesting the generality
of the effect of F5 on a variety of prostate cancer cells.
We next performed a clonogenic or colony formation assay to evaluate the capacity of a
cell to proliferate to form a colony upon removal of the drug. F5’s antiproliferative activity was
demonstrated when several PC-3 colonies were observed in case of control, while the F5-treated
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cells were found to only partially retain their colony forming ability (Figure 2.7F). The relative
clonogenicity of control versus F5-treated PC-3 cells can be visually observed in the
representative micrographs shown above the bar graphical quantitation of the colonies in Figure
2.7F.
Having identified the differential bioactivity of SPGE fractions, our next step was to
perform a comparative quantitation of the phenolics present in all the 7 SPGE fractions by LCUV/MS analysis. Three major phenolics, quinic acid (QA, m/z=191), caffeic (CA, m/z=179) and
chlorogenic (ChA, m/z=353) acids were identified to be present in SPGE, along with other
isochlorogenic

acids

like

4,5-di-caffeoylquinic

acid

(4,5-di-CQA,

m/z=515),

3.5-di-

caffeoylquinic acid (3,5-di-CQA, m/z=515) and 3,4-di-caffeoylquinic acid (3,4-di-CQA,
m/z=515) (Figure 2.8Aii,B-Bi). Further analysis of F1 through F7 compared to SPGE
demonstrated the differential relative abundance of the major phenols, QA, CA and ChA and the
3 isochlorogenic acids (Figure 2.8A, Ai-Aii). For example, F1 and F2, the fractions of lower
polarity, showed an absence of QA, CA and 4,5-di-CQA (Figure 2.8A, 2.8Ai-Aii). The CA
content was found to be high in F3 and F4 as opposed to the ChA amounts (Figure 2.8Ai).
However, the most-active fraction, F5 exhibited the highest amounts of QA and ChA (Figure
2.8A, 2.8Ai-Aii). The enrichment of 4,5-di-CQA, 3,4-di-CQA and 3,4-di-CQA was observed
from F3 onwards (Figure 2.8A,Aii). However, there was a decrease in their quantities in F6 and
F7 as compared to F4 and F5 (Figure 2.8Aii). F4 was found to be enriched in all the 3
isochlorogenic acids with 3,5-di-CQA being the most abundant, whereas the content of 3,4-diCQA is enhanced in F5 (Figure 2.8A,Aii). Fractions 6 and 7 exhibited a decrease in the
composition of isochlorogenic acids.
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Figure 2.8 F5 exhibited the presence of major phenols of SPGE.
(A) LC-UV/MS comparison of constituents present in F1–F7 with respect to SPGE. Quantitation
of the identified phenols, that is, QA, CA and ChA in F1–F7 and SPGE was obtained by
performing a standard curve analysis using pure standards. Three other compounds, 4,5-di-CQA,
3,5-di-CQA and 3,4-di-CQA, were quantitated relative to each other using the area under the
curves. (Ai) Varying concentrations of QA, CA and ChA in all SPGE fractions. (Aii) Varying
concentrations of 4,5-di-CQA, 3,5-di-CQA and 3,4-di-CQA in all SPGE fractions. (Bi) Different
amounts of bioactive constituents such as neochlorogenic acid (nChA, m/z = 353),
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cryptochlorogenic acid (cChA, m/z = 353), quercetin-glucoside (QnG, m/z = 463) and its isomer
(QnG isomer, m/z = 463), quercetin (Qn, m/z = 447) and astragalin (m/z = 447) in SPGE versus
F5 were identified using HPLC–UV/MS and tandem mass spectrometry (LC-MS/MS) analyses.
(B) Tandem-mass spectrometry identification of 12 constituents (QA, nChA, cChA, ChA, CA,
QnG, QnG isomer, 4,5-di-CQA, astragalin, Qn, 3,5-di CQA and 3,4-di-CQA) and 10 other
unknown m/z values (u1–u10) in F5 and SPGE. Values and error bars represent average and
standard deviations, respectively, of three independent experiments.
The remarkable efficacy of F5 prompted us to examine the composition of this potent
fraction. LC-UV/MS analysis of both SPGE and F5 confirmed the differential abundance of
several phenolic compounds (Figure 2.8B-Bi), which were found to be enriched in F5. The
hydroxycinnamic acids, ChA and CA along with QA in SPGE and F5 were quantitated using the
respective pure standards. Tandem-mass spectrometric analysis affirmed the presence of QA,
ChA and CA in SPGE and F5 (Figure 2.8B-Bi). The selected ion monitoring (SIM) of QA (191),
ChA (353) and CA (179) confirmed their elution in both F5 and SPGE exactly at the same
retention times (Figure 2.8A,Bi). Notably, the ratio between QA, ChA and CA differed between
F5 and SPGE. The ratio of QA:ChA:CA in F5 has been (as observed in Figure 2.8Ai) calculated
to be 6:1:0.005, whereas these same compounds existed in a 9:1:0.6 ratio in SPGE (Figure
2.8Ai). On the other hand, the isochlorogenic acids were found to be in a ratio of 1:3:4.6 in F5 as
compared to the 1:3:1.4 seen in SPGE (Figure 2.8Aii). Furthermore, the chemical fingerprints of
F5 and SPGE as seen in Figure 2.8B-Bi, establish an obvious difference between their
compositions. For example, the compound u4 with m/z value of 385 could not be observed in
SPGE, whereas it was present at quantifiable levels in F5. QnG including 4 other unknown
compounds, u5-u8, were absent in F5. Among the major phenolics, there was an approximately
2.6 (QA), 3.6 (ChA), and 3 (3,4-di-CQA) fold increase in F5 compared to SPGE. It is thus
reasonable to speculate that these differences might be responsible for the higher bioactivity of
F5 compared to SPGE in prostate cancer cells.
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2.4.5

Subfractionation of F5 results in loss of bioactivity indicating synergism among F5
phytochemicals
Our next question was to examine if sub-fractionation of F5 into its constituent

components employing analytical liquid chromatography resulted in identification of singleagents that were much more active compared to the whole fractions. Repeated injections of 10µl
of F5 were made into the HPLC system and the eluate from 0-25 min was collected as subfraction, F5-A (Figure 2.9Ai) and the remaining part from 25.1-50 min as F5-B (Figure 2.9Aii).
As seen in Figure 2.9Ai-Aiii, F5-A is a combination of QA, ChA and CA, whereas F5-B
constituted the 3 isochlorogenic acids. These sub-fractions thus obtained were concentrated and
lyophilized. Next, we again employed a bioactivity-guided approach to determine the efficacy of
F5 sub-fractions. Both the sub-fractions were reconstituted in DMSO to yield 1 mg/ml stock
solutions which were then used to dose PC-3 cells at gradient concentrations for 48 h. An MTT
assay performed post-incubation showed that neither of the individual sub-fractions was as active
as F5. Intriguingly, F5-A and F5-B did not show 50% inhibition of cell growth even at the
highest test concentration (250 µg/ml) and hence, their IC50 values could not be determined
(Figure 2.9B). This clearly indicated that F5-A needs F5-B and vice versa to mimic F5’s activity,
hence suggesting a synergistic interplay among F5’s constituents. Additionally, the clear
differences between the compositions of each sub-fraction compelled us to investigate if the loss
of activity in the sub-fractions was related to their respective compositions.
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Figure 2.9 Subfractionation of F5.
(Ai) The chromatographic profile of F5 in MS scan mode. F5 was collected as two parts, F5-A
(0–25 min) and F5-B (25.1–50 min) by injecting F5 for 17 times in the analytical HPLC system.
MS scan mode chromatograms confirm the presence of (Aii) QA, ChA and CA in F5-A, (Aiii)
4,5-di-CQA, 3,5-di-CQA and 3,4-di-CQA in F5-B. (B) Line plot of percentage cell survival
versus concentration of F5 sub-fractions, F5-A and F5-B, tested against PC-3 cells. Cells were
treated for 48 h with increasing gradient concentrations of the two sub-fractions of F5 and F5.
The percentage of cell proliferation was measured by MTT assay. (C) Line plot of percentage
cell survival versus concentration of a combination of QA, ChA and CA in increasing gradient
concentrations treated for 48 h in PC-3 cells. The percentage of cell proliferation was measured
by MTT assay. The test mixture of the three pure standards was constituted based upon their
individual concentrations as in F5. Results shown are means from three independent
experiments.
To corroborate this observation, we next tested commercially-available QA, ChA and CA
in combination at varying concentrations against PC-3 cells (Figure 2.9C). Quantitative data
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points out that 1 mg of F5 contains 115 µg of QA, 16 µg of ChA and 0.1 µg of CA. Given the
IC50 value of F5 is approximately 1 µg/ml (based on the range of 0.794-1.5 µg/ml, Figure 2.7D),
F5 (1 µg) actually consists of 115 ng QA, 16 ng ChA and 0.1 ng CA. Assuming that these three
compounds are the major players that contribute to F5-A’s activity, we tested the bioactivity of
the mixture of the three pure standards by measuring the percentage of cell proliferation using
the MTT assay. PC-3 cells were treated with this mixture in an increasing gradient concentration
(0.075, 0.1, 0.5, 1, 5 and 10 µg/ml) ensuring that the relative quantities of the three compounds
(QA+ChA+CA, the major constituents of F5-A), at each test concentration bore the same
ratiometric relationship as was observed between them in F5. This mixture formulation thus
mimicked the composition of F5-A (as it exists in F5). Evaluation of the in vitro efficacy of this
subfraction might also enable exclusion of the possible antagonism of other yet unknown
phytochemicals in F5-A. Our data suggested that even at the highest concentration tested (10
µg/ml), the formulated mixture of pure standards did not show 50% inhibition in cell growth. As
the pure standard mixture of three compounds could not reproduce equivalent efficacy as of F5,
we speculate that the other unknown components in F5-A perhaps did not exert an antagonistic
influence (Figure 2.9C). Thus our results from in vitro experiments testing various combinations
of pure standards (QA, ChA and CA) suggested that higher efficacy of F5 could not only be
ascribed to enhanced total polyphenolic content but also to possible synergistic interactions
associated with definitive ratiometric composition of these phenolics.
The other sub-fraction, F5-B also tested to be non-active (Figure 2.9B). Hence, the loss of
bioactivity in both sub-fractions F5-A and F5-B individually suggested existence of synergism
among the characterized and the yet unknown F5 components. It is perhaps likely that other
identified compounds such as Qn, nChA, cChA, QnG, AGN contribute to uphold the superior
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activity of F5. These data also emphasize the importance of the occurrence of QA, ChA, CA,
4,5-diCQA, 3,5-di-CQA and 3,4-di-CQA in a distinct ratio, as found in F5 to display remarkable
activity. To further substantiate our in vitro data, we tested the efficacy of F5 in an in vivo
prostate xenograft model as discussed in the next section.
2.4.6

Oral feeding of F5 inhibits prostate tumor growth in vivo and is non-toxic
Given the significant difference in the in vitro anti-proliferative activity of F5 compared

to SPGE, we next evaluated its in vivo efficacy to inhibit human prostate tumor xenografts
subcutaneously implanted in athymic nude mice. We employed a PC-3 cell-line stablyexpressing luciferase (PC-3-luc), which enables real-time visualization and longitudinal
monitoring of prostate cancer growth non-invasively in mice. We have previously shown that
SPGE inhibits the in vivo tumor growth by 69% (Karna et al., 2011b). We found that the
treatment group fed with 400 mg/kg bw F5 daily by oral-gavage for six weeks (Figure 2.10Ai)
showed a time-dependent inhibition of tumor growth (Figure 2.10Ai-ii, B), compared to the
vehicle-treated control animals. A relative total flux quantitation revealed a ~75% inhibition in
tumor-volume with a confidence level of p<0.05 (n=8, Figure 2.10Aii) as measured at week 6 for
the F5-fed group compared to vehicle-treated controls. All animals in the control group were
euthanized due to tumor overburden, in compliance with institutional IACUC guidelines. At the
end of week 6, the excised tumors (Figure 2.10Ci-ii) were weighed post-euthanasia and a ~74%
reduction in tumor weight was observed in F5-treated groups respectively, compared to controls.
Body weights were recorded twice a week to evaluate the general-health and well-being of
animals during treatment. Mice in the F5 treatment group exhibited normal weight gain with no
signs of discomfort during the treatment regimen (Figure 2.10D).
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Figure 2.10 Dietary feeding of F5 showed enhanced inhibition of human prostate tumor
xenograft growth in nude mice compared with SPGE.
Male nude mice were subcutaneously injected with 106 PC-3-luc cells. (Ai) Representative
bioluminescent images of one animal per group, indicating progression of tumor growth over 6
weeks. (Aii) Graphical representation of quantitative radiance measured as the number of
photons leaving a square centimeter of tissue and radiating into a solid angle of 1 steradian
(photons/s/cm2/sr) from vehicle- and F5-treated mice for 6 weeks. (B) Tumor growth monitored
(by vernier calipers) and presented as tumor volume in cubic millimeter over a period of 6
weeks. (Ci) Graphical representation of tumor weight. (Cii) Photographic images of excised
tumors. (D) Graphical representation of body weight of vehicle- and F5-treated mice [*, P < 0.05
(two-way analysis of variance), Aii, B and C].
To evaluate in vivo inhibition of tumor growth upon oral feeding of F5, we
immunostained for Ki67 (MIB-1), a well-known marker of cell proliferation. Essentially, the
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Ki67 antigen is a non-histone protein expressed in all phases of the cell cycle except G0. We
found that Ki67-stained tumor sections from F5-fed animals showed decreased immunoreactivity
(Figure 2.11A) compared with vehicle-fed animals. Tumor sections from F5-treated groups also
showed an increase in cleaved caspase-3 and PARP staining (Figure 2.11Ci and Cii) compared
with vehicle-fed controls, suggesting induction of robust apoptosis in tumors from SPGE-treated
mice. Furthermore, the tumor tissue lysates were immunoblotted for cyclin D1 and the apoptotic
markers, cleaved caspase-3 and cleaved PARP (Figure 2.11B). Cyclin D1 plays a central role in
the regulation of proliferation, linking extracellular signaling environment to cell cycle
progression. There was a decrease in cyclin D1 expression in F5-fed tumor lysates suggesting a
cessation of cell-cycle progression. Further, as expected, the cleaved caspase-3 and PARP
expression (Figure 2.11B) were higher in F5-treated tumors compared with controls. Similar
trend was observed in PC-cell lysates, where F5 treatment showed increased cleaved PARP
expression compared with controls.
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Figure 2.11 F5 induces apoptosis.
Histochemical micrographs of tumor tissue sections from control and 400 mg/kg F5-fed groups
stained for (Ai) hematoxylin and eosin and (Aii) Ki67. (B) Western blot analysis of tumor tissue
lysates probed for cleaved caspase-3, cleaved PARP and cyclin D1. β-Actin was used as a
loading control. Immunofluorescence micrographs of tumor sections from control and 400 mg/kg
body wt F5-treated mice stained for (Ci) cleaved caspase-3 and (Cii) cleaved PARP. All images
and blots shown are representative of three independent experiments.
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Toxicity is overly concerning and is often observed in prostate cancer patients
undergoing either radio or chemotherapy. The histopathological evaluation of the tissues of
intestine, spleen, liver, lung, brain, heart, adrenal gland, and testes from both vehicle- and F5-fed
mice (Figure 2.12A), revealed no detectable differences in architecture. Furthermore, analysis of
biochemical markers in the sera (alanine transaminase, aspartate transaminase, alkaline
phosphate, lactic acid dehydrogenase, creatinine kinase, and urea nitrogen) collected from both
vehicle- and F5-fed mice was observed to be within the normal range (Figure 2.12Bi-iii).

Figure 2.12 F5 is non-toxic.
(A) The panels represented above are paraffin embedded; 5 µm thick tissue sections of intestine,
liver, spleen, lung, brain, heart, testes and adrenal glands stained with hematoxylin and eosin and
observed using a Å~20 objective. No visible differences were observed between the vehicle- and
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F5-fed groups. (B) Organ-associated toxicity was not observed in F5-fed group. (Bi) Urea
nitrogen levels in F5-fed group were comparable with that of vehicle-fed group. (Bii) The lactate
dehydrogenase (LDH) and creatinine kinase levels in both the groups did not show any abnormal
differences. (Biii) The biomarkers of liver, alkaline phosphatase (ALP), alanine aminotransferase
(ALT) and aspartate aminotransferase (AST) were comparable for both the groups.
2.5

Discussion
The management of advanced prostate cancer or prostate cancer after androgen therapy

failure poses a critical challenge because options such as radiotherapy and chemotherapy are
associated with serious side effects. Several studies in recent years have convincingly shown that
chemopreventive agents affect the process of carcinogenesis by targeting pathways such as
carcinogen activation, detoxification, DNA repair, cell cycle progression, differentiation and
induction of apoptosis in transformed cells. Besides displaying potent anticancer activity, the
’golden-rule’ for an agent to qualify as a chemopreventive is that it should be well-tolerated,
non-toxic, easily available and inexpensive.
Fruits and vegetables are excellent sources of chemotherapeutic and chemopreventive
agents (Block et al., 1992) and there is a uniformity of opinion emphasizing consumption of five
or more servings of fruits and vegetables daily to minimize the risk of cancer (Williams, 1995).
Several plant-based food extracts have been shown to be effective in cancer therapy and
prevention such as ripe berry extracts and grape seed extracts (Kaur et al., 2009; Li et al., 2009;
Sharma et al., 2004; Xie et al., 2009). Essentially, the beneficial effects of fruits and vegetables
are due to their constituent phytochemicals that include polyphenolics, anthocyanins,
carotenoids, alkaloids and nitrogen and sulfur compounds. These phytochemicals have been
shown to target multiple events of neoplastic stages to confer therapeutic benefits and reduce
overall cancer risk (Boyer and Liu, 2004; Ulrich et al., 2006). In addition, several reports indicate
that a variety of naturally occurring compounds such as grape seed extract, silibinin, green tea
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catechins and apples also play an important role in the prevention and treatment of prostate
cancer (Bettuzzi et al., 2006; Chen et al., 2004; Raina et al., 2007a; Raina et al., 2007b).
Although widely consumed as a vegetable in several parts of the world such as West
Africa and Asia (Mosha and Gaga, 1999), SPG represent an untapped food resource in the USA.
According to a United States Department of Agriculture report, the greens can be consumed in
several forms including raw, cooked, steamed and processed. In addition, the polyphenolic
content in leaves is much higher than in other parts of sweet potato such as the petioles, outer
skin and storage root (Islam, 2006). Several other reasons exist that merit the encouragement of
SPG as a more common vegetable in the USA. Firstly, oxalic acid content, which is a concern in
vegetables because of its predisposition to form crystals within the kidneys is roughly one-fifth
in SPG compared with spinach. Secondly, as a crop, SPG is more tolerant to diseases, pests and
moisture than any other leafy vegetable grown tropically. SPG may be grown even during
monsoon season of the tropics thus making it the only vegetable that can be grown right after
floods or typhoons. Finally, this vegetable can be harvested several times during the year (Islam
et al., 2002b). Because of these attributes, sweet potatoes one of the crops selected by US
National Aeronautics and Space Administration (NASA) to be grown in a controlled ecological
life support system as a primary food source (Wilson et al., 1998).
Several groups, mostly from Japan, have characterized various polyphenolics and
anthocyanins present in SPG (Islam et al., 2002a). A recent study reported the growthsuppressive activity of sweet potato leaves in colon cancer cells (Kurata et al., 2007). Given the
several health-promoting attributes of SPG, the principle objective of the present study was to
evaluate and establish the anticancer efficacy and associated mechanisms of SPGE treatment in
human prostate cancer cells in vitro and to translate these findings to an in vivo preclinical cancer
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model. Our study reveals that SPGE causes cell growth inhibition induces G1 phase arrest
accompanied by upregulation of p21 and induction of apoptosis in PC-3 cells. In these studies,
downregulation of cell cycle effectors, in particular the G1 cyclins, including cyclins D1, A and
E is revealed as a plausible antiproliferative mechanism of SPGE in PC-3 cells.Selective
induction of apoptosis is a highly desirable trait of ideal chemopreventive and chemotherapeutic
regimens. Our data showed that SPGE efficiently induces apoptosis in PC-3 cells as determined
by Annexin-V- and TUNEL-staining assays. Insights into molecular mechanisms reveal that
SPGE-induced apoptosis is largely mitochondrially mediated and associated with the collapse of
the transmembrane potential which results in the expulsion of key apoptogenic molecules such as
cytochrome c from the mitochondria. Oral feeding of SPGE remarkably inhibits tumor growth,
which is accompanied by antiproliferative and proapoptotic effects together with a decline in
cyclin levels, increased expression of p21 and activated caspase-3.
Although dismaying, it is true that present day chemotherapeutic approaches for cancer
patients can be as deadly as the disease itself. Toxicity normally includes myelosuppression,
immunosuppression, cardiotoxicity and peripheral neuropathy. To assess safety of SPGE, we
evaluated hematologic and histopathological toxicity and found no deviations in hematologic
variables andorgan-associated toxicities in treated mice compared with controls. In addition, the
acid–base and electrolyte balances in SPGE-treated animals were also normal compared with
controls. Finally, evidence for the potential usefulness of SPGE as a chemopreventive agent in
humans was postulated using a body surface area normalization method (Reagan-Shaw et al.,
2008). Using calculations involving the effective in vivo dose (400 mg/kg) data, the human
equivalent dose was determined to be 30 mg/kg SPGE. For an average, 70 kg adult, this
translates to an equivalent dosage of 2.1 g SPGE. Considering these facts and the United States
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Department of Agriculture’s Food Guide Pyramid, the human equivalent dose can be obtained
from 85 g, or about a half-cup of raw greens, which can be easily incorporated in a normal daily
diet.
The presence of polar acids eluting early (ChA and CA) with retention time, 10 min
(Gundala et al., 2013), and relatively non-polar compounds eluting later (peaks with retention
times >30 min) (Gundala et al., 2013), might facilitate fractionation of SPGE into two fractions
via HPLC–UV, using semipreparative higher diameter HPLC columns (allowing higher sample
loading) to further identify and characterize the bioactive constituent(s) present in SPGE. In the
light of a recent paradigm shift which recognizes that the anticancer attributes of fruits and
vegetables are due to an additive or synergistic interplay of the complex phytochemical mixtures
in whole foods (Liu, 2003), it is perhaps likely that the whole SPG extract works through
complementary and overlapping mechanisms to offer the most optimal benefits (Liu, 2003,
2004). In this case, single bioactive constituents may show anticancer activity at much higher
doses that may be toxic, whereas a mixture of multiple compounds may show enhanced activity
at lower non-toxic doses.
Although studies reporting the bioactive components of SPGE (Islam et al., 2002a; Islam
et al., 2002b; Truong et al., 2007; Yoshimoto et al., 2002) exist, variability in the extraction
methods employed preclude reliable interpretation of those bioactivity studies. In this study, we
have employed a relatively simple and holistic approach to make SPGE and have followed a
bioactivity-guided fractionation of the whole leaf extract to obtain and identify active
fractions/constituents. Our strategy using mobile-phase systems of varying polarity to elute
SPGE down the classical silica gel column to fractionate and elute components of different
polarities in different solvent systems has identified a medium-polar fraction, F5, (eluted via
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50:50 and 40:60 ethyl acetate and methanol system) that exhibited the highest antiproliferative
efficacy in prostate cancer cells (Figure 2.7C-D). F5 was determined to be ~100 fold more potent
compared to the parent, SPGE, which prompted us to further investigate F5’s composition.
Among the repertoire of bioactive polar phenols enriched in F5 we have identified quinic,
chlorogenic and caffeic acids in a distinct ratio (Figure 2.8A-Ai). The analytical data revealed
higher abundance of QA, and ChA over CA in F5 compared to the whole extract. As it can be
observed in Figure 2.8Ai, the pattern of QA:ChA:CA in F5 is similar to that in SPGE, but these
compounds are highly enriched in F5 compared to the parent whole extract. On the contrary, the
signature of isochlorogenic acids in SPGE differs from F5 (Figure 2.8Aii) wherein the most
abundant in the whole extract is 3,5-di-CQA and 3,4-di-CQA is maximally present in F5.
Furthermore, a seven-day stability study suggested a stable shelf-life of F5 when stored at 4oC,
as there were no variations in the concentrations of individual constituents that make up this
most-active fraction.
The in vitro efficacy of F5 was supported by the synergy study performed with the pure
standards in combinations (Figure 2.9C). This strengthened the concept that QA, ChA, CA, 4,5di-CQA, 3,5-di-CQA and 3,4-di-CQA act synergistically among themselves and with other
unknown components to exert maximum efficacy, and emphasized the importance of the ratio of
phytochemicals for the observed antiproliferative activity. This observation is further supported
by the quintessential green tea polyphenol concoction, Polyphenon E, which has been proven to
confer optimal anticancer benefits via a specific combination of five different catechins,
including epicatechin, gallocatechin gallate, epigallocatechin, epicatechingallate, and most
abundantly, EGCG (Bode and Dong, 2009). This specific formulation of green tea is in clinical
cancer trials funded through the National Cancer Institute to investigate the benefits of tea
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catechins in humans. Furthermore, sub-fractions of F5 could not outperform F5, suggesting the
potential additive or synergistic interactions among F5 phytochemicals (Figure 2.9B) supporting
our speculation. A similar observation made by Liu, et al., where the sub-fractions of black
raspberry extract’s active fraction, WBR-95, showed diminished antiangiogenic efficacy
compared to the refined parent (Liu et al., 2005), lends support to our observations as seen in
Figure 2.9.
Several studies suggest that individual foods or extracts may offer advantages over their
isolated constituents, suggesting that factors within foods may improve the absorption,
metabolism or retention of the bioactive food components, or that multiple bioactive compounds
within the food/extracts can exert additive or synergistic effects. However, in other scenarios, the
whole food or its extract itself may not be as effective as its isolated components, suggesting that
the food may contain other constituents, which can attenuate the response by negatively
modifying the absorption, metabolism, or site of action of the bioactive food constituent.
Surprisingly, we found that the in vivo efficacy of F5 was only slightly higher than the whole
parent SPGE extract, which may be due to the inherent complexity of in vivo physiological
systems. Though bioluminescence imaging measurement showed a ~75% tumor growth
inhibition observed in F5-fed group (Figure 2.10) compared to the vehicle-treated group, this
most-active fraction of SPGE could only improve the efficacy of the parent by a small ~10%
increment (Karna et al., 2011b). We speculate that this could be because of the disorganization
of the plant matrix or disruption of ‘natural milieu’ during the fractionation process, which could
have led to the loss of bioactive components that played a crucial role in dictating favorable
pharmacokinetic characteristics. We cannot exclude the possibility that F5 may require
interreactivity or dependency on other components in the whole food source to augment oral
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bioavailability, which means that systemic levels of the polyphenols achieved may be severalfold less than their effective concentrations in in vitro systems.
Although the rationale of pharmacological efficacy of single-isolated compounds over
whole foods exists, there are several factors like dose, bioavailability, metabolism and toxicity
favoring the latter. In particular, specific factors affecting phenolic bioavailability include matrix
of food sources, processing condition during food preparations, chemical compositions, and
molecular physicochemical properties of the phenolic molecules (Epriliati, 2012). The diverse
molecular forms of phenolics due to alterations in sugar moiety such as glycone or aglycone
analogs are known to cause variations in bioavailability levels (Epriliati, 2012). Furthermore,
gastrointestinal pH and enzymatic secretion levels, microbiota, and age have been established as
crucial factors affecting digestion and absorption of phytochemicals. Equally, the role of
interactions amongst food components and their interplay with gastrointestinal secretions
contribute significant effects in determining bioavailability of phytochemicals (Epriliati, 2012).
Quinic acid, enriched in F5 compared to the parent extract, is a common constituent of
our diet. Reports suggest that although quinic acid is not responsible for any efficacy, it
nutritionally supports the in situ synthesis of essential metabolites like tryptophan and
nicotinamide in the gastrointestinal (GI) tract. Hence, it in turn leads to DNA repair enhancement
and NF-kB inhibition via increased nicotinamide and tryptophan production (Pero et al., 2009).
The other phenolic acids in F5, namely CA and ChA, belong to the most abundant class of
polyphenols called hydroxycinnamic acids, that are widely present in a large variety of fruits and
vegetables (Clifford, 1999; Manach et al., 2004). Caffeic acid is the major representative of this
class and extensively exists as a conjugate with quinic acid as seen in chlorogenic acid (Clifford,
1999). Several reports have established that the bioavailability and efficacy of these
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hydroxycinnamic acids depend on their uptake and metabolism in the gut mucosa (Crespy et al.,
2003; Lafay et al., 2006; Manach et al., 2004). Literature suggests that while CA is readily
absorbed in the small intestine and can be detected in the blood plasma (Azuma et al., 2000;
Scalbert et al., 2002; Simonetti et al., 2001), ChA is poorly absorbed. However, ChA, is detected
only in the urine with no structural changes (De Maria, 2004; Ito et al., 2005), indicating its
differential metabolism as compared to CA. Though the metabolism of ChA is not well studied
and is controversial (Lafay et al., 2006), some groups believe that it is usually hydrolyzed into
CA and O-methylated metabolites in the lower intestine due to enzymatic reactions by the gut
microflora (Azuma et al., 2000; Lafay et al., 2006), suggesting that the bioactivity could be due
to CA. Considering this evidence, our quantitation data (Figure 2.8Ai) leaves us pondering if
higher levels of ChA in F5 are limiting its in vivo bioavailability and thus leveling its efficacy to
that observed for the whole extract. Another line of thought that seems plausible is that the
remarkable activity of F5 (containing high ChA) as observed in vitro is not recapitulated in vivo
due to limited absorption and metabolic conversions of ChA. Nonetheless, detailed
pharmacokinetic evaluation is warranted to delineate the discrepancy between the in vitro and in
vivo data.
Hence, as the natural balance of polyphenol content in SPGE is perturbed during the
fractionation process, the differences in the in vitro and in vivo absorption and metabolism
efficiencies due to this perturbation are likely to be responsible for the discrepancy observed
between the in vitro and in vivo efficacy. Intriguingly, our unpublished data reveal that the
composition of whole sweet potato greens extract and its sub-fractions thereof, is dependent on
the variety (Jewel or TU155), age of leaves at the time of harvest (30, 45, 60 or 75 days) and the
mode of processing of the leaves (air-dried, frozen or freeze-dried). Several other confounding
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variables such as cultivation season, soil, rainfall etc. are highly likely to play a role in
influencing the nature and composition of the plant extract. We thus envision that these varietal
differences in the total phenolic content, QA/ChA/CA and isochlorogenic acid content among
other unknown components may possibly affect the antiproliferative efficacy of the whole
extract and its derived fractions.
Nevertheless, the idea of non-toxic dietary supplements of specific phytochemicals in
defined ratios as in F5, would be beneficial to bypass the potential limitations in absorption and
assimilation of active whole food components, like variations in human genetic profiles affecting
nutritional absorption (German, 2005). Also, it is highly likely that the variability of unidentified
components in F5 and their standardization to constitute a therapeutic blend might provide
valuable insights for a clinical dietary intervention. It is extremely encouraging that F5 was able
to retain the anticancer attributes of the whole extract while demonstrating increased solubility,
generating impetus to propose its usefulness as a non-toxic dietary supplement, comprised of
specific phytochemicals in distinct ratios.
Our study is the first of its kind to provide evidence that phytochemicals, when present in
specific compositions, can impart superior efficacy and generates enthusiasm for testing the
efficacy of F5 in preventing disease recurrence as well as imparting chemopreventive benefits.
Our study reiterates the importance of the ‘natural milieu’ created by Mother Nature that exists
in whole foods and is perhaps preserved and enhanced in fractionated extracts for excellent
anticancer benefits. In conclusion, our study strengthens the evidence that plant polyphenols
exhibit synergism to confer efficacy to fruits and vegetables. This approach, attempting to
deconstruct the possible inherent synergies among the mixture of phytochemicals present in
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SPGE fractions, unveiled specific enrichment of components in F5 that nestle together to exert
superlative activity.
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3

IMPORTANCE OF SYNERGISTIC INTERACTIONS AMONG CONSTITUENT
PHYTOCHEMICALS OF WHOLE FOOD EXTRACTS3

3.1

Abstract
It is appreciated far and wide that increased and regular consumption of fruits and

vegetables is linked with noteworthy anticancer benefits. Extensively consumed as a spice in
foods and beverages worldwide, ginger (Zingiber officinale Roscoe) is an excellent source of
several bioactive phenolics, including non-volatile pungent compounds such as gingerols,
paradols, shogaols and gingerones. Ginger has been known to display anti-inflammatory,
antioxidant and antiproliferative activities, indicating its promising role as a chemopreventive
agent. In this chapter, we show that whole ginger extract (GE) exerts significant growthinhibitory and death-inductory effects in a spectrum of prostate cancer cells. Comprehensive
studies have confirmed that GE perturbed cell-cycle progression, impaired reproductive capacity,
modulated cell-cycle and apoptosis regulatory molecules and induced a caspase-driven,
mitochondrially mediated apoptosis in human prostate cancer cells. Remarkably, daily oral
feeding of 100 mg/kg body weight of GE inhibited growth and progression of PC-3 xenografts
by approximately 56% in nude mice, as shown by measurements of tumor volume. Tumor tissue
from GE-treated mice showed reduced proliferation index and widespread apoptosis compared
with controls, as determined by immunoblotting and immunohistochemical methods. Most
importantly, GE did not exert any detectable toxicity in normal, rapidly dividing tissues such as
gut and bone marrow. Nevertheless, the nature of interactions among the constituent ginger

3

This chapter has been published verbatim in Br J Nutr 2012 as Benefits of whole ginger
extract in prostate cancer, Nutr Cancer 2013 as Ginger phytochemicals exhibit robust synergy
to inhibit prostate cancer cell proliferation and Carcinogenesis 2014 as Enterohepatic recirculation of bioactive ginger phytochemicals is associated with enhanced tumor growthinhibitory activity of ginger extract.

68
biophenolics, viz. 6-gingerol, 8-gingerol, 10-gingerol, and 6-shogoal, remains elusive. We report
the antiproliferative efficacy of the most-active GE biophenolics as single-agents and in binary
combinations, and investigate the nature of their interactions using the Chou-Talalay
combination index (CI) method. To appreciate synergy among phytochemicals present in GE, the
natural abundance of ginger biophenolics was quantitated using LC-UV/MS. Our data
demonstrate that binary combinations of ginger phytochemicals synergistically inhibit
proliferation of PC-3 cells with CI values ranging from 0.03 to 0.88. However, no study has yet
examined the in vivo collaboration among ginger phytochemicals or evaluated the importance, if
any, of the natural “milieu” preserved in whole extract. Hence, we comparatively evaluated in
vivo efficacy of GE with an artificial quasi-mixture (Mix) formulated by combining four mostactive ginger constituents at concentrations equivalent to those present in whole extract. Orallyfed GE showed 2.4-fold higher tumor growth-inhibitory efficacy than Mix in human prostate
tumor xenografts. Pharmacokinetic (PK) evaluations and bioavailability measurements addressed
the efficacy differences between GE and Mix. Plasma concentration-time profiles revealed
multiple peaking phenomenon for ginger constituents when they were fed as GE as opposed to
Mix, indicating enterohepatic recirculation (EHR). Bioavailability of 6G, 8G, 10G and 6S was
1.6, 1.1, 2.5 and 3.4 fold higher, respectively, when dosed with GE compared to Mix. In
addition, gingerol glucuronides were detected in feces upon intravenous administration
confirming hepatobiliary elimination. These data ascribe the superior in vivo efficacy of GE to
higher AUCs, greater residence time, and enhanced bioavailability, of ginger phytochemicals,
when fed as a natural extract compared to artificial Mix, emphasizing the usefulness of
consuming whole foods over single agents.
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3.2

Introduction
Prostate cancer is the most common non-cutaneous malignancy in American men,

afflicting one in six men. It is estimated that in the USA, one new case occurs every 2.4 min and
a death results every 16.4 min from prostate cancer. Clinically significant prostate cancer appears
to develop over 20–30 years, thus presenting a ‘large window’ of opportunity for interventional
chemopreventive strategies (Nelson et al., 2003; Syed et al., 2007). Although the traditional
focus has been on treating existing tumors with chemotherapeutic agents that most often exert
toxic side effects, development of chemopreventive approaches that can prevent, suppress or
reverse progression to invasive cancer represents a relatively young field with tremendous
promise to reduce cancer burden (Mann et al., 2005; Sporn, 1976). Laboratory and
epidemiological research during the past three decades has provided indisputable evidence,
indicating that high intake of fruits and vegetables is linked to a reduced cancer susceptibility
including prostate cancer risk (Cooke et al., 2005; Kaur et al., 2009; Yang et al., 2001). Several
National Cancer Institute (NCI) initiatives continue to underscore the importance of including
fruits and vegetables in the daily diet as a cancer chemopreventive measure (Colli and Amling,
2009; Kaur et al., 2009; Steinkellner et al., 2001; Traka et al., 2008). Fruits and vegetables
contain phytochemicals (carotenoids, polyphenolics, anthocyanins, alkaloids, N and S
compounds) that have been shown to target multiple neoplastic stages to reduce overall cancer
risk (Craig, 1999). About thirty-five plant-based foods identified by the NCI to be effective in
cancer prevention include garlic, ginger, turmeric, cruciferous vegetables (broccoli, brussel
sprouts, cabbage) and grape seed extracts (Surh, 2003).
Although the clinical armamentarium of chemotherapeutic drugs has been expanding
with remarkable momentum, the rate of cancer incidence and mortality is exponentially
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increasing. The barriers to the development of “tumor-eradicating” drugs can perhaps be
attributed to the fact that carcinogenesis in humans is a complex, multistep process that involves
dysfunction of several molecules including oncogenes and tumor suppressors (Hanahan and
Weinberg, 2000). These molecules exquisitely control multifarious signaling circuitries that
dictate cell survival and death pathways and their genetic alterations vary temporally;
consequently, the acquisition of malignant phenotypes can be quite variable across different
cancer types. Thus, it appears that the current mono-targeted therapy approach using rationally
designed pharmacological inhibitors against a particular target has its own limitations.
Furthermore, because tumors represent a heterogeneous population, a multi-targeted approach
using single agent or a combination regimen might offer an edge over the more prevalent monotargeted strategy. Therefore, an ideal chemopreventive or therapeutic regimen should be
relatively nontoxic and concurrently hit multiple targets to achieve superior anticancer benefits.
Several reports suggest that the anticancer benefits of fruits and vegetables are due to an
additive or synergistic interplay of the complex mixture of phytochemicals present in them (Liu,
2003, 2004). This emerging notion further lends support to the premise of concomitantly
targeting multiple pathways. For example, studies of green tea polyphenols have demonstrated
that EGCG and at least 4 other catechins are necessary for maximum in vivo efficacy, suggesting
that synergistic interreactivity or dependency on other components of the whole food is required
for optimal activity (Bode and Dong, 2009). Similarly, the highest antioxidant activity was
realized with the combination of polyphenols in pomegranate juice as opposed to the constituent
polyphenols alone (Seeram et al., 2005). In a comparable investigation of cranberry extract,
enhanced antiproliferative activity was attributed to the synergistic and additive interactions of
its main components, including anthocyanins, proanthocyanidins, and flavanol glycosides
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(Seeram et al., 2004). Such studies thus offer a plausible explanation as to why clinical trials
with pure, single phytochemicals, such as α-tocopherol, β-carotene, and vitamin C, have met
with limited success (Greenberg et al., 1994; Liu, 2004; Tsao et al., 2004). It is thus likely that
disrupting the natural balance of phytochemicals as it exists in fruits and vegetables by extracting
individual phytochemicals from the “food matrix” (Jacobs et al., 2009; Jacobs and Tapsell, 2007)
may result in suboptimal health benefits.
Thus, it is plausible that isolating a single compound from complex foods may not be
effective even at high, relatively toxic doses, whereas combinations of lower, less-toxic doses of
each compound may be effective. This might also explain why clinical trials with pure single
phytochemicals such as α-tocopherol, β-carotene, and vitamin C have failed in the past,
reinforcing the futility of isolating a single constituent from a phytochemical mixture as it may
lose its bioactivity or even cause undesirable cancer-promoting effects, as in the case of βcarotene. Concomitantly, it highlights the importance of the lesser-known, relatively understudied, minor components of the complex mixtures of fruits and vegetables that have been
mistakenly ignored in evaluating the superior bioactivity of whole extracts.
Fruits and vegetables present a treasure trove of polyphenolic compounds that upon
ingestion undergo extensive metabolism during passage through the gastrointestinal system
primarily to prevent unwanted accumulation and to prompt their elimination from the system
(Manach et al., 2004; Manach et al., 2005; Silberberg et al., 2006; Williamson and Manach,
2005). Most phytochemicals are metabolically modified within the gut before entering the blood
circulation. The conjugated sugar groups, if any, are cleaved in the intestinal lumen, followed by
glucuronidation, sulfation and/or methylation of the aglycones, to facilitate elimination of
phytochemicals subsequent to conjugation mechanisms that enhance their polarity (Manach et
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al., 2005; Williamson and Manach, 2005). However, the residence time of phytochemicals in
systemic circulation is responsible for their beneficial activity. Recently, identification of a vast
array of phenolic metabolites in circulation has offered useful insights and allowed us to realize
and explore the bioavailability, especially of poorly absorbable compounds, such as the
phenolics (Calani et al., 2012; Silberberg et al., 2006).
An extensively consumed spice worldwide, Ginger (Zingiber officinale Roscoe) is an
excellent source of several bioactive phytochemicals. A variety of active components have been
identified in the oleoresin, the non-volatile pungent fraction of ginger, mainly including
gingerols and shogaols (Govindarajan, 1982a, b; Tao et al., 2009; Vasala, 2004). The other active
ginger constituents include 6-paradol, 6- and 10-dehydrogingerdione, 6- and 10-gingerdione, 4-,
6-, 8-, and 10-gingerdiol, 6-methylgingerdiol, zingerone, 6-hydroxyshogaol, 6-, 8-, and 10dehydroshogaol, and diarylheptanoids (Govindarajan, 1982a, b; Vasala, 2004; Yoshikawa et al.,
1993). Nevertheless, gingerols and shogaols are most abundant in ginger compared to any of the
other constituents. Extensive literature has successfully shown that 6-gingerol (6G), 8-gingerol
(8G), 10-gingerol (10G) and 6-shogaol (6S) are the main bioactive components of ginger (Chen
et al., 2009; Dugasani et al., 2010; Govindarajan, 1982a, b; Jeong et al., 2009; Kundu et al.,
2009; Lee et al., 2008; Lumb, 1994; Park et al., 1998; Park et al., 2006; Shukla and Singh, 2007;
Wang et al., 2003; Zick et al., 2008; Zick et al., 2010). While several reports exist on the
antioxidative, anti-inflammatory, and antitumor properties of ginger, only marginal benefits of
ginger constituents as single-agents are yet known from clinical trials (Zick et al., 2008; Zick et
al., 2010). Although the constituent phytochemicals present in ginger, in particular, gingerols,
shogaols and paradols, are being rigorously tested for their anticancer properties, it is becoming
increasingly recognizable that the gainful effects of fruits and vegetables are due to an additive
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and/or synergistic interplay of the composite mixture of phytochemicals present in whole foods
rather than the constituent single agents alone. In the context of ginger root, sufficient evidence
suggests that achievable plasma concentrations of individual phytochemicals are in a very low
micromolar range (2 mg/ml or less). In addition, these phytochemicals are found primarily in the
form of their non-active glucuronide or sulphate metabolites, and therefore the anticancer effects
observed with much higher concentrations in vitro may not be relevant in the in vivo milieu. A
careful examination of several studies reveals that the effective in vitro doses of these ginger
phytochemicals are much higher than their achievable plasma concentrations, which impose
serious limitations on their potential efficacy and utility as chemopreventive supplements in
humans (Chen et al., 2009; Dugasani et al., 2010; Jeong et al., 2009; Kim et al., 2005; Kundu et
al., 2009; Lee et al., 2008; Park et al., 1998; Park et al., 2006; Wang et al., 2003). Thus,
sufficient accumulating evidence suggests that the repertoire of phytochemicals present in
dietary agents works together through complementary and overlapping mechanisms to present
optimal cancer chemopreventive and therapeutic benefits.

With this mindset, we sought to undertake a detailed evaluation of the in vitro and in vivo
anticancer activity of whole ginger extract (GE) in prostate cancer. To the best of our knowledge,
there is not even a single report that presents a thorough mechanistic investigation to develop GE
for prostate cancer management. Herein, we examined the in vitro and in vivo anticancer effects
of GE in prostate cancer by evaluating its effects on cellular proliferation, cell-cycle progression
and apoptosis. Further, we evaluated the antiproliferative efficacy of the most active ginger
phytochemicals (6G, 8G, 10G, and 6S) as single agents as well as in binary combinations in
prostate cancer PC-3 cells. The dose reduction index (DRI) that quantitates the magnitude by
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which the dose level of whole GE can be reduced on using a combination regimen of GE and
ginger phytochemicals was calculated to emphasize the translational relevance of GE in prostate
cancer prevention and therapy.

Whether or not this in vitro synergistic collaboration among the most-active ginger
phenolics holds up in in vivo to elicit much higher therapeutic efficacy than the observed tumor
inhibition efficacy of GE is yet an uncharted territory. Clearly, it is comprehensible that in vitro
methods fail to account for in vivo complexities such as absorption of ginger phenolics from
gastrointestinal tract, their metabolic biotransformation, systemic bioavailability and clearance
and thus preclude a logical explanation of in vivo therapeutic efficacy. Hence, we demonstrate
the remarkably superior efficacy of GE compared to an artificial quasi-mixture (Mix) produced
by combining the most active individual phytochemicals in the same ratios as they appear in the
natural setting. Then, we asked whether these active ginger phenolics solely collaborate among
themselves or recruit other ginger phenolics in their complex in vivo agenda to ultimately elicit
optimal therapeutic activity. Given the significance of metabolism and bioavailability to dictate
the in vivo biological effects of phytochemicals, we addressed the discrepancy in the efficacy
outcomes of GE and Mix using pharmacokinetic approaches. We monitored absorption and
bioavailability of 6G, 8G, 10G and 6S upon oral feeding of GE compared to the Mix to
underscore the presence of beneficial in vivo interactions among GE biophenolics that are largely
absent in the Mix. In addition, we developed a sensitive, accurate and robust LC/MS/MS method
for the quantitation of 6-, 8-, 10- gingerols and 6-shogaol to study their collaborative interactions
when present in their natural milieu and the consequential pharmacological significance.
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3.3
3.3.1

Materials and Methods
Cell lines, media, antibody and reagents
Normal prostate epithelial cells (PrEC) and prostate cancer (LNCaP, C4-2, C4-2B,

DU145 and PC-3), breast (MDA-MB-231 and MCF-7) and cervical (HeLa) cancer cell lines
obtained from American Type Culture Collection (Manassas, VA) ATCC, were used in the
present study. The medium used to culture these cells was Roswell Park Memorial Institute-1640
(RPMI-1640) or Dulbecco’s modified Eagle’s medium supplemented with 10% fetal bovine
serum and 1% antibiotic (penicillin/streptomycin). Primary antibodies to p21, cyclin E and BAX
and horseradish peroxidase-conjugated secondary antibodies were from Santa Cruz
Biotechnology (Santa Cruz, CA, USA). Cyclin D1, cdk4, p-Rb, Bcl2, cytochrome c, cleaved
caspase-3 and cleaved poly (ADP-ribose) polymerase (PARP) were from Cell Signaling
(Beverly, MA, USA), Ki67 was from Zymed (South San Francisco, CA, USA) and β-actin was
from Sigma (St Louis, MO, USA). The MTT dye (thiazolyl blue tetrazolium bromide, 98% TLC)
and dimethyl sulfoxide (DMSO) were from Sigma-Aldrich (St. Louis, MO). Cells were cultured
at 37◦C with 5% CO2. Ginger extract (GE) was a gift from Sabinsa Corportation, NJ.
Acetonitrile (ACN), and methanol (MeOH) were obtained from Fisher Scientific (Pittsburgh,
PA). The silica used for classical chromatography was from EMD Biosciences (Billerica, MA).
Thin-layer chromatography (TLC) plates were from EMD chemicals (Billerica, MA).
Luciferase-expressing PC-3 cells (PC3-luc) were from PerkinElmer (Hopkinton, MA) and were
maintained in MEM medium with 10% FBS, Hyclone, (Pittsburgh, PA). Carboxy methyl
cellulose (CMC) and β-glucuronidase were from Sigma (St. Louis, MO). The active ginger
constituents, 6-gingerol (6G), 8-gingerol (8G), 10-gingerol (10G) and 6-shogaol (6S) were
extracted from ginger extract (GE) and was characterized for >99% purity.
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3.3.2

Preparation of GE stocks and isolation of ginger phenolics
Ginger extract (GE) powder from Sabinsa Corporation, was used to make a GE stock

solution by dissolving 100 mg GE in 1 mL of dimethyl sulfoxide, and various concentrations
were obtained by appropriate dilutions. However, the variation among different batches of ginger
extracts was determined based upon the quantitative values of 6G, and 10G.
The methanolic extract of ~20 g ginger powder (obtained from Sabinsa) was adsorbed on
silica gel 60-120 mesh size and purified using 50 cm × 6 cm i.d. column packed with stationary
phase. Gradient elution steps were performed from 100% hexane to 100% ethyl acetate to
separate 6G, 8G, 10G and 6S by column chromatography. Different fractions were eluted and
collected and monitored by TLC using p-anisaldehyde stain. All the fractions were then further
purified by High Performance Liquid Chromatography (HPLC) using semi-preparative reversed
phase column with mobile phase consisting acetonitrile in water in linear gradient from 45% to
100% at a flow rate of 1 mL/min with a run time of 55 min. Mass spectrometry was employed to
analyze the purified 6G, 8G, 10G and 6S.
100 mg of the remaining fraction of GE containing trace amounts of 6S after isolating
6G, 8G, 10G and 6S was loaded onto preparative TLC plate and was developed in a glass
chamber consisting a binary mobile phase of ethyl acetate and hexane (2:8). Pure 6S was used as
a standard to separate and remove the 6S from this fraction. The rest of the fraction was scraped,
dissolved in methanol, filtered, and concentrated for testing. HPLC analysis of this fraction
confirmed the absence of 6G, 8G, 10G and 6S. This fraction devoid of the active ginger
phytochemicals, known as GE-Mix, was employed in future studies.
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3.3.3

In vitro proliferation and colony survival assay
Cells were plated in ninety-six-well plates and treated with gradient concentrations (1–

1000 µg/ml) of GE the next day. After 72 h of incubation, cell proliferation was determined
using the Alamar blue cell proliferation assay. The magnitude of the fluorescent signal is
proportional to the number of live cells, and is monitored using 530–560 nm excitation
wavelength and 590 nm emission wavelength. For the colony assay, PC-3 cells were treated with
250 µg/ml of GE for 48 h, washed and replaced with regular RPMI medium. After 10 d, colonies
were fixed with 4% formaldehyde, stained with crystal violet and counted.
MTT [3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide] assay was also
used to evaluate the proliferative capacity of cells. Essentially, MTT is a colorimetric assay,
which uses the colorless tetrazolium dye and converts it into a colored formazan salt, which can
be quantified by measuring absorbance at 570 nm. Briefly, a 96-well format was used to seed
100 µl medium containing cells at a density of 5 × 103 cells per well. After 24 h of incubation,
cells were treated with gradient concentration of GE, gingerols, and shogoal, which were
dissolved in DMSO. The final concentration of DMSO in the culture medium was maintained at
0.1%. After 48 h of incubation, the spent medium was removed and the wells were washed twice
with PBS. 100 µl of fresh medium and 10 µl of MTT (5 mg/ml in PBS) was added to the wells
and cells were incubated at 37◦C in dark for 4 h. The formazan product was dissolved by adding
100 µl of 100% DMSO after removing the medium from each well. The absorbance was
measured at 570 nm using a Spectra Max Plus multi-well plate reader (Molecular Devices,
Sunnyvale, CA).
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3.3.4

Cell-cycle progression studies by flow cytometry
For cell-cycle analysis, PC-3 cells were treated with vehicle (dimethyl sulfoxide) or GE

at various doses (50, 100, 250, 500 and 1000 µg/ml) for 24 h or at a fixed dose of 250 µg/ml for
various time points (12, 24, 48 and 72 h). At the end of incubation, cells were fixed with 70%
ethanol overnight, stained with propidium iodide containing RNase A, followed by data
acquisition on a FACSCalibur flow cytometer (BD Biosciences, San Jose, CA, USA) and
analyses using Flo-Jo software (Ashland, OR, USA).
3.3.5

Immunoblot analysis
GE-treated cell lysates were collected at various time points, lysed, sonicated and

estimated for protein content. Proteins were then resolved by polyacrylamide gel electrophoresis
and transferred onto polyvinylidene difluoride membranes (Millipore, Billerica, MA, USA). The
membranes were blocked in Tris-buffered saline containing 0·05% Tween-20 and 5% fat-free
dry milk and incubated first with primary antibodies and then with horseradish peroxidaseconjugated

secondary

antibodies.

Specific

proteins

were

visualised

with

enhanced

chemiluminescence detection reagent according to the manufacturer’s instructions (Pierce
Biotechnology, Rockford, IL, USA).
3.3.6

Mitochondrial and cytosolic fractionation
To determine the release of cytochrome c from the mitochondria to the cytosol by

immunoblotting, control or GE-treated (250 µg/ml) PC-3 cells were incubated on ice for 5 min in
100 µl of ice-cold cell lysis and mitochondria intact buffer (250mM-sucrose, 70mM-KCl and
100 µg digitonin/ml in PBS). The cells were pelleted and the supernatant containing cytosolic
protein was stored at -80oC. The pellets were incubated at 4oC for 10 min in immunoprecipitation
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buffer (50mM-Tris-HCl (pH 7·4), 150mM-NaCl, 2mM-EDTA, 2mM ethylene glycol tetra-acetic
acid, 0·2% Triton X-100, 0·3% Nonidet P-40, 1 x Complete protease inhibitor; Roche
Diagnostics Corporation, Indianapolis, IN, USA). The samples were centrifuged at high speed
for 10 min at 48oC, and the supernatant containing mitochondrial protein was stored at -80oC.
Proteins were subjected to immunoblot analysis as described above.
3.3.7

Immunofluorescence microscopy
After treatment with 250 µg/ml of GE, PC-3 cells taken on glass coverslips were fixed

with ice-cold methanol, followed by blocking with 2% bovine serum albumin in PBS. Ki67,
cleaved caspase-3 and PARP antibodies (1:250 dilution) were incubated with coverslips for 2 h
at 37oC. The cells were washed with 2% bovine serum albumin/PBS for 10 min at room
temperature before incubating with a 1:500 dilution of Alexa 488- or Alexa 555-conjugated
secondary antibodies. Cells were mounted with Prolong Gold antifade reagent that contains 4,6diamidino-2-phenylindole (Invitrogen, Carlsbad, CA, USA).
3.3.8

JC-1 staining for mitochondrial transmembrane potential
Control and 250 µg/ml of GE-treated cells were labeled with JC-1 reagent for 15 min at

37oC. After washing, cell fluorescence was measured on a flow cytometer using orange–red
emission filters.
3.3.9

Caspase-3/7 activity assay
Control or 250 µg/ml of GE-treated lysates were tested for caspase-3-like activity using

Ac-DEVD-7-amino-4-trifluoromethyl-coumarin, which detects the activities of caspase-3 and
caspase-7 according to the manufacturer’s protocol (Calbiochem, San Diego, CA, USA). The
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results were evaluated using a fluorescence microplate reader and are expressed as relative
fluorescence units.
3.3.10 Experimental design of the binary combination studies
IC50 values of GE, 6G, 8G, 10G, and 6S were obtained and a series of combinations at
varying concentrations were tested against PC-3 cells. For 6G, 8G, 10G, and 6S the
concentrations used in combinations were 0.075 (IC50/2), 0.125 (IC50/2), 0.25 (IC50/2), 0.5
(IC50/2), 0.75 (IC50/2), 1 (IC50/2), and 1.25 (IC50/2). For GE, the concentrations were 0.075
(IC50), 0.125 (IC50), 0.25 (IC50), 0.5 (ICv), 0.75 (ICv), 1 (IC50), and 1.25 (IC50). Gingerols and
shogoal were added in combination with GE and with one another at the aforementioned
concentrations. In each combination, a constant ratio of the IC50 for each drug was maintained.
The following combinations were tested: 6G + 8G, 8G + 10G, 10G + 6G, 6S + 6G, 6S + 8G, 6S
+10G, GE + 6G, GE + 8G, GE + 10G, and GE + 6S.
3.3.11 Determination of CI and DRI
Dose effects were analyzed using the computer software, CalcuSyn (Biosoft, Cambridge,
UK), beginning with single agent dose-response curves, followed by dose-response curves
involving combinations of 2 test agents (Pannu et al., 2011). The Chou-Talalay drug combination
method was used to yield the combination index (CI) and DRI values. The CI values thus
obtained are based on the multiple drug-effect equation of the enzyme kinetic models of ChouTalalay. For mutually exclusive drugs exhibiting similar modes of action, where (Dx)1 and
(Dx)2 are the doses of drug 1 and drug 2 alone, respectively, causing × % inhibition, the
combination index is described as CI = (D)1/(Dx)1 + (D)2/(Dx)2. A CI value <1, = 1 or close to
1, or >1 indicates synergistic, additive, or antagonistic interaction, respectively. Further, the
factor by which the dose of each agent may be reduced at a given effect when in combination
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compared with the dose when each agent is used alone can be measured by the DRI value. This
value holds clinical importance because the dose reduction could result in reduced toxicity while
retaining the therapeutic efficacy. The dose-effect relationship was derived through mathematical
induction method using enzyme kinetic models. The correlation between the dose and effect in
its simplest form can be described as, Fa = 1/[1 + (Dm/D)m], where D is the dose of the agent,
and Fa is the fraction affected by the dose. Dm is the median-effect dose signifying the potency
and m is an exponent signifying the sigmoidal shape of the dose-effect curve, where the former
is determined from x-intercept and the latter by the slope of the median-effect plot. A DRI >1 is
ideal, as the greater the DRI value, the higher the dose reduction is for a given therapeutic effect.
The number of agents in combination as well as the combination ratio affects the DRI value.
3.3.12 High-Performance Liquid Chromatography and Mass-Spectrometric Detection
Liquid chromatographic separations were achieved on a HP1100 series Instrument
(Agilent Technologies, Wilmington, DE) equipped with a photodiode array detector, using an
Agilent XDB reversed phase C-18, 1.8 µm, 4.6 × 50 mm, ODS-2 column. The solvent gradient
system consisted of solvent A (2.5% formic acid in water) and solvent B [2.5% formic acid in
acetonitrile (ACN)]. The gradient elution was 20% B for 45 min, followed by 80% B for 20 min
and 95% B over the next 5 min, which was held at an isocratic composition of 95% B for 20 min,
reconditioning to initial mobile phase concentration for 10 min with a flow rate of 0.2 ml/min. In
addition, 0.5 mg/ml of GE, 6G, 8G, 10G, and 6S dissolved and filtered in pure methanol (10 µl)
were injected into the system and the resultant spectra were observed at 280 nm. Standard
calibration curves for gingerols and shogaol were obtained and the area under the curve was
considered to quantify their amount in GE.
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The HPLC-MS analyses were performed in tandem with HPLC-UV using the same
column and mobile phase as described above on HP1100 series instrument (Agilent
Technologies, Wilmington, DE) interfaced to an Agilent 6400 Series Triple Quadrupole LCMS/MS equipped with an electrospray ionization source, which was operated in negative-ion
mode. The MS analysis was performed in multiple reaction monitoring (MRM) mode. The
nebulizer and collision gases were nitrogen and helium, respectively, and the former was set at
40 psi. A drying gas temperature of 300◦C, drying gas flow rate of 9 liter/min and capillary
voltage of ±3 kV were the spray chamber parameters to quantify the ginger phytochemicals in
GE. The quantitation of 6G, 8G, 10G, and 6S in GE was performed using MRM, where each of
these phytochemicals were identified based on their fragmentation patterns using the transitions;
6G 293→99, 8G 321→127, 10G 349→153, and 6S 275→139. Collision energy of 15 eV was
used to obtain the product ions at a fragmentor voltage of 135V.
3.3.13 Formulation recipe of GE, Mix and GE-Mix for in vivo PK studies
Required amount of GE, Mix and GE-Mix were weighed and appropriate volume of
ethanol (10%) and polyethylene glycol 300 (30%) were added, vortex mixed and sonicated for 5
min. The volume was made up with 0.25% Tween 80 in 0.5% CMC in Milli-Q® water q.s. For
Mix, pure standards of 6G, 8G, 6S and 10G were mixed in the same proportion as in GE.
3.3.14 Choice of in vivo dose for efficacy and pharmacokinetic studies
The choice of 250 mg/kg dose is based on the human PK studies performed by Zick et al
(Zick et al., 2008; Zick et al., 2010), where free forms of ginger biophenolics were detected in
the human blood plasma upon oral administration of 2 g ginger extract. Upon normalizing for a
75 kg bw, this 2 g dose is equivalent to 25 mg/kg. Given the faster metabolic rate in mice
compared to humans and the allometric scaling factor of 10 (Reagan-Shaw et al., 2008), a dose
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of 250 mg/kg bw was chosen for mouse studies. Furthermore, the total amount of the active
ginger biophenolics (6G, 8G, 10G, 6S) present in GE used in this study was similar to that used
in the clinical studies (5%, i.e., ~13 mg in 250 mg of GE). Since dose toxicology studies are
often conducted for 7, 14 or 28 days (Gad, 2007), we chose to observe the tumor growth
inhibition upon oral administration of GE/Mix/GE-Mix over a period of 28 days.
3.3.15 In vivo tumor growth and treatment
Male Balb/c nude mice (6 weeks old) were obtained from the NCI (Frederick, MD,
USA), and 106 PC-3 cells in 100 ml PBS were injected subcutaneously in the right flank without
any basement membrane extracts such as Matrigel. The animals were given autoclave-sterilized
standard diet pellets and water ad libitum. When tumors were palpable, mice were randomly
divided into two groups. From each group, six mice were housed individually in one cage. The
control group received vehicle and the treatment group received 100 mg/kg body weight of GE
daily by oral administration. Tumor growth was monitored weekly using a vernier caliper and
body weight was also recorded.
PC-3-luc cells (1x106) were subcutaneously injected on either flank of six-week old male
BALB/c nude mice (Harlan Laboratories, Inc., Indianapolis, IN). When tumors were palpable,
mice were randomly divided into four groups of five mice each. Control group received vehicle
and the treatment groups received 250 mg/kg GE, Mix and GE-Mix by oral gavage daily for 28
days. Tumor growth was monitored by measuring the luciferase activity in live mice by
bioluminescent imaging in real-time using the IVIS in vivo imaging system (PerkinElmer, Inc.,
Hopkinton, MA) with the Live Imaging software. Briefly, mice anesthetized with isoflurane
were intraperitoneally injected 30 mg/mL luciferin and imaged with a CCD camera. An
integration of 20 s with four binnings of 100 pixels was used for image acquisition. The relative
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photon counts at the tumor sites of the mice from vehicle or GE, Mix and GE-Mix treated groups
were quantitated twice a week along with tumor volume measurements for four weeks. Body
weights were recorded twice a week to evaluate the general-health and well-being of animals
during treatment. Mice in treatment groups exhibited normal weight gain with no signs of
discomfort. All animals in control group were euthanized after 4th week due to tumor overburden
in compliance. All animal experiments were performed in compliance with institutional IACUC
guidelines.
3.3.16 Histopathological and immunohistochemical staining
After 8 weeks of vehicle or 100 mg/kg GE treatment, tumour, lung, spleen, adrenal, liver,
gut, brain, kidney, heart, testes and bone marrow were formalin-fixed, paraffin-embedded and
5mm thick sections were stained with Ki67, cleaved caspase-3, PARP and hematoxylin and
eosin. Terminal deoxynucleotidyl transferase dUTP nick-end labelling (TUNEL) staining of
tumor tissue sections was performed using the DeadEnd Fluorometric TUNEL System (Promega
Inc., Madison, WI, USA) according to the manufacturer’s instructions.

3.3.17 Pharmacokinetic studies of GE versus Mix
Pharmacokinetic studies were performed in male C57BL6J mice following a single oral
(PO) administration of GE and Mix at 250 mg/kg and intravenous (IV) dose administration at 1
mg/kg of pure 6G, 8G, 10G and 6S individually. All animals were acclimatized for 3 days before
dosing in the experimental area. Mice were fasted for 3 h before dose administration and food
was provided 3 h post dose. Water was provided ad libitum through the study period. Animals
were marked and housed (three per cage) in polypropylene cages and maintained in controlled
environmental conditions with 12 h light and dark cycles. The temperature and humidity of the
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room was maintained between 22 ± 3oC and 30 to 70%, respectively, and approximately 10-15
fresh air change cycles per hour. A sparse sampling design was used to collect blood samples
from animals at 5 min, 10 min, 15 min, 30 min, 1 h, 2 h, 4 h, 6 h, 8 h, 12 h and 24 h into
K2EDTA coated tubes. Plasma was harvested from blood by centrifugation of samples at 8000 g
for 10 min. Feces samples were collected from mice treated with intravenous dose of individual
gingerols at 0-2 h, 2-4 h, 4-6 h, 6-8 h, 8-12 h and 12-24 h intervals. All samples were stored
below -60oC until bioanalysis.
3.3.18 Enzymatic hydrolysis of gingerol conjugates
To confirm the presence of glucuronide conjugates, plasma (200 µL) and feces samples
(homogenized with buffer 1:3, 200 µL) were treated with β-glucuronidase (50 µL, 500 units) and
incubated at 37°C for 1 h.
3.3.19 Plasma Protein Binding Assay
Binding potential of 6G, 8G, 10 G and 6S in GE and Mix was assessed using ultracentrifugation technique. The study was conducted at 0.3 mg/mL, 1 mg/mL and 3 mg/mL in
triplicate. Appropriate volumes of GE or Mix stock solution (10 µL) were spiked into plasma
(990 µL) to attain the final concentrations. The microfuge tube was mixed by inversion and
incubated at 37oC for 30 min. An aliquot (50 µL) of the incubated samples was collected in
microfuge tube. The remaining samples were subjected to ultra-centrifugation at 40,000 g for 1 h
and aliquots of supernatant (50 µL) were carefully collected into microfuge tubes.
3.3.20 Bioanalysis
All in vitro and in vivo samples were processed by protein precipitation method. An
aliquot (50 µL) of sample was added with 20 µL internal standard (capsaicin), 180 µL ACN, and
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vortex mixed for 3 min. The tubes were centrifuged at 8000 g for 10 min and an aliquot of
supernatant was transferred into auto-sampler vials for analysis.
The stock solutions of 6G, 8G, 10G, 6S and capsaicin (internal standard) were prepared
in ACN:water (95:5) at 1 mg/mL. A calibration curve range of 0.002 µg/mL to 2 µg/mL was
employed for the quantification of analytes and internal standard concentration was 100 ng/mL
for each analysis. The calibration curve consisted of blank, blank with internal standard and 6
non-zero calibration standards. The calibration standards were within ±15% of the nominal
concentration and lower limit of quantification was within ±20% of nominal.
All samples were analyzed using liquid chromatography tandem mass spectrometric
method (Agilent 6410 series). A positive ionization mode with multiple reaction monitoring
(MRM, m/z Q1/Q3) of 6-gingerol (m/z 277.2/177.2, RT 5.8 min), 8-gingerol (m/z 305.2/137.2,
RT 9.4 min), 10-gingerol (m/z 333.2/137.2, RT 14.6 min), 6-shogaol (m/z 277.2/137.1, RT 10.9
min), IS (m/z 306.2/137.1, RT 6.8 min) was employed. The ion spray voltage was set at 3000 V,
ionization temperature set as 200°C and drying gas flow rate was 10 L/min. Data acquisition and
quantitation were performed using Mass Hunter software (Agilent Technologies). Separation
was achieved using HP1100 series LC (Agilent Technologies, Wilmington, DE) equipped with a
photodiode array (PDA) detector, using an Agilent Zorbax reversed-phase (SB-C18, 3.0×250
mm, 5.0 µm) column. A gradient method was employed to separate the individual GE
components using mobile phase A (0.1% formic acid in water) and mobile phase B (ACN). The
gradient elution method with 60% B at 0 min, 90% B at 20 min, held for 10 min, back to 60% B
at 40 min with a flow rate of 0.4 mL/min. An injection volume of 10 µL was used for analysis.
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3.3.21 Pharmacokinetic analysis
Pharmacokinetic parameters were calculated from the concentration-time data using the
non-compartmental analysis tool of validated WinNonlin® software (Version 5.2, Pharsight,
USA). The area under the concentration time curve (AUClast and AUCinf) was calculated by the
linear trapezoidal rule. Following oral administration, peak concentration (Cmax) and time for the
peak concentration (Tmax) were the observed values. The clearance (CL) and volume of
distribution (Vss) were estimated following intravenous dose administration. The elimination rate
constant value (k) was obtained by linear regression of the log-linear terminal phase of the
concentration-time profile using at least 3 declining concentrations in terminal phase with a
correlation coefficient of >0.8. The terminal half-life value (T1/2) was calculated using the
equation ln2/k. Oral bioavailability was calculated by taking the ratio of dose normalized AUClast
following oral administration to intravenous administration.
3.3.22 Statistical analysis
All the experiments were repeated at least three times. Results are expressed as mean
values of at least three independent experiments and standard deviations (mean values ± SD),
and P values (Student’s t test) were calculated in reference to control values using Excel
software. The criterion for statistical significance was P < 0.05. Furthermore, a two-way analysis
of variance (ANOVA) was performed to evaluate the differences between vehicle- and GE/Mixfed groups for in vivo efficacy studies and P-values were obtained from two-sided tests for
statistical significance.
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3.4
3.4.1

Results
Ginger extract displays selective antiproliferative activity, arrests cell-cycle progression,
and induces apoptosis in prostate cancer cells
Although the whole GE has been shown to inhibit proliferation of breast (Lee et al.,

2008) and colon (Jeong et al., 2009) cancer cells, there are no available reports that have tested
the potential usefulness of GE in prostate cancer. Thus, we first asked whether GE affected the
proliferation of prostate cancer cells. To this end, we investigated the effect of GE on PC-3,
LNCaP, C4-2, C4-2B and DU145 cells, which are well-characterized representatives of
androgen-responsive (LNCaP) and androgen independent (PC-3, C4-2 and C4-2B) human
prostate cancers. Cells were treated with increasing gradient concentrations of GE or vehicle
(0·1% dimethyl sulfoxide) for 72 h, and cell survival was assessed by the Alamar blue assay. Our
data showed that GE inhibited cellular proliferation of all prostate cancer cells, with a halfmaximal concentration of growth inhibition (IC50) in the order C4-2 (512 µg/ml). PC-3 (250
µg/ml), C42-B (240 µg/ml), DU145 (95 µg/ml), LNCaP (75 µg/ml) (Figure 3.1A and 3.1B).
These data suggested the generality of the growth inhibition effect of GE on prostate cell lines
with varying genotypic backgrounds. Hereupon, we focused on PC-3 cells for further
experimentation to delineate molecular mechanisms of growth inhibition and cell death. We also
performed a complementary trypan blue assay to examine cell viability on GE treatment in a
concentration and time-dependent manner in PC-3 cells.
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Figure 3.1 GE has potent antiproliferative activity
Human prostate cancer LNCaP, DU145, PC-3, C4-2, C4-2B cells, as well as normal prostate
epithelial cells (PrEC) and human dermal primary fibroblasts (HDF) were treated with gradient
concentrations of GE for 72 h. The percentage of cell proliferation at indicated concentrations,
compared with untreated control cells, was measured by the in vitro cell proliferation assay, as
described in Materials and methods. (A) Plot of percentage of cell survival vs. GE concentrations
used for the determination of half-maximal concentration of growth inhibition (IC50) values.
Values are means of three independent experiments performed in triplicate, with standard
deviations represented by vertical bars (P<0·05). (B) Bar graph representation of the IC50 of the
indicated cell lines. (C) Bar graph representation and photograph of crystal violet-stained
surviving colonies from the control and GE-treated (250 and 1000 µg/ml) groups. (D)
Fluorescence micrographs of control and GE-treated PC-3 cells stained for (Di) Ki67 (green) or
(Dii) 4’,6-diamidino-2-phenylindole (DAPI, blue). Scale bar, 20 µm. (Diii) Quantification of
Ki67-postive or DAPI-stained cells in control and 250 µg/ml of GE-treated PC-3 cells from
random image fields totaling 200 cells. Values are means, with standard deviations represented
by vertical bars. Mean values were significantly different from the controls (P<0·05).
Yet another screen of an array of cancer cell lines from different tissue types, namely
breast and cervical cancer, showed that GE affected the proliferative capacity of these cancer
cells, suggesting generalization of GE effects on cell lines from other tissue types. Tumor cell
selectivity is a highly desirable trait of any chemopreventive or chemotherapeutic regimen. To
investigate whether GE-mediated suppression of PC-3 cell growth was selective to cancer cells,
we determined the effect of GE treatment on a normal PrEC and serum-starved human dermal
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primary fibroblast (HDF) cells. Our choice of cell lines was based on the fact that PrEC and HDF
exhibit features most consistent with the epithelial cells of prostate and dermal origin,
respectively. The present results showed that the viability of PrEC or HDF was not significantly
affected by GE treatment at concentrations in the range of 100–750 µg/ml (Figure 3.1B). The
IC50 of PrEC (1750 µg/ml) and HDF (1000 µg/ml) was approximately 6.9- and approximately 4fold higher, respectively, compared with PC-3 cells, reflecting the wide therapeutic window that
imparts tumor selectivity. Collectively, these results indicated that PC-3 cells, but not normal
prostate epithelial or primary fibroblast cells, were significantly sensitive to growth inhibition by
GE treatment.
Next, we performed a clonogenic cell survival assay to determine the ability of cells to
proliferate indefinitely upon drug removal, thereby measuring their reproductive capacity to form
colonies. Our data showed that 250 µg/ml of GE decreased colony numbers by approximately
66% (Figure 3.1C) compared with vehicle-treated controls. Representative pictures of surviving
crystal violet-stained PC-3 cell colonies from control and GE-treated cells are shown in Figure
3.1C. Several model systems have shown that Ki67 expression shows a good direct relationship
with growth fraction, and thus serves as a reliable method for evaluating actively proliferating
cell populations. Immunostaining with an antibody that reacts with the Ki67 nuclear antigen
showed significantly intense staining in control cells compared with 250 µg/ml of GE-treated
cells (Figure 3.1Di). Figure 3.1Diii is a bar graph representation of Ki67-positive cells scored as
an average in both control and GE-treated samples from at least ten fields of vision totaling 200
cells. These data correlated with our previous in vitro proliferation and colony survival data, thus
confirming the antiproliferative activity of GE. Several characteristics of apoptosis, such as
morphological and cellular changes, including chromatin condensation, membrane blebbing and
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DNA fragmentation, lend themselves to assessment. Thus, we microscopically examined DAPI
stained control and 48 h GE-treated (250 µg/ml) cells to observe condensed chromatin material
and other morphological features reminiscent of apoptosis. Representative fluorescence
micrographs are shown in Figure 3.1Dii and their bar graph quantification is depicted in Figure
3.1Diii.

Figure 3.2 GE and ginger phytochemicals inhibit proiferation of prostate cancer cells.
PC-3 cells were treated with gradient concentrations at (A) 1, 10, 25, 50, 75, 100, and 250 µM
for 6-gingerol (6G) (0.29, 2.94, 7.36, 14.72, 22.07, 29.43, and 73.58 µg/ml, respectively), 8gingerol (8G) (0.32, 3.22, 8.06, 16.12, 24.18, 32.24, and 80.61 µg/ml, respectively), 10-gingerol
(10G) (0.35, 3.51, 8.76, 17.53, 26.29, 35.05, and 87.63 µg/ml, respectively), and 6-shogoal (6S)
(0.28, 2.76, 6.91, 13.82, 20.73, 27.64, and 69.09 µg/ml, respectively); and (B) 1, 10, 25, 50, 75,
100, and 250 µg/ml, respectively, of GE for 48 h. The percent cell survival upon various
treatments was measured using MTT assay, as described in Materials and Methods. A and B:
Plot of percentage of cell survival versus concentrations used for determination of halfmaximal
concentration of growth inhibition (IC50). Data shown above represent the means of 3
independent experiments performed in triplicate, with standard deviations represented by vertical
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bars (P < 0.05). (C) Chemical structures of ginger phytochemicals (i) 6G, (ii) 8G, (iii) 10G, (iv)
6S.
Because the major bioactive constituents of ginger are gingerols and shogaols, the
antiproliferative activity of GE could be attributed to these components of ginger extract, viz.,
6G, 8G, 10G, and 6S. Thus, we first determined the half-maximal growth inhibitory
concentration (IC50) for GE and its phytochemicals in prostate cancer, PC-3 cells. To this end,
we used an in vitro cell proliferation assay, MTT, to quantify the percent survival of PC-3 cells
in the presence of test agents. The IC50 values obtained were 75 µM (22.07 µg/ml) for 6G, 10 µM
(3.22 µg/ml) for 8G, 50 µM (17.53 µg/ml) for 10G, 4 µM (1.12 µg/ml) for 6S (Figure 3.2A), and
250 µg/ml for GE (Figure 3.2B). The carbon chain length of ginger phytochemicals (Figure
3.2C) has been reported to play a role in the differential potencies of the gingerols and shogaols
(27). On similar lines, the results observed in our study showed a variability of IC50s in the
context of prostate cancer cells. In addition, our data suggested a significant difference in the
IC50 values of ginger constituents compared to whole GE. As evident from Figure 3.2A and
3.2B, the constituent ginger phytochemicals were more potent than GE.
Several dietary agents have been shown to arrest the cell cycle, leading to growth
inhibition and apoptosis. For example, grape seed proanthocyanidins, green tea polyphenols,
epigallocatechin-3-gallate, resveratrol (red grapes, peanuts and berries), silymarin/silibinin (milk
thistle), genistein (soyabean), curcumin (turmeric) and ginger (gingerols) affect cell-cycle
progression at various stages by specifically modulating cell-cycle-associated proteins
(Aggarwal and Shishodia, 2006). Specific gingerols, such as 6-gingerol and 8-gingerol, have
been shown to perturb cell-cycle progression as a chemopreventive strategy (Park et al., 2006).
Thus, our next aim was to gain mechanistic insights into GE-mediated antiproliferative activity
by determining the specific cell-cycle stage at which GE intervenes. To this end, we examined
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the cell-cycle distribution profile of GE-treated PC-3 cells by employing a flow cytometric assay
using the DNA intercalator dye, propidium iodide. Figure 3.3A shows the effect of varying GE
dose levels on cell-cycle progression of PC-3 cells at 24 h of treatment in a three-dimensional
disposition. Next, we used the half-maximal sub-G1 dose (250 µg/ml) to explore in depth the
effect of GE on each cell-cycle phase at the time of treatment (Figure 3.3B). The present results
showed that GE at a dose level of 250 µg/ml caused accumulation of cells in the G1 and S phase
at as early as 6- and 12 h of GE treatment, respectively. The cell-cycle arrest was followed by an
emergence of a hypodiploid sub-G1 population, a hallmark of dying apoptotic cells.
We next sought to determine molecular mechanisms underlying GE-induced cell-cycle stasis and
subsequent apoptosis. Essentially, cell-cycle progression involves sequential activation of cdks
by their cyclical association with cell-cycle phase-specific regulatory cyclin molecules. To
examine GE-induced alterations, we first determined the effect of 250 µg/ml of GE on protein
levels of G1/S-specific cyclins and cdks by immunoblotting methods. GE treatment caused a
marked decrease in cyclin D1 levels in PC-3 cells, which was evident as early as 12 h posttreatment (Figure 3.3C). In addition, GE-treated PC-3 cells exhibited a slight decrease in cdk4
levels (Figure 3.3C). Our data also showed that GE caused a significant reduction in cyclin E
levels, which drive the cell cycle primarily through the S phase in association with cdk2.
Elevated levels of p21, a cdk inhibitor, function to stall the cell cycle. Essentially, p21 plays a
crucial role in the regulation of the G1/S and G2/M transition by binding to and inhibiting the
kinase activity of cyclin/cdk complexes. To explore further, we determined the effect of GE
treatment on protein expressionand/or phosphorylation of p21 and Rb by immunoblotting
methods. As shown in Figure 3.3C, GE treatment caused an induction of p21 protein expression
in PC-3 cells, which was evident at 12–24 h. In addition, GE treatment caused suppression of Rb
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phosphorylation in PC-3 cells (Figure 3.3C)

Figure 3.3 GE effects cell cycle progression kinetics by causing S and G2/M arrest followed
by an increase in sub-G1 cell population
Cell-cycle progression over (A) dose (0–1000 µg/ml) and (B) time (0–72 h) are depicted in a
three-dimensional format. Cell populations in G0/G1 appear as 2N (unduplicated) DNA content
and G2/M populations are indicated by 4N (duplicated) DNA content. (C) Immunoblots of cell
lysates treated in the absence or presence of 250 mg/ml of GE for cyclin D1, cdk4, cyclin E, p21
and p-Rb. Uniform loading was confirmed by β-actin. (Di) Flow cytometric histogram profiles
showing percentage of cells with cytosolic monomeric JC-1-associated green fluorescence
(indicating collapse of mitochondrial membrane potential) in PC-3 cultures treated with dimethyl
sulfoxide (DMSO; control, pink profile) or GE (blue profile) for 24 h. Representative data from a
single experiment are shown. (Dii) Quantification of the increase in mean fluorescence intensity
(MFI, i.e. the percentage of green JC-1-stained cells) in PC-3 cultures treated with DMSO
(control) or GE for 24 h. (Ei) Histogram profiles showing a spectral shift and loss of red
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fluorescence, consistent with the loss of transmembrane potential on GE treatment (control,
green; GE, red). (Eii) Quantification of the decrease in mean fluorescence intensity (i.e. the
percentage of red JC-1-stained cells) in PC-3 cultures treated with DMSO (control) or GE for 24
h. Values are means of three independent experiments performed in triplicate, with standard
deviations represented by vertical bars (P<0·05).
Multiple apoptotic pathways are recruited by cells for executing their own demise via
apoptosis. Among them, one major mechanism involves the loss of mitochondrial membrane
integrity and transmembrane potential (Ψm). We thus asked whether GE affected mitochondrial
transmembrane potential. To this end, we stained GE-treated cells with JC-1, a cationic dye that
displays potential-dependent accumulation in the mitochondria. A decrease in the red:green
fluorescence intensity ratio suggested mitochondrial depolarization (Figure 3.3Di). The increase
in the green JC-1 monomeric form, indicative of collapse of transmembrane potential, was
quantitatively determined using flow cytometry. Quantification of fluorescence-activated cell
sorting data indicated an approximately 3.6-fold increase (Figure 3.3Dii) in the mean
fluorescence intensity of GE-treated JC-1-stained cells compared with controls (Figure 3.3Dii).
A spectral shift and loss of red fluorescence, which is consistent with decreased polarization, was
also observed (Figure 3.3Ei and Eii). The collapse of Ψm is closely associated with alterations in
the ratio of antiapoptotic: pro-apoptotic members of the Bcl2 family, which determines
susceptibility to apoptosis. Particularly, loss of Ψm is coupled with hyperphosphorylation and
thus inactivation of the anti-apoptotic molecule Bcl2, which promotes recruitment of BAX onto
the outer mitochondrial membrane. BAX incorporation results in uncoupling of the respiratory
chain and efflux of small pro-apoptotic factors, such as cytochrome c, leading to the activation of
key executioner caspases, caspase-3/7.

Thus, our next step was to investigate the effect of GE treatment on levels of Bcl-2
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family proteins by immunoblotting and the results are shown in Figure 3.4A. GE treatment
caused a rapid and marked increase in BAX expression over time, whereas levels of total Bcl2
were decreased (Figure 3.4A). The GE-mediated alterations in the pro-apoptotic/anti-apoptotic
molecules were evident as early as 12 h post-treatment and increased thereafter (Figure 3.4A).
Biochemical events, such as the release of cytochrome c from the mitochondria into the cytosol,
caspase activation and PARP cleavage, predominantly occur during mitochondria-mediated
apoptotic cell death. Thus, we asked whether GE-induced cell death promoted the release of
apoptogenic factors from the mitochondria that triggered the downstream executioner events of
apoptosis. Our data showed that cytochrome c was detectable at 12 h and peaked at 48 h of GE
treatment in the cytosolic fraction, as observed using immunoblotting methods (Figure 3.4A).
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Figure 3.4 GE induces mitochondrially mediated intrinsic apoptosis
(A) Immunoblot analyses for BAX, Bcl2, cytoplasmic cytochrome c (Cyt c), cleaved caspase-3
and poly(ADP-ribose)polymerase (PARP). β-Actin was used as a loading control. (B)
Quantification of the time-dependent increase in caspase-3 (Casp-3) activity on GE treatment.
Cells were created with GE for 0, 12, 24 and 48 h, and caspase-3 activity was analysed using the
fluorogenic substrate Ac-DEVD-7-amino-4-trifluoromethyl-coumarin. Values are means of three
independent experiments performed in triplicate, with standard deviations represented by vertical
bars (P<0.05). Immunofluoresence micrographs of control and 250 µg/ml of GE-treated cells
stained for cleaved (Ci) caspase-3 and (Di) PARP. (Cii, Dii) Quantification of activated caspase3-positive and cleaved PARP-positive cells.
Our next aim was to explore the involvement of caspases that are activated by the release
of cytochrome c and are known to cleave a variety of substrates. Since caspase-3 activation is
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considered as a hallmark of apoptosis, we monitored the active form of the cysteine protease
using a small, conserved, and modified peptide substrate that becomes fluorogenic upon
cleavage. As shown in Figure 3.4B, GE stimulated a time-dependent increase of caspase-3
activity in PC-3 cells. However, treatment of cells with a specific inhibitor of caspase-3
significantly blocked GE-induced apoptotic cell death (data not shown). Furthermore,
immunoblots showed a time-dependent increase in expression levels of activated caspase-3,
suggesting that GE-induced cell death is caspase-3 dependent (Figure 3.4A). On caspase-3
activation, a number of cellular proteins are cleaved, including PARP. The present results
showed a time-dependent increase in cleaved PARP levels, a substrate of caspase-3. An increase
in the expression of both activated caspase-3 and cleaved PARP was also confirmed in GEtreated cells by immunofluorescence microscopic methods (Figure 3.4Ci and Cii).
3.4.2

Oral ginger extract feeding achieves inhibition of PC-3 tumors in nude mice and in
vivo mechanisms of ginger extract-mediated inhibition of tumor growth
Having identified significant antiproliferative and pro-apoptotic activity of GE, an

intriguing question was to determine whether the anticancer effects of GE were restricted to in
vitro cultures or extended to in vivo systems. To validate this, we examined the efficacy of GE to
inhibit human prostate PC-3 xenografts subcutaneously implanted in athymic nude mice.
Animals in the treatment group were fed daily with 100 mg/kg GE. GE was dissolved in PBS
containing 0·5% Tween-80 and was fed by oral administration for 8 weeks; responses to GE
treatment were followed by tumor volume measurements every consecutive day using vernier
calipers (Figure 3.5A). Tumors in vehicle-treated control animals showed unrestricted
progression (Figure 3.5A), whereas GE feeding showed a time-dependent inhibition of tumor
growth over 8 weeks (Figure 3.5A). A reduction in tumor burden by approximately 56% was
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observable after 8 weeks of 100 mg/kg per d oral feeding, and the difference between the mean
final tumor volumes in animals receiving GE and those receiving vehicle orally was statistically
significant (P<0.05). All animals in the control group were euthanised by day 60 postinoculation, in compliance with the IACUC guidelines. To assess the overall general health and
well-being of animals during GE treatment, body weights were recorded twice a week. GEtreatment was well tolerated, and mice maintained normal weight gain (Figure 3.5B) and showed
no signs of discomfort during the treatment regimen. At the end point of the animal experiments
(week 8), the excised tumors were weighed and an approximately 53% reduction in tumor
weight was observed in the GE-treated group compared with controls.

Figure 3.5 GE caused in vivo inhibition of tumor growth
(A) Progression profile of tumor growth in control vehicle-treated and GE-treated mice at the
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time of treatment. (B) GE treatment was well tolerated, and the body weights of the control and
GE-treated groups were comparable. Values are means, with standard deviations represented by
vertical bars (n=6, P<0.05). (C) Tumor micrographs from control and GE-treated mice,
respectively, at 100X and 200X magnification. GE-treated tumor micro sections reveal large
areas of tumor cell death, consistent with the therapeutic effects of GE. Micro sections from
control tumor tissue show sheets of tumor cells with high-grade pleomorphic nuclei with
minimal cell death. (D) Western blot analysis of tumor tissue lysates from control and GEtreated mice for cyclin B, cyclin D1, cyclin E, p21 and cleaved caspase-3.

To investigate the in vivo mechanisms of tumor inhibition, we first examined
hematoxylin- and eosin-stained tumor sections from control and GE-treated mice. Tumor micro
sections from GE-treated mice showed large areas of tumor cell death, seen as tumor necrosis
adjacent to normal-looking healthy cells. Significant loss of tumorigenic cells in GE-treated
animals (Figure 3.5C) was consistent with the therapeutic effect of GE. However, some viable
tumor cells were observed at the periphery of cell death zones. In contrast, micro sections from
control tumor tissues revealed sheets of tumor cells with high-grade pleomorphic nuclei (Figure
3.5C). We next evaluated the in vivo effect of GE feeding on the antiproliferative response
associated with the inhibition of tumor growth. To this end, tumor tissue lysates were analyzed
for cyclins (D1, E and B1) and a cyclin-dependent kinase inhibitor, p21, using immunoblotting
methods (Figure 3.5D). GE treatment caused a decrease in cyclin D1, cyclin E and cyclin B1,
whereas it increased p21 expression levels, which allied with the present in vitro findings in PC3 cells (Figure 3.3C). Alterations of these cell-cycle regulatory molecules in tumor tissue from
GE-treated mice suggest a potential mechanism for inhibition of tumor proliferation, in keeping
with the inhibition of cell-cycle kinetics observed in vitro (Figure 3.3A and B). In vivo apoptotic
responses of GE feeding in mice bearing PC-3 tumor xenografts were evaluated by
immunoblotting of tumor lysates for cleaved caspase-3 expression.
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We further correlated the in vivo molecular mechanisms of GE treatment by
immunostaining for Ki67, a marker for cell proliferation, as well as apoptotic markers such as
cleaved caspase-3, cleaved PARP and TUNEL (Figure 3.6A). Tumor samples from the treated
groups receiving GE showed marked reduction in Ki67-positive cells compared with controls
(Figure 3.6A). There was a significantly higher expression of cleaved caspase-3 (approximately
12-fold) and PARP (approximately 35-fold) in tumor-tissue from the GE-treated groups
compared with controls (Figure 3.6A and B). We found an approximately 18-fold increase in
TUNEL-positive cells in GE-treated tumors compared with controls (Figure 3.6A and B). Figure
3.6B shows bar graph quantitative representation of the immunostaining data from the control
and GE-treated groups.
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Figure 3.6 GE induced in vivo apoptosis
(A) Immunohistochemical staining of paraffin-embedded tumour tissue sections from the control
and ginger extract (GE)-treated groups for proliferation marker (Ki67) and apoptotic markers
(cleaved caspase-3 (casp-3), cleaved poly(ADP-ribose)polymerase (PARP) and terminal
deoxynucleotidyl transferase dUTP nick-end labelling (TUNEL)). (B) Quantification of Ki67,
cleaved casp-3, cleaved PARP and TUNEL-positive cells counted from several randomly
selected fields for a total of 200 cells. Values are means, with standard deviations represented by
vertical bars (P<0.05).
Toxicity, particularly in tissues with actively proliferating cells, remains a major concern
in the chemotherapy of prostate cancer patients. We observed that there was no gross toxicity
(data not shown), as measured in terms of body weight, grooming or lethargy in GE-treated
mice. Our data showed that there were no detectable differences in the histological appearance of
tissues, including in the gut, liver, spleen, lung, brain, heart, testes and bone marrow, from
vehicle- and GE-treated tumor bearing mice (data not shown). To determine whether GE
treatment affected proliferation of normal tissues with rapidly proliferating cells, colonic crypts
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from GE-treated and vehicle-treated mice were stained with Ki67, a marker for proliferative
index. We found that colonic crypts from both mice groups showed comparable nuclear Ki67
staining. These data suggested that GE did not affect normal tissues with rapidly proliferating
cells. In addition, serum biochemical markers (alanine transaminase, alkaline phosphatase, gglutamyl transpeptidase for hepatic function, and creatinine and electrolytes, e.g. K, Na, Ca and
Cl, for renal function) were similar between the control and GE-treated groups, indicating the
absence of apparent toxicity (data not shown).
3.4.3

HPLC-UV Quantification of Ginger Phytochemicals in GE and determination of
synergy among GE phytochemicals
To gain further insights into the obvious differences in the IC50s of ginger

phytochemicals and GE, our next step was to quantitate the natural abundance of constituent
phytochemicals in ginger extract. HPLC-UV analysis was used to investigate the relative
abundance of 6G, 8G, 10G and 6S in GE (Figure 3.7). We first obtained the calibration curves of
commercially available pure ginger phytochemicals at various concentrations using the analytical
method described in Materials and Methods. Next, GE was injected into the system to obtain the
HPLC-UV profile, where all the peaks corresponding to individual ginger phytochemicals were
identified and manually integrated. The areas under the curve for each of these peaks in GE were
used to calculate their abundance (Figure 3.7). The quantitation table in Figure 3.7 indicates that
6G is the most abundant phytochemical. This result is consistent with literature reports, which
suggest that 6G is the most abundant constituent of fresh ginger.
Accounting for the natural abundance of 6G at ∼6% in GE, its contribution to the IC50 of
GE calculates to be 15 µg/ml. This is equivalent to a ∼32% reduction in the IC50 of 6G when it is
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present in the “food matrix” with other ginger phytochemicals compared to 6G as a single agent.
Similarly, 10G at an abundance of 2.61% in GE exhibited a ∼57% reduction in IC50 when in its
native environment compared to 10G as a single agent. These data suggested the existence of a
synergistic relationship between ginger phytochemicals, which is perhaps responsible for their
enhanced efficacy at lower-dose levels when present in GE.

Figure 3.7 Quantitation of gignerols in GE.
6G, 8G, 10G and 6S were quantified employing LC/MS/MS with electrospray ionization in
positive-ion mode. The presence of 6G [MRM: 277.2/177.2, RT: 5.8 min, 8G (MRM:
305.2/137.2, RT: 9.4 min), 10G (MRM: 333.2/137.2, RT: 14.6 min) and 6S (MRM: 277.2/137.1,
RT: 10.9 min) were confirmed using analytical standards and quantified using calibration curve
for each individual component (shown in the inset).
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To explore the nature of interactions among ginger constituents, we designed binary
combination regimens at fixed ratios of pure ginger phytochemicals (Materials and Methods).
The concentrations chosen were lower than their respective IC50 values. PC-3 cells were treated
with combinations of 6G + 8G, 8G+10G, 10G+6G, 6S+6G, 6S+8G, 6S+10G, GE+6G, GE + 8G,
GE + 10G, and GE + 6S at various concentrations, and the fractions of cells affected (Fa) upon
these treatments were determined using the MTT assay. These data were then computed using
the CalcuSyn software (Version 2.1) to obtain the corresponding CI values. A drug combination
showing CI < 1 is considered as synergistic, >1 as antagonistic, and equal to 1 as additive. Our
results showed that the combination of 6G + 8G (Figure 3.8A) exhibited significantly strong
synergistic interactions for concentrations 0.25 (IC50/2), 0.5 (IC50/2), 0.75 (IC50/2), with CI
values of 0.276, 0.158, 0.191, respectively. Interestingly, the corresponding CI vs. Fa graph in
Figure 3.9A demonstrated that 2 out of the 5 concentrations tested lie above the red dotted line,
signifying that their interactions were antagonistic, with CI values >1.
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Figure 3.8 Ginger phytochemicals act in concert to confer antiproliferative activity.
Bar graph representation of fraction of cells affected (Fa) upon treatment with (A) 6-gingerol
(6G) and 8-gingerol (8G), (B) 8G and 10-gingerol (10G), (C) 10G and 6G, (D) 6-shogaol (6S)
and 6G, (E) 6S and 8G, and (F) 6S and 10G as single agents and in binary combinations. The
concentrations of the ginger phytochemicals (in µM) are plotted on the x-axis, while the fraction
affected is represented on the y-axis. The choice of concentrations for combinations tested has
been described in Materials and Methods. PC-3 cells were treated with the phytochemical binary
combinations for 48 h. Data shown above represent the means of 3 independent experiments
performed in triplicate, with standard deviations represented by vertical bars (P<0.05).
Similarly, the combination of 8G + 10G (Figure 3.8B) at concentrations 0.125 (IC50/2),
0.25 (IC50/2), 0.5 (IC50/2), 0.75 (IC50/2), resulted in CI values less than 0.3, indicating strong
synergism. The CI vs. Fa line plot in Figure 3.9B demonstrated that all combinations tested
displayed synergy. Three out of the five 10G+6G combinations (Figure 3.8C) exhibited
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synergism, with CI values > 0.5, whereas the other 2 were observed to be antagonistic in nature.
Similar to 8G + 10G, we found that all combinations of 6G + 6S (Figure 3.8D) were strongly
synergistic, as the CI values (0.05–0.11) lie below the red dotted line. Furthermore, at low
concentrations of 0.075 (IC50/2), 0.125 (IC50/2), synergistic interactions were observed for 10G +
6G combinations (Figure 3.8E) with CI values of 0.44 and 0.49, respectively. In comparison,
slight synergism was observed at a concentration of 0.5 (IC50/2), with CI value of 0.87. The
concentrations 0.25 (IC50/2) and 0.75 (IC50/2) interacted in a nearly additive manner lying right
below the red line (Figure 3.9E), with CI values of 0.96 and 0.94, respectively. Finally, strong
synergism was observed for 6S+10G (Figure 3.8F) at a concentration of 0.075 (IC50/2) with a CI
value of 0.24. Instead, concentrations of 0.125 (IC50/2) and 0.25 (IC50/2) exhibited moderate
synergism with CI values of 0.44 and 0.58, respectively. The concentration 0.5 (IC50/2), showed
a high CI value of 0.87, which indicated slight synergy. However, the concentration 0.75 (IC50/2)
was nearly additive as its CI value lies above the red dotted line at 1.07 (Figure 3.9F).
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Figure 3.9 Line plots of combination index (CI) versus fraction of cell affected (Fa).
The various concentrations of the combinations correspond to Fig. 3A–3F). The degree of
synergistic interaction was calculated using Calcusyn software and quantitated in terms of CI.
The red dotted line indicates a CI value of 1, below which the combination of ginger
phytochemicals are considered to show a synergistic effect. 6G = 6-gingerol; 8G = 8-gingerol;
10G = 10-gingerol; 6S = 6-shogaol.
These observations suggest that the majority of binary combinations of ginger
biophenolics affected cell proliferation in a synergistic manner. The CI versus Fa plots in Figure
3.9 indicate that 83% of gingerol combinations (6G + 8G, 8G + 10G, and 6G + 10G) inhibited
PC-3 proliferation, with Fa values ranging between 0.4 and 0.5 (Figure 3.9A-C) synergistically.
Furthermore, 90% of the gingerol and 6-shogaol combinations, (6S + 6G, 6S + 8G, and 6S +
10G) exhibited synergism irrespective of the fraction of cells affected. In fact 80% of the 6G +
6S combinations were observed to display very strong synergism (CI < 0.1). Having determined
significant synergism between pure phytochemicals derived from ginger at low concentrations,
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we next asked if an increase in the efficacy of GE could be achieved by increasing the ratio of
these biophenolics in the extract.

To discern the importance of the natural ‘milieu’ of GE and in vivo interactions between
the most-active ginger phytochemicals, we artificially created a quasi-mixture of the active GE
constituents, 6G, 8G, 10G and 6S, hereafter called as Mix. Essentially, the first step was to
isolate, purify and spectrally characterize the aforementioned GE biophenolics using column
chromatography. Further, to formulate the quasi-mixture (Mix), the purified ginger
phytochemicals (6G, 8G, 10G and 6S) were then mixed exactly in the same ratio and
concentrations at which they appear in the ginger extract (GE). The quantitation of individual
ginger phytochemicals in GE was performed using LC/MS/MS which indicated that 1 mg of GE
consists of 30.03 µg of 6G, 6.86 µg of 8G, 7.77 µg of 10G and 5.96 µg of 6S (Figure 3.7).
Having formulated a quasi-mixture with matched concentrations of the most-abundant and active
ginger phytochemicals, we asked if oral feeding with Mix recapitulated or surpassed GE’s
remarkable in vivo efficacy. To this end, we performed an in vivo experiment to evaluate tumor
inhibition by Mix compared to GE in a real time non-invasive bioluminescent prostate cancer
model.
3.4.4

GE is superior to the quasi “Mix” of active GE constituents in inhibiting prostate
tumor growth
We compared the in vivo tumor growth-inhibiting efficacy of GE and Mix in human

prostate cancer xenografts implanted subcutaneously in the right flanks of athymic nude mice. A
human prostate cancer PC-3 cell line stably expressing luciferase enzyme (PC-3-luc) was
employed, which facilitates real-time non-invasive monitoring of prostate cancer growth.
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Animals were randomized and divided into three groups of five mice each for the study. The
study included one vehicle-fed control group and 2 treatment groups fed daily with 250 mg/kg of
GE and Mix via oral gavage for four weeks. Our results indicated that both treatment groups
exhibited a time-dependent inhibition of tumor growth (Figure 3.10A-C), compared to vehicletreated controls. Quantitative comparison of the relative total photon flux that reflected tumor
volume revealed that GE caused ~68% inhibition of tumor growth compared to Mix, which was
only ~28% as measured at the end of week 4 (P<0.05, Figure 3.10B, C, E).
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Figure 3.10 Oral administration of GE exhibited enhanced inhibition of human prostate
tumor xenograft growth in nude mice compared to Mix.
Male nude mice were subcutaneously injected with 106 PC-3-luc cells. (A) Representative
bioluminescent images of one animal per group indicating progression of tumor growth over four
weeks. (B) Graphical representation of quantitative radiance measured as the number of photons
leaving a square cm of tissue and radiating into a solid angle of 1 steradian (photons/sec/cm2/sr)
from control vehicle, GE and Mix fed mice for four weeks. (C) Tumor growth monitored (by
vernier calipers) and presented as tumor-volume in mm3, over a period of 4 weeks. (D) Graphical
representation of body weight of vehicle, GE- and Mix-treated mice. (E) Graphical
representation of tumor weight. (F) Representative photographic images of excised tumors (*,
P<0.05 (two-way analysis of variance), as compared to controls; B, C and E). Error bars refer to
± SD. Statistical significance in percent tumor growth between control and treatment groups was
achieved after week 3.
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3.4.5

GE biophenolics exhibit potential enterohepatic recirculation in vivo, while other less
abundant GE phenolics collaborate with main GE constituents to enable delivery of
optimal in vivo benefits
Intriguingly, despite identical concentrations of the four major active biophenolics in both

GE and Mix, we found a remarkable difference (40%) in the inhibitory efficacy of GE and Mix.
To gain insights into this discrepancy, we evaluated the levels of these four ginger biophenols in
the plasma following oral administration of GE and Mix (250 mg/kg) in C57/BL6J mice (3 mice
per group). All the plasma samples were then evaluated for the presence of 6G, 8G, 10G and 6S
followed by their quantitation using LC/MS/MS (Figure 3.11A-C). To assess the bioavailability
of these components, 6G, 8G, 10G and 6S, were dosed individually at an intravenous dose of 1
mg/kg. The pharmacokinetic parameters of individual GE biophenolics following intravenous
and oral administration were calculated using the plasma concentration time profiles (Figure
3.12A-B). Following oral administration, the clearance of all gingerols was more than normal
liver blood flow in mice (90 mL/min/kg). The volume of distribution was 20-fold higher than
normal body water (0.7 L/kg) suggesting extensive distribution of these components. The halflife of gingerols varied between 0.8 h to 6 h. Following oral administration, all gingerols showed
Cmax at 10 min with GE and 5 min with Mix (Figures 3.11A-B, 3.12B).
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Figure 3.11 GE feeding results in enterohepatic recirculation causing multiple peaking
phenomenon.
Plasma concentration-time profiles of gingerols following oral administration of 250 mg/kg (A)
GE, (B) Mix and following intravenous administration of 1 mg/kg (C) individual gingerols (D)
comparison of plasma concentration-time profiles of gingerols achieved at each time point upon
feeding GE and Mix. Error bars refer to ± SD.
Furthermore, a comparison of mean plasma concentration time profile of 6G, 8G, 10G
and 6S as shown in Figure 3.11D, revealed that these components, when fed as a Mix without the
“natural milieu” are eliminated at a faster rate compared to GE. Upon oral feeding, 10G achieved
a higher Cmax (756.62 ± 7.62 ng/mL) in case of Mix compared to GE (327.26 ± 40.12 ng/mL)
and was statistical significant (P<0.001, Figure 3.12B). Similarly 8G also showed statistically
significant (P=0.02) difference in Cmax between Mix (44.71 ± 0.49 ng/mL) and GE (71.74 ±
32.61 ng/mL). However, 6G, and 6S) showed similar Cmax when fed as GE or Mix (P>0.05,
Figure 3.11, Figure 3.12B). Interestingly, the exposure (AUClast) of 6G, 10G and 6S was 2 to 3-
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fold higher when GE was fed orally compared to Mix except for 8G which showed a similar
profile for both. No statistical analysis was performed on AUClast as it was a sparse sampling
design with composite profile. Surprisingly, a second and third Cmax peak was observed for all
ginger phytochemicals in case of GE at 2 h and 6 h, a phenomenon usually observed in case of
enterohepatic recirculation of molecules from the intestine back to systemic circulation (Roberts
et al., 2002). A similar profile was observed in case of intravenous administration of pure
standards (Figure 3.11C). Surprisingly, this multiple peaking phenomenon was not observed in
case of Mix, thus setting grounds for further investigation of GE’s peculiar PK profile.

Figure 3.12 Pharmacokinetic parameters of GE versus Mix.
The pharmacokinetic parameters were calculated using non-compartmental analysis tool of
validated WinNonlin software (version 5.2). The bioavailability of individual gingerols when fed
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as GE is more compared to when fed as Mix at same concentration. The Cmax values of 6G, 8G,
10G and 6S in blood plasma samples obtained following oral administration of GE and Mix were
compared using independent sample t-test. There was no significant difference in Cmax values of
6G and 6S (P>0.005) but were different for 8G (P=0.02) and 10G (*, P<0.001). No statistical
analysis was performed on AUClast as it was a sparse sampling design with composite profile.
Following intake of drugs or natural products, the disposition of these molecules occurs
by several pathways, of which biotransformation is the most notable. Also, the drug or natural
product metabolites may even be excreted into the bile or to general circulation. Multiple peaks
were observed in case of 6G, 8G and 10G upon GE feeding at 2 h and 6 h following an initial
Cmax at 5 min. This multiple peaking phenomenon is perhaps the consequence of enterohepatic
re-circulation (EHR) of GE phenolics, where their glucuronidated forms that are ready to be
eliminated via feces are broken down by the glucuronidase enzymes in the intestine to be
released as free forms of gingerols, which are then available for reabsorption. To confirm this,
plasma and feces samples obtained after intravenous administration of pure GE biophenolics
were subjected to β-glucuronidase hydrolysis, an enzyme responsible for de-conjugation of
glucuronide metabolites in the intestine. The hydrolyzed samples were then analyzed and
quantitated for 6G, 8G, 10G and 6S using HPLC-MS. Their amounts (ng/mL) in enzyme-treated
and untreated samples were then compared (Figure 3.13Ai, Aii). The presence of significant
amounts of 6G and 8G in enzyme-treated plasma samples at 5, 10 and 15 min (Figure 3.13Ai)
indicate these gingerols undergo conjugation in the intestine/liver to enable elimination. On the
other hand, 10G and 6S were present in very low amounts in their glucuronidated forms.

116

Figure 3.13 Proof of enterohepatic recirculation of active ginger constituents.
(Ai) Comparison of plasma concentration-time profile of 6G, 8G, 6S and 10G in untreated and βglucuronidase treated plasma samples following IV dose administration of individual ginger
phytochemicals. The values of 6G, 8G, 10G and 6S in the enzyme-treated plasma samples were
compared to the untreated samples using independent sample t-test. There was no significant
difference in values of 8G, 10G and 6S (P>0.005) but were different for 6G (*, P<0.005). (Aii)
Comparison of concentration-time profiles of 6G, 8G, 6S and 10G in untreated and βglucuronidase treated feces samples following IV dose administration. The values of 6G, 8G,
10G and 6S in treated feces samples were compared to untreated samples using independent
sample t-test. There was no significant difference in values of 6G, 8G and 10G (P>0.005) but
were different for 6S (*, P<0.001). (B) Plasma protein binding of gingerols in GE vs Mix.
Percentage of unbound gingerols in GE is more than in Mix when compared at different
concentrations. Error bars refer to ± SD.
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While the plasma concentration profile of ginger conjugates indicate their rapid
elimination from the system, the data from feces samples subjected to β-glucuronidase
hydrolysis (Figure 3.13Aii) corroborated that all the 4 components are conjugated and eliminated
through bile. In the treated feces samples, the free forms of 6G, 8G, 10G and 6S upon
quantitation were found to exist in very high amounts. This observation clearly indicates that
upon GE feeding, even though the ginger biophenolics are conjugated as early as 5 min and for a
possible elimination (Figure 3.13Ai), they can undergo systemic circulation for prolonged time
(Figure 3.11C, 3.13Aii), thus resulting in higher exposure and greater residence times in the
system. It is thus clearly evident from the above observations that GE biophenolics undergo
enterohepatic re-circulation (Figure 3.11C). The PK profiles of GE and Mix containing the same
amounts of 6G, 8G, 10G and 6S (Figure 3.11A, B) clearly indicate that in their natural setting,
these GE phenolics undergo EHR, while in a quasi-mixture, they get eliminated within 2 h. Thus,
we next asked as to why these components exhibit different behavior when present in different
matrices.
Binding of a drug to plasma proteins plays a major role in influencing efficacy, drug
distribution, and toxicity. Extensive literature underscores that only unbound drugs circulating in
the blood have better access to target tissues. To discern the differences in plasma protein
binding of ginger phytochemicals present in GE and Mix, we conducted a plasma protein
binding study. We found that the binding of 6G, 8G, and 10G to plasma proteins was lesser in
GE compared to Mix. With an increase in concentration from 10 µg/mL to 100 µg/mL, the free
fraction increased except for 6S, which showed similar binding profile in both GE and Mix
(Figure 3.13B). To summarize, GE phenolics when present in GE are primarily present in free
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form (more unbound) thus facilitating their free transportation to the target tissues, which thus
contributes towards the better efficacy of GE compared to Mix.

Figure 3.14 Oral administration of GE-Mix also exhibited inhibition of human prostate
tumor xenograft growth in nude mice.
Male nude mice were subcutaneously injected with 106 PC-3-luc cells. (A) Representative
bioluminescent images of one animal per group indicating progression of tumor growth over four
weeks. (B) Graphical representation of quantitative radiance measured as the number of photons
leaving a square cm of tissue and radiating into a solid angle of 1 steradian (photons/sec/cm2/sr)
from vehicle and GE-Mix fed mice for four weeks. (C) Tumor-growth monitored (by vernier
calipers) and presented as tumor-volume in mm3, over a period of 4 weeks. (D) Graphical
representation of body weight of vehicle control and GE-Mix treated mice (*, P<0.05 (two-way
analysis of variance), as compared to controls; B, and C). Error bars refer to ± SD. Statistical
significance in percent tumor growth between control and treatment groups was achieved after
week 3.
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Given that 6G, 8G, 10G and 6S in GE are present in their natural plant matrix along with
other ginger phytochemicals like 6-paradol, 8-, 10- shogaol, zingerone, zerumbone etc. (Baliga et
al., 2011; Govindarajan, 1982a, b; Tao et al., 2009; Vasala, 2004; Yoshikawa et al., 1993), we
cannot exclude the contributions from these minor components. To rule out their input, we
prepared another fraction lacking in 6G, 8G, 10G and 6S, which we referred to as GE-Mix (aka
GE minus Mix). Essentially, it was obtained by combining all the ginger sub-fractions collected
after isolating 6G, 8G, 10G and 6S from GE. We tested the in vivo efficacy of GE-Mix to
account for the activity of the residual ginger extract components (Figure 3.14). Intriguingly,
GE-Mix fed animals showed ~35% inhibition in tumor growth compared to vehicle-fed controls
indicating that several other ginger phytochemicals beyond the most abundant ones too can exert
anticancer activity, possibly through additive/synergistic interactions.
3.5

Discussion
‘An ounce of prevention is worth a pound of cure’ goes the famous adage that holds true

for cancer chemoprevention strategies using dietary agents such as fruits and vegetables.
Phytochemical extracts from fruits and vegetables are increasingly being shown to exert potent
antioxidant and antiproliferative effects (Liu, 2003). It is widely becoming appreciated that
chemopreventive agents offer superior potential in the long term than chemotherapeutic agents,
as lifestyle and dietary habits have been identified as major risk factors, particularly in prostate
cancer growth and progression (Kelloff et al., 1999). Ginger rhizome is extensively used in the
form of a fresh paste or dried powder to flavor food and beverages in places such as India and
China (Shukla and Singh, 2007). The present study reports a novel finding that oral consumption
of the extract of whole ginger, a commonly consumed vegetable worldwide, significantly inhibits
prostate tumor progression in both in vitro and in vivo mice models. The anticancer effect of GE
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was coupled with its significant antiproliferative, cell-cycle inhibitory and pro-apoptotic activity
in cell culture as well as in prostate tumor xenograft models. In addition, we also identified that
GE strongly suppressed in vitro and in vivo expression of cyclins/cdks that intricately orchestrate
cell cycle progression.

Ginger is rich in both hydrophilic and hydrophobic constituents, with the hydrophobic
portion mainly comprising different kinds of mono terpenes, oxygenated mono terpenes,
sesquiterpenes, zingerone, paradols, gingerols and shogaols other than essential oils (Karna et al.,
2011a). Shogaol is a dehydrated product of structurally similar gingerols. Just as large quantity
of gingerols is found in fresh ginger, shogaols are abundant in dried and thermally treated ginger;
on the other hand, the hydrophilic portion of GE mostly has a variety of polyphenolic
compounds (Karna et al., 2011a). Quantitative reports have suggested that the main constituents
such as 6-gingerol, 8-gingerol, 10-gingerol and 6-shogaol are present in GE to an extent of 2·15,
0·72, 1·78 and 0·37 %, respectively (Zick et al., 2010). Recent studies have shown that 6gingerol, the major pungent constituent of ginger, suppresses carcinogenesis in skin,
gastrointestinal, colon and breast (Jeong et al., 2009; Lee et al., 2008; Omenn et al., 1996; Park et
al., 1998; Yoshimi et al., 1992). The effective in vitro dose level for 6-gingerol in a variety of
cancer cells has been reported to be in the range of 300–400 µM (Park et al., 2006), which
translates to 88–177 µg/ml. This is interesting as on the basis of our whole GE data (IC50 value ¼
250 µg/ml), IC50 for 6-gingerol computes to only 5·38 µg/ml (approximately 18µM). These
observations raise the possibility of the presence of more active ingredients or existence of an
additive and/or synergistic relationship between the bioactive constituents in GE. Furthermore,
pharmacokinetic studies have reported the maximum achievable plasma concentrations of 6-
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gingerol as 1.90 (SD 0.97) µg/ml (approximately 6.4 (SD 3.3) µM) on oral administration of 120
mg/kg of 6-gingerol in rats (Wang et al., 2009). This suggests that the maximum levels of 6gingerol achievable in the plasma are much lower compared with the reported in vitro effective
half-maximal dose (300–400 µM), thus limiting its potential efficacy in humans. This notion is
in agreement with accumulating data that suggest that the additive/synergistic effects of the
constituent phytochemicals in fruits and vegetables are accountable for their potent antioxidant
and anticancer activities (Liu, 2003, 2004). This emerging paradigm is further supported by
clinical trials with pure single phytochemicals such as α-tocopherol, β-carotene and vitamin C
(Liu, 2004; Omenn et al., 1996) that have met with limited success, reinforcing the fact that an
isolated single constituent of a complex mixture of phytochemicals present in foods may lose its
bioactivity.
In the light of these arguments, the remarkable anticancer activity of whole GE, without
any detectable toxicity in the present study, certainly underscores the importance of using whole
food extracts. Essentially, the beneficial effects of constituent phytochemicals at much lower
dose levels when present together compared with high, relatively toxic doses when used as single
agents may be ascribable to complex inter-reactivity or interdependence existent among various
constituent phytochemicals. This may also be attributable to the fact that the various
phytochemicals comprising whole foods vary in their molecular size, hydrophilicity and
solubility. Thus, there is a strong likelihood that a particular combination of phytochemicals
perhaps offers the optimal pharmacokinetic and pharmacodynamic properties that dictate
favorable anticancer responses. However, if the constituents that participate in the ‘optimal
combination’ are singled out, it may result in altered bioavailability and distribution of the
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phytochemicals in different macromolecules, subcellular organelles, cells, organs and tissues to
yield suboptimal or an absence of favorable therapeutic responses (Liu, 2004).

Given our anticancer therapeutic doses of GE in reducing tumor burden in mice bearing
human prostate xenografts, we performed allometric scaling calculations to extrapolate the mice
data to humans, and the human equivalent dose of the GE was found to be approximately 567 mg
for a 70 kg adult (Reagan-Shaw et al., 2008), which perhaps can be obtained from about 100 g of
fresh ginger. Although various other pharmacokinetic and pharmacodymanic factors need to be
considered before any such conclusions on dose extrapolations can be drawn, our data present
the potential usefulness of GE in prostate cancer and warrant further studies. In conclusion, the
present study is the first report to describe identification and detailed evaluation of in vitro and in
vivo anticancer activity of whole GE in the therapeutic management of human prostate cancer.

Several studies have reported synergistic interactions among phytochemicals at low
concentrations, which would mimic their natural abundance (Mertens-Talcott et al., 2003; Yang
and Liu, 2009). Therefore, the dose ranges we chose to implement with these binary
combinations involved sub-half maximal inhibitory concentrations of each phytochemical to
assess “real” synergy. These findings are consistent with previous studies that have also shown
that increasing the abundance of a phytochemical within an extract enhances its anticancer
activity. Although these combination studies have revealed strategies to significantly improve
activity, the mechanisms underlying this improved inhibition are yet to be unraveled. The
robustly enhanced activity of combination therapy could yield avoidance of single-agent drug
resistance in cancer cells and offer a multi-targeted approach in inhibiting proliferation.
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Extensive literature suggests that each ginger phytochemical functions via a multitude of
different mechanisms, as ginger polyphenols possess several pharmacological and physiological
properties. For example, 6S has been shown to exhibit antioxidant and anti-inflammatory
properties by enhancing the free-radical scavenging activity selectively in cancer cells (Dugasani
et al., 2010). Further, 10G has been reported to slowly increase the intracellular calcium Ca2+
levels in a concentration-dependent manner, leading to death in colon cancer SW480 cells by
releasing Ca2+ from the endoplasmic reticulum (Chen et al., 2009). The major pungent
phytochemical, 6G, possesses anti-inflammatory and antioxidant properties and has been shown
to exert anti-prostatic activity through various mechanisms like depolarization of mitochondrial
membrane potential, thereby increasing the expression of proapoptotic molecules like Bax and
Bak (Baliga et al., 2011; Govindarajan, 1982a, b; Yoshikawa et al., 1993). Quantitative reports
from randomized human clinical trials (Desai et al., 1990; Lumb, 1994) have indicated the safety
profile of GE, suggesting that a daily dose of ginger extract as high as 5 g in its dry form does
not cause any toxicity with the exception of mild stomach upset in individuals who infrequently
consume spicy foods.
However, human subjects administered with large doses (∼6 g daily) showed signs of
gastric irritation and loss of protective intestinal mucosa (Desai et al., 1990). A recent
pharmacokinetic study indicates that human subjects dosed with 250 mg GE containing about
5.38 mg of 6G, achieved a mean maximal blood plasma concentration of 0.9 µg/ml 6G.
Assuming a linear increase in the achieved plasma level, a dose of 250 mg GE with 6G at a ∼6%
level would yield ∼2.5 µg/ml of 6G in plasma. Because the in vitro IC50 of 6G in PC-3 cells is
75 µM (Figure 3.2A), it translates to 22 µg/ml based upon a molecular weight of 294 for 6G.
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Thus, a human blood plasma level of 2.5 µg/ml 6G is possibly achievable on consuming 250 mg
of GE. However, this concentration would not match up with the half-maximal dose-effect in
vitro. To obtain a 6G plasma concentration that corroborates with its IC50 in prostate cancer cells
(22 µg/ml), one perhaps would need to consume a large quantity (2.2 g) of GE. Further, if 6G
was to be consumed alone, and assuming that bioavailability is not a limiting factor, a daily dose
level of 6 g/kg bw of 6G would be required to achieve its in vitro IC50 dose. Such high doses of
individual phytochemicals may not be relevant to the in vivo anticarcinogenic process, thus
limiting the potential efficacy of individual ginger phytochemicals in humans.
Several lines of evidence indicate that a single constituent isolated from a complex
phytochemical mixture present in whole foods or their extracts may even lose its bioactivity or
cause undesirable cancer-promoting effects, as in the case of β-carotene (Greenberg et al., 1994;
Liu, 2004; Omenn et al., 1996; Tsao et al., 2004). Contrastingly, several studies have reported
that intake of whole foods rich in β-carotene, such as carrots, may reduce the risk of lung cancer
(Galeone et al., 2007; van Breda et al., 2005). For example, a case-controlled study involving the
consumption of carrots exhibited an inverse relationship to lung cancer (van Breda et al., 2005).
Another study showed that C57BL/6 mice fed with carrots had the highest expression of
anticarcinogenic genes when compared to the control group (Galeone et al., 2007). Therefore, it
is likely that isolating a single compound from complex foods may not be effective even at high,
relatively toxic doses. However, combinations of lower, less-toxic doses of each compound, as
found in whole foods, may be effective. The natural abundance, low cost, and nontoxicity of this
very common spice, are strong attributes that favor ginger as a chemopreventive as well as a
potential chemotherapeutic alternative in the treatment of prostate cancer. Population-based
studies suggest that Southeast Asians, who regularly consume ginger, have a decreased risk for
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breast, prostate, gastrointestinal, and colon cancers when compared to Americans and Europeans
(Aggarwal and Shishodia, 2006; Dorai and Aggarwal, 2004), thus strengthening the notion that
ginger phytochemicals work together through common and complementary mechanisms to
produce chemopreventive benefits. Specifically, prostate cancer is a potential target for
chemoprevention because of its high prevalence in American men, treatment-associated
morbidity, long latency prior to premalignant lesions, and defined molecular pathogenesis
(Baliga et al., 2011). We strongly believe that dietary supplements of synergistic combinations of
GE and ginger phytochemicals could prove to be both effective chemotherapeutic and preventive
agents and warrant further preclinical evaluation.

Over the past several years, the debate on the use of whole foods versus single agents to
achieve optimal health benefits has spurred numerous studies that have consistently proven that
consumption of whole food extracts underlies improved therapeutic efficacy over single-isolated
constituents. Primarily, this has been speculatively attributed to the presence of
additive/synergistic interactions among the phytochemicals in the former along with other factors
including solubility, physiochemical characteristics and pharmacokinetics of the compounds
(HemaIswarya and Doble, 2006; Jacobs et al., 2009; Jacobs and Tapsell, 2007; Liu, 2003, 2004;
Ulbricht and Chao, 2010; Wagner, 2011). Nonetheless, attempts to improve the efficacy of
whole extracts by isolating the most-active fraction(s) or single agents alone are also being
intensely investigated. Given the perplexing phytocomplexity of plant extracts, several questions
arise. Is it even possible to selectively isolate only the components responsible for efficacy, while
ignoring the insignificant partners? Would the resultant “most-active” fraction(s) show
significant improvement, while working via the same pathways as the parent extract? Would the
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“single-isolated component” or “most-active fraction” be absorbed by the body in the same way
as the whole extract? These are some of the stimulating questions that led us to formulate this
study, wherein we provide compelling in vivo evidence that ginger biophenolics collaboratively
interact with each other to deliver maximum health benefits.

Given the existence of additive and/or synergistic interactions among the active ginger
constituents, 6G, 8G, 10G and 6S in vitro (Brahmbhatt et al., 2013), an obvious next step was to
investigate if these in vitro interactions hold up in an in vivo situation. Our data demonstrate
existence of in vivo interactions among GE phytochemicals as evidenced by the tumor growthinhibiting efficacy of GE (~68%) compared to that of Mix (~28%). The superior efficacy of GE
by 40% unmasked other partners that contribute towards GE’s remarkable activity in addition to
6G, 8G, 10G and 6S (Figure 3.10A, B). Further credence to this notion accumulated when we
“created” a sub-fraction of ginger extract called GE-Mix that lacked the majorly well-known
four bioactive components, and tested for its in vivo anticancer efficacy. Surprisingly, GE-Mix
showed ~35% inhibition of tumor growth (Figure 3.14) indicating that the less known partners
other than 6G, 8G, 10G and 6S also possess significant anticancer potential.

Despite the increasing popularity of whole food extracts, their pharmacokinetic (PK) and
absorption, distribution, metabolism and excretion (ADME) data are scant or lacking. Many
components of most food extracts undergo Phase I and/or Phase II metabolism in vivo, with
cytochrome P450s (CYPs) and uridine diphosphate glucuronosyltransferases (UGTs) majorly
dictating overall bioavailability of the active components in the human body upon ingestion
(Calani et al., 2012; Manach et al., 2004; Manach et al., 2005; Silberberg et al., 2006). To the
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best of our knowledge, no studies have yet compared the PK and bioavailability of the active
components when fed as single-agents or fed in their natural extract setting. Indeed, the
pharmacological activity is gained only when the “active agents” or “active metabolites” attain
as well as sustain appropriate levels so that they can be optimally distributed to the tumor tissue
for therapeutic action. In our context, we found no studies that have compared the bioavailability
of ginger phytochemicals when they are fed as an artificially formulated mixture of single-agents
(at concentrations identical to those present in the natural extract), to the whole extract
(phytochemicals present in their natural milieu). Keeping in mind the collaborative interactions
among GE phytochemicals, we conducted PK studies to recognize any differences in the
bioavailability of 6G, 8G, 10G and 6S when they are consumed as GE or Mix.

The pharmacokinetic profiling of the four GE components upon oral administration of
250 mg/kg of GE or Mix revealed that there were multiple Cmax peaks observed in case of GE,
compared to a single peak in Mix (Figure 3.11A,B). This multiple peaking phenomenon,
associated with re-circulation of compounds from intestine to systemic circulation after getting
eliminated through bile was not observed when pure GE phytochemicals were orally gavaged as
a Mix (Figure 3.11B). Furthermore, the plasma concentrations of the four GE components were
short-lived, when present in Mix (Figure 3.11D). The β-glucuronidase hydrolysis of both plasma
and feces samples obtained post-intravenous administration of pure ginger biophenolics (Figure
3.13Ai, Aii) confirmed that the gingerols re-enter the liver via hepatic portal vein from the
intestine for re-absorption into the systemic circulation. Gingerols when fed as GE mimicked this
phenomenon and exhibited multiple Cmax values whereas Mix was eliminated from the body
within 2 h of feeding. In addition, a higher percentage of unbound gingerols were observed in
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GE compared to Mix (Figure 3.13B), which may aid in the enhanced availability of ginger
phenolics at the target sites in the former setting. Our observations clearly indicate that GE
phytochemicals exert maximum therapeutic properties when present in their natural setting of a
complex plant matrix along with other indispensable partners.

Figure 3.15 GE is more efficacious than the Mixture of its active constituents.
After oral dose administration of Mix to mice, gingerols were eliminated at a faster rate
compared to when GE was dosed. After administering GE, the exposure of gingerols was more
due to enterohepatic recirculation of gingerols, thus conferring GE improved efficacy in
inhibiting prostate tumor growth compared to Mix.
However, the intriguing question to ponder is how EHR of 6G, 8G and 10G is facilitated
in case of oral GE feeding and why is it not the same with Mix? A major challenge associated
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with consumption of xenobiotics that undergo phase II metabolism like anthocyanins, flavanoids,
polyphenols etc. is their lack of in vivo bioavailability. The therapeutic benefits of polyphenols
are often the result of coupled metabolic activities of efflux/uptake transporters and conjugating
enzymes, which play a major role in drug metabolism, elimination and detoxification (Bravo,
1998; Jana and Mandlekar, 2009; Olson et al., 1992; Wells et al., 2004). Conjugating enzymes
like UGTs and sulfotransferases (SULTs) conjugate phenolic compounds to produce hydrophilic
metabolites (Gregory et al., 2004; McCarver and Hines, 2002; Ritter, 2000), which by the action
of chemical pumps, also known as efflux transporters, can be diffused out of the cells. Gingerols
undergo conjugation in various organs including small intestine, liver and kidneys to avoid their
toxic accumulation and hence get eliminated from the system. However, sometimes, these pumps
function as gatekeepers of excess metabolism and thus enable enterohepatic recycling of
phenolics resulting in their re-absorption and improved half-lives. This phenomenon is better
explained via the “revolving door” theory (Liu and Hu, 2007; Manach et al., 2004), which
emphasizes that effective elimination of hydrophilic phase II metabolites of xenobiotics depend
on chemical pumps. When their rate of conjugation exceeds that of elimination, these
metabolites tend to accumulate inside the cell, which may lead to toxicity. During such adverse
conditions, a reverse reaction, where the de-conjugating enzymes like glucuronidases present in
various organs including liver and intestine, release the free forms of these metabolites into the
system, can be favorable (as illustrated in Figure 3.15). In such cases, the re-absorption of active
constituents in lower amounts may actually prove to be beneficial than become toxic due to the
build up (Liu and Hu, 2007).
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Considering the perks of the revolving door mechanism in the cells of gastrointestinal
system, we thus strongly believe that the re-absorption of gingerols after oral feeding of GE
could be responsible for its superior efficacy over Mix (Figure 3.15). It is reasonable to speculate
that that EHR as seen in case of whole extract (GE) could likely be occurring due to the fact that
a wide variety of molecules (from GE) undergo conjugation at a given time resulting in a
possible elimination lag of the “bioactive” components compared to Mix, which is only made up
of the four bioactive phenolics. It is also likely that the whole extract offers a competition due to
the varying binding affinities of different molecules for UGTs, and the most-active molecules are
retained in their unconjugated state at the expense of the “less active” components, which get
eliminated. This would perhaps explain enhanced transport of free active gingerols to the tumor
tissues. This intricate “compensatory” or “buffering” mechanism offered by the complex
phytochemical network is lacking for the gingerols in Mix, and perhaps may result in their faster
elimination, which might underlie the sharp attenuation of efficacy. Indeed, mechanistic insights
on the different phase II enzyme systems that occupy ‘center-stage’ in the elimination kinetics of
ginger phytochemicals will empower us with new knowledge and may result in a conceptual
advancement to develop logically driven rational chemoprevention.

In conclusion, our study is the first of its kind to provide encouraging evidence that
several ginger phytochemicals display significant synergistic antiproliferative effects in prostate
cancer cells when combined at low concentrations with each other. Nonetheless, various binary
combinations of ginger phytochemicals at defined concentrations relative to each other showed
antagonistic effects. Our study further emphasizes the existence of a complex collaborative
interplay among GE phytochemicals to confer maximum therapeutic benefits due to its favorable
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absorption kinetics and bioavailability. Our observations of possible EHR of gingerols, when
delivered in their natural matrix are compelling and provide impetus to investigate and design
futuristic combinations/dietary supplements for prostate cancer management.
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4

“XENOHORMETIC” PROOXIDANT/ANTIOXIDANT POTENTIAL OF
DIETARY PHYTOCHEMICALS4

4.1

Abstract
Plant extracts, a concoction of bioactive non-nutrient phytochemicals, have long served

as the most significant source of new leads for anticancer drug development. Explored for their
unique medicinal properties, the leaves of Piper betel, an evergreen perennial vine, are a
reservoir of phenolics with antimutagenic, antitumor, and antioxidant activities. Here we show
that oral feeding of betel leaf extract (BLE) significantly inhibited the growth of human prostate
xenografts implanted in nude mice compared to vehicle-fed controls. To gain insights into the
‘active principles’, we performed a bioactivity-guided fractionation of methanolic BLE
employing solvents of different polarity strengths using classical column chromatography. This
approach yielded 15 fractions, which were then pooled to 10 using similar retention factors on
thin-layer chromatographs. Bioactivity assays demonstrated that one fraction in particular, F2,
displayed a 3-fold better in vitro efficacy to inhibit proliferation of prostate cancer cells than the
parent BLE. The presence of phenols, hydroxychavicol (HC) and chavibetol (CHV), was
confirmed in F2 by NMR, HPLC, and mass spectroscopy. Further, the HC containing F2 subfraction was found to be ~8-fold more potent than the F2 sub-fraction that contained CHV, in
human prostate cancer PC-3 cells as evaluated by the MTT assay. Removing CHV from F2
remarkably decreased the IC50 of this fraction, indicating that HC is perhaps the major bioactive
constituent, which is present to an extent of 26.59% in BLE. Further, hydroxychavicol (HC),
extracted and purified from Piper betel leaves, was observed to significantly inhibit growth and
4

This chapter has been published verbatim in Carcinogenesis 2013 as Piper betel leaf
extract: anticancer benefits and bio-guided fractionation to identify active principles for prostate
cancer management and	
   Toxicol. Appl. Pharm. 2014 as Hydroxychavicol, a betel leaf
component, inhibits prostate cancer through ROS-driven DNA damage and apoptosis.
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proliferation via ROS generation in human prostate cancer, PC-3 cells. HC perturbed cell-cycle
kinetics and progression, reduced clonogenicity and mediated cytotoxicity by ROS-induced
DNA damage leading to activation of several pro-apoptotic molecules.

In addition, HC

treatment elicited a novel autophagic response as evidenced by the appearance of acidic vesicular
organelles and increased expression of autophagic markers, LC3-IIb and beclin-1. Interestingly,
quenching of ROS with tiron, an antioxidant, offered significant protection against HC-induced
inhibition of cell growth and down regulation of caspase-3, suggesting the crucial role of ROS in
mediating cell death. The collapse of mitochondrial transmembrane potential by HC further
revealed the link between ROS generation and induction of caspase-mediated apoptosis in PC-3
cells. Our data showed remarkable inhibition of prostate tumor xenografts by ~72% upon daily
oral administration of 150 mg/kg bw HC by quantitative tumor volume measurements and noninvasive real-time bioluminescent imaging. HC was well-tolerated at this dosing level without
any observable toxicity. This is the first report to demonstrate the anti-prostate efficacy of HC in
vitro and in vivo, which is perhaps attributable to its selective prooxidant activity to eliminate
cancer cells thus providing compelling grounds for future preclinical studies to validate its
potential usefulness for prostate cancer management.
4.2

Introduction
Demographic studies have reported discernible variations in prostate cancer incidence

across the globe. Known to be one of the deadliest diseases, its mortality rate is higher in
Westerners compared to Asians (Parkin et al., 2005). Given the long latency of prostate cancer, it
is believed that, although the disease initiates concurrently among these cultures, its progression
is much slower compared to the Western population. Such ethnic disparities have been
reportedly linked to differences in dietary regimens that impart both chemotherapeutic and
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preventive benefits (Shukla and Gupta, 2005). Indisputable evidence indicates that a diet rich in
lycopenes, legumes, cruciferous vegetables, curcumin, and gingerols has been associated with a
reduced risk of prostate cancer (Chan et al., 2009).

Fruits, vegetables, and spices with their antioxidant and detoxifying properties, can revert
and delay the progression of prostate cancer mainly due to their abundance in polyphenols that
offer multifarious health-promoting benefits (Cooke et al., 2005; Craig, 1999; Kaur et al., 2009;
Surh, 2003; Yang et al., 2001). Polyphenols have been reported to be highly effective in fighting
various chronic diseases like diabetes and cancer. Recent years have indeed witnessed a revival
of interest in plant phytochemicals, especially polyphenols, as potential chemopreventive and
chemotherapeutic agents. Intriguingly, the redox moieties of these compounds display a twopronged approach to confer their unique “dual ability” (Quideau et al., 2011). While the
chemopreventive efficacy at low concentrations in normal cells is due to these compounds’
antioxidant properties (Quideau et al., 2011), other species of polyphenols can act as prooxidants at higher concentrations in cancer cells and generate ROS, further inducing DNA
damage and eventually apoptosis, thereby acting as potential chemotherapeutic agents (Quideau
et al., 2011). The relative natural abundance of polyphenols, their specificity towards cancer
cells, and thus lack of side effects has generated tremendous interest in these versatile molecules,
emphasizing their advantages over traditional anticancer drugs (Kaur et al., 2009).

Although these phytochemicals exist in leaf, root, or bark as a complex mixture offering
chemical diversity, their relative abundance is influenced by a number of factors such as
environmental conditions, cultivation, time of collection, means of extraction, etc. (Johnson et
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al., 2010; Sasidharan et al., 2011). Since the content of pharmacologically-active constituents
may vary among crude extracts; hence, it is imperative to identify the bioactive compounds as
well as establish their optimum concentrations for maximum therapeutic activity (Rathee et al.,
2006; Sasidharan et al., 2011). Isolation of these bioactive constituents and optimization of their
effective concentrations would result in enhanced bioavailability, pharmacokinetics, and thus
efficacy (in comparison with their respective crude extracts). For example, the major components
of Curcuma longa (commonly referred to as turmeric) are curcumin, demethoxycurcumin
(DMC), and bisdemethoxy curcumin (BDMC). Extensive studies have revealed the enhanced
efficacy of curcumin thus potentiating its use as an anticancer agent (Kunnumakkara et al.,
2008). No wonder curcumin, capsaicin, and gingerols derived from the spices turmeric, red chili,
and ginger, respectively, have entered clinical trials as potential anticancer agents (Sung et al.,
2012).

Polyphenols are major class of phytochemicals known for their disease-fighting and
stress-defeating properties. The emerging hypothesis of Xenohormesis, a phenomenon by which
polyphenols resist stress, combat disease, and confer health benefits (Hooper et al., 2010; Howitz
and Sinclair, 2008) has propelled the evaluation of the role of reactive oxygen species (ROS) in
dictating health benefits exerted by phenolic phytochemicals. Extensive literature describes the
two-pronged approach launched by these phenolic compounds, one that regulates
chemopreventive benefits by enhancing the antioxidant defenses, while the other confers
chemotherapeutic efficacy due to induction of cellular stress (ROS levels) leading to cell death
(Lamming et al., 2004; Surh, 2011; Trachootham et al., 2009). Several studies suggest that
cancer cells display higher reactive oxygen species (ROS) concentrations compared to normal
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cells (Schumacker, 2006; Szatrowski and Nathan, 1991; Trachootham et al., 2009) and thus an
increase in ROS levels can easily tip off the balance in cancer cells due to their higher baseline
levels of ROS to result in cell death (Trachootham et al., 2009).

Inequalities in basal ROS levels in normal and cancer cells can perhaps be ascribed to
increased metabolic activity in the latter, which creates a persistent prooxidative condition
(Trachootham et al., 2009). In cancer cells, while moderate or controlled ROS levels lead to
survival adaptations that promote their growth and progression, a further increase to higher levels
can induce cell death. Excessive levels of ROS disrupt the redox balance maintained in cancer
cells by either irreversibly damaging cellular macromolecules including carbohydrates, lipids,
proteins and DNA or by interfering with the regulation of redox signaling proteins at
transduction or transcriptional levels (Gibellini, 2010). Cancer cells can succumb to death due to
these high ROS levels via several mechanisms including apoptosis, necrosis, autophagy, mitotic
catastrophe, and even due to the loss of drug-resistance adaptation (Surh, 2003). Intrinsically
driven apoptosis due to excess ROS is mediated directly through the mitochondria and involves
the opening of permeability transition (PT) pore complex followed by release of cytochrome c
into the cytosol, which triggers the caspase cascade culminating in cell death (Gibellini, 2010).
Thus, drugs that act as prooxidants and tip over the ROS balance in cancer cells by promoting
the leakage of free radicals from the mitochondria may prove to be valuable anticancer
therapeutics. Although plant phenolics have been long known to have antioxidant functions, their
role in enhancing ROS levels is emerging.

Chemically, polyphenols are redox moieties and this property confers on them the unique
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dual ability to quench as well as generate ROS (Decker, 1997; Sakihama et al., 2002). The
chemopreventive efficacy of certain polyphenols lies in their antioxidant properties and their
ability to scavenge ROS thereby reducing oxidative stress. Such species at low concentration and
in normal cells would act as chemopreventive agents (Bouayed and Bohn, 2010; Surh, 2011).
Other species of polyphenols can act as prooxidants and generate ROS. The ROS surge induces
DNA damage and eventually apoptosis thereby exerting a potential chemotherapeutic action
(Martin and Barrett, 2002; Trachootham et al., 2009). Such species are effective at higher
concentrations in cells with higher levels of oxidative stress (Azam et al., 2004). Literature
suggests that polyphenols with catechol and/or pyrogallol groups can exhibit prooxidant
properties, either by reducing iron (III) or copper (II) ions while chelation or by the reaction of
ortho-hydroxyphenoxy radical, produced from their oxidation, with other free-radical species to
oxidize ortho-quinones and O2-

(Mira et al., 2002)

. Thus, the unique properties that include relative

abundance in nature, lack of selectivity-related side effects, and patient compliance, which
potentially underscore their anticancer benefits, have kindled a lot of interest in the recent times
to further investigate the phenolic phytochemicals.

Piper betel leaves (Piper betel Linn.), also referred to as green gold (Bhide et al., 1991b),
are widely consumed as a condiment in Africa and Asia (especially India and Taiwan). The
medicinal properties of Piper betel can be traced back to ancient Vedic literature. Rich in
phenols and terpenes, these leaves have been reported to exhibit antioxidant, anti-inflammatory,
immunomodulatory, and antitumor activities (Bajpai et al., 2010; Bhattacharya et al., 2005;
Kumar, 2010). Literature reports suggest that hydroxychavicol (HC), an active constituent of
betel leaves, is effective in impeding cell cycle progression of prostate cancer and oral KB
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carcinoma cells. Also, HC has been shown to impart anti-mutagenicity, antiulcerogenic, and
antioxidative properties specifically against cancer cells. There have also been speculations
regarding its stress-inducing properties. However, there is a dearth of data emphasizing the in
vivo efficacy of HC and its prooxidant nature in prostate cancer cells, which could potentially
lead to its development as a single-agent chemotherapeutic agent or in an adjuvant setting.

In this chapter we report the previously unknown benefits of betel leaves in prostate
cancer, as well as a systematic fractionation of the leaf extract to identify the active principles.
This study presents the first identification of the anticancer attributes of betel leaf extract (BLE)
in inhibiting prostate cancer growth in mice models, as well as emphasizes hydroxychavicol as a
major contributor of its in vitro and in vivo efficacy in prostate cancer models. Also, we present
the prooxidant property of HC obtained from betel leaves, as well as its anticancer mechanisms
in in vitro and in vivo prostate cancer models emphasizing the HC-induced ROS effects on
various pathways.
4.3
4.3.1

Materials and Methods
Cell culture, chemicals and reagents
Piper betel leaves were purchased from the local farmer's market in Atlanta, GA.

Hexanes, ethyl acetate (EtOAC), dichloromethane (DCM), and methanol (MeOH) were obtained
from Fisher Scientific (Pittsburgh, PA). Thin-layer chromatography (TLC) plates were from
EMD chemicals (Billerica, MA). Androgen-independent prostate cancer cells, PC-3, DU145,
C4-2 and 22Rv1 were purchased from American Type Culture Collection (ATCC, Manassas,
VA) were cultured in RPMI-1640 media supplemented with 10% heat-inactivated fetal bovine
serum (FBS) and 5% penicillin/streptomycin. The normal prostate epithelial, RWPE-1 cells
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purchased from American Type Culture Collection (ATCC, Manassas, VA) were cultured in
Keratinocyte-SFM medium kit (Invitrogen, Grand Island, NY) supplemented with 10% heatinactivated fetal bovine serum (FBS). Luciferase-expressing PC-3 cells (PC3-luc) were from
PerkinElmer (Hopkinton, MA) and were maintained in MEM medium with 10% FBS, Hyclone,
(Pittsburgh, PA). All the cell lines were made sure to be devoid of mycoplasma contamination
using Universal Mycoplasma Detection Kit from ATCC (ATCC, Cat#30-1012K, Manassas,
VA). The MTT dye (thiazolyl blue tetrazolium bromide, 98% TLC), Acridine orange (AO),
2’,7’-dichlorofluorescein diacetate (DCFDA), chloroquine, 3-methyladenine (3-MA), dimethyl
sulfoxide (DMSO), Hoechst stain, eugenol (EU), and preparative TLC plates and β-actin
antibody were from Sigma (St. Louis, MO). Dihydroethidium (DHE), 4,5-dihydroxy-1, 3benzenedisulfonic acid disodium salt monohydrate (tiron), 5,5’,6,6’-tetrachloro-1,1’,3,3’tetraethylbenzimidazolyl carbocyanine iodide (JC-1), apocynin, rotenone and cyclosporin A
were from Fisher Scientific. The concentrations of the above reagents used in the study were:
100 µM HC, 25 µg/ml of AO, 5 µM DHE, 25 µM DCFDA, 2.5 µg/ml of JC-1, 0.5 mM 3-MA; 1
mM tiron, 100 nM rotenone, 10 µM apocynin and 5 µM cyclosporin A. Primary antibodies for
beclin-1, light chain 3 (LC3IIb), cleaved caspase-3, cleaved PARP, γ-H2AX, and cytochrome c
were from Cell Signaling (Beverly, MA). MitoTracker Red, Alexa 488- or 555-conjugated
secondary antibodies were from Life Technologies (Grand Island, NY). Horseradish peroxidaseconjugated secondary antibodies were from Santa Cruz Biotechnology, Inc. Hydroxychavicol
(HC) was extracted from betel leaves and was characterized for >99% purity.
4.3.2

Preparation of methanolic betel leaf extract and Isolation of HC from betel leaves
Freshly cut betel leaves were lyophilized to remove any moisture present. Freeze-dried

leaves were soaked in methanol overnight for three consecutive days. The supernatant was
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collected daily, concentrated under reduced pressure, and lyophilized to remove any traces of
moisture. The dried BLE was then stored at -80oC. Batch-to-batch variation was assessed by
quantitating HC content via HPLC-UV analysis, and no significant variations were observed in
the three batches processed.
Freshly chopped Piper betel leaves were submerged in deionized water and extraction
was carried out in a boiling apparatus for 3 h followed by collection of the supernatant by
filtration for three consecutive days. The pooled supernatant was then concentrated to 1/12th of
the original volume under reduced pressure at a temperature of 50oC. This concentrated aqueous
extract was further extracted 6 times in a separating funnel with 250 ml of DCM each time,
followed by vacuum filtration through celite bed. The resultant clear DCM fraction was then
concentrated under reduced pressure. The residue was then subjected to silica gel column
chromatography (100-200 mesh) where the elution was initiated with a total of 1400 ml of DCM
followed by 800 ml of 1% MeOH in DCM. Fractions of 100 ml each were collected and
subjected to TLC in DCM:MeOH (19:1). The fractions 4-22 were found to contain pure HC and
thus were pooled and concentrated under vacuum. HC was further characterized by spectral
analysis for both quantitation and >99% purity via HPLC.
4.3.3

Fractionation of BLE and identification of constituents using chromatography
techniques
We employed column chromatography, a commonly used analytical technique to

separate the constituents of betel leaves. Three grams of BLE was dissolved in methanol, and
adsorbed on silica gel (0.063-0.2 mm, 70-230 mesh) using a rotary evaporator. The column (3.5
cm*45 cm) was filled with silica and the BLE-adsorbed silica mixture was added atop the silica
followed by a layer of anhydrous sodium sulfate to remove any moisture. The column was then
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subjected to solvents of increasing polarity, the order being hexane < dichloromethane < ethyl
acetate < methanol. The eluents were 100, 70, 50, and 30% hexane/ethyl acetate (500 ml each)
followed by 500 ml of 10, 20, 30, 40, and 50% ethyl acetate/dichloromethane and 99.5, 99, 97,
95, 90, and 70% dichloromethane/methanol. The 15 fractions eluted were concentrated, and
traces of solvents were removed by lyophilization and then subjected to thin layer
chromatography (TLC). Pre-coated alumina TLC silica gel 60 F254 plates were used and the spots
were analyzed under UV light. Based on similar pattern and retention factors, the fractions were
pooled together to finally yield 10 fractions.
Each fraction obtained from column chromatography was spotted on a TLC plate
(Alumina TLC silica gel 60 F254) along with the standards, HC and EU, and run through a series
of solvent systems. The solvent systems used for TLC of various fractions were as follows: F1F3--70:30 hexane/ethyl acetate; F4-F7--10:90 ethyl acetate/dicholoromethane; F8-F12--5:95
methanol/dicholoromethane; F13-F15--15:85 methanol/dicholoromethane. Once developed, the
plates were screened for HC and EU by comparing the bands obtained for each fraction with the
bands corresponding to the standards. The presence of HC and EU was confirmed by co-spotting
the fraction with the standard compounds.
The individual constituents of BLE were further separated using preparative TLC
method. 100 mg of each fraction was loaded on the plate, a binary mobile phase of 30% ethyl
acetate in hexane was used as the solvent system, and the plate was developed in a glass
chamber. The constituents separated as bands were scraped, dissolved in DCM, filtered, and
concentrated for testing.

142
4.3.4

Nuclear magnetic resonance (NMR), High-performance liquid chromatography
(HPLC) with UV and mass-spectrometric detection
1

H NMR spectra were recorded on Bruker Avance (400 MHz) spectrometer vertical bore

spectrometer using 5 mm high-resolution probes, using CDCl3, CD3OD, or DMSO-d6 as solvent.
Mass spectra (ESI-MS, positive ion mode) were recorded on a nanoLC-Q-TOF micro (Waters
Micromass) mass spectrometer.
The HPLC-UV analysis of BLE was achieved on a HP1100 series instrument (Agilent
Technologies, Wilmington, DE) equipped with a photodiode array detector, using an Agilent
XDB reversed phase (C-18, 1.8 µm, 4.6 x 50 mm, ODS-2) column. The mobile phase system
consisting of solvent A (1.5% acetic acid in water) and solvent B (1.5% acetic acid in acetonitrile
(ACN)) was employed to achieve the separations. The gradient elution was set as follows: initial
8% B for 5 min, achieving 20% B at 60 min, which was held for an additional 5 min; this was
followed by reconditioning to 8% B at 70 min and holding it for the next 5 min with a flow rate
of 1 ml/min. 20 µl of BLE (1 mg/ml), dissolved and filtered in pure methanol, was injected into
the system and the resultant HPLC-UV peaks were detected at 280 nm.
The HPLC-MS analyses were performed in tandem with HPLC-UV using the same
column interfaced to an Agilent 6400 Series Triple quadrupole LC/MS equipped with an
electrospray ionization source, operable in both positive and negative ion modes. The nebulizer
and collision gases were nitrogen and helium, respectively, with nitrogen set at 40 psi. A drying
gas temperature of 300oC, drying gas flow rate of 9 l/min, and capillary voltage of ±3000V were
the spray chamber specifications. The presence of HC (m/z = 151) in BLE was confirmed using
MS-scan mode against pure standard.
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4.3.5

Antiproliferative MTT assay
Androgen-independent human prostate cancer cells, PC-3, DU145, C4-2 and 22RV1,

were seeded in 96 well plates at a density of 3500 cells per plate. After 24 hours of incubation,
the medium was aspirated and replaced by media dosed with BLE at concentrations of 1, 10, 25,
50, 75, 100 and 250 µg/ml and HC at concentrations of 1, 10, 25, 50, 75, 100 and 250 µM.
Primary stocks were prepared by dissolving each fraction in DMSO at a concentration of 1
mg/ml BLE and 25 mM HC. The secondary stock of each fraction was made at a concentration
of 250 µg/ml BLE and 250 µM HC followed by further dilutions. A total volume of 100 µl was
added to each well. After 48 hours of incubation the drug-containing medium was aspirated and
100 µl of MTT (Tetrazolium bromide 5mg/ml) dye dissolved in RPMI was added. Following 4
hours of incubation, the MTT dye was aspirated and the formazan crystals were solubilized in
DMSO. Chromophoric groups in MTT (yellow) were reduced to a purple tetrazolium complex
by viable cells and the absorbance was read at 570 nm using a SpectraMax Plus (Molecular
Devices, Sunnyvale, CA) multi-well plate reader.
4.3.6

Trypan blue and colony survival assay
5000 PC-3 cells plated in a six-well format were treated with 100 µM of HC the next day.

Following 24 h of HC treatment, cell-proliferation was determined using Trypan blue assay. For
the colony assay, PC-3 cells were seeded at appropriate dilutions (~100 cells/well) and were
treated with 100 µM HC for 24 h, washed, and replaced with regular RPMI-medium. The
crystal-violet colonies (each consisting of at least 50 cells) were counted post fixation with 4%
formaldehyde solution.
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4.3.7

Measurement of ROS
PC-3 cells were seeded in 96 well plates and after 24 h of incubation, the medium was

aspirated and the cells were pre-treated with either DHE (oxidized by ROS into ethidium
bromide and fluoresces red) or DCFDA (oxidized by ROS to DCF) for 30 min and then treated
with HC at concentrations of 50, 100 and 150 µM. Following treatment for 0.5, 1, 3, 6 and 12 h,
the induction of ROS was measured using fluorimetry. Further, fluorescently labeled cells
stained with either DHE or DCFDA were analyzed flow cytometrically. Furthermore, DHE and
DCFDA stained cells on coverslips were examined using fluorescence microscopy. The source
of ROS was determined by fluorimetry in the presence of inhibitors like rotenone, cyclosporine
A and apocynin.
4.3.8

Cell-cycle studies
PC-3 cells treated with 100 µM HC for 6, 9, 12, 18, and 24 h, were lysed, centrifuged,

washed with ice-cold PBS, fixed in 70% ethanol and stored at 4°C. Pellets were collected,
washed twice with PBS and stained with propidium iodide in the presence of RNaseA for 45 min
in the dark. Cell cycle profile was analyzed by flow cytometry.
4.3.9

Immunofluorescence Microscopy
PC-3 cells grown on coverslips were treated with 100 µM HC, and/or followed by live

staining with MitoTracker (100 nM; Ex:Em::579:599) and were then fixed with ice-cold
methanol for 10 min. This was followed by blocking with 2% bovine serum albumin/PBS at
37°C for 1 h. The coverslips were then incubated with γ-H2AX, cleaved PARP, cleaved caspase3 and cytochrome c antibodies (1:100 dilution) 37°C for 1 h, which were then washed with 2%
bovine serum albumin/PBS for 10 min at room temperature and incubated with 1:500 dilution of
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Alexa 488- (Ex:Em::499:519) or 555- (Ex:Em::553:568) conjugated secondary antibodies. The
coverslips were then mounted with Prolong Gold antifade reagent containing 4’,6-diamidino-2phenylindole (Invitrogen).
4.3.10 Immunoblotting
Protein lysates were collected from cells treated with or without 100 µM HC and were
resolved by SDS-PAGE, followed by a transfer onto polyvinylidene difluoride membrane that
was incubated with a primary antibody of choice overnight at 4°C. Appropriate secondary
antibody

was

used

followed

by

visualization

of

the

immune-reactive

bands

by

chemiluminescence detection kit (Pierce). β-actin was loading control. The cleaved caspase-3
(Figure 3Ai) and beclin-1 (Figure 5Bi) protein expressions were developed from the same blot.
4.3.11 Detection and Quantification of Acidic Vesicular Organelles (AVOs)
PC-3 cells grown on coverslips followed by treatment with 100 µM HC for 24 h along
with controls were stained with 25 µg/ml of AO for 30 min, washed twice with PBS, and fixed
using ice-cold methanol. The mounted coverslips were examined under a Zeiss (Axioplan-2)
fluorescence microscope (63X objective) for the presence of AVOs, which were also further,
confirmed and quantified by flow cytometry. The fluorescence emissions, green (510–530 nm)
and red (650 nm), from 5000 cells obtained by illuminating with blue (488 nm) excitation light
were measured using a FACS Calibur flow cytometer. The red:green fluorescence ratio for each
cell was obtained using FlowJo software (Karna et al., 2010; Millot et al., 1997).
4.3.12 Electron Microscopy
Cells from control and 100 µM HC-treated samples were collected and fixed for 2 h in
2% paraformaldehyde, 0.1% glutaraldehyde in 0.1 M sodium cacodylate, then fixed for 1.5 h
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with 1% osmium tetroxide, followed by washing, and staining en bloc in 1% aqueous uranyl
acetate (pH 3.3) for 1 h. The samples were then washed and dehydrating with a series of ethanol
solutions (through 3 x 100%). These were then embedded in Spurr epoxy resin (Electron
Microscopy Sciences) of which ultrathin sections were cut on a RMC-MYX ultramicrotome, and
examined on a LEO 906e transmission electron microscope after counterstaining with lead
citrate.
4.3.13 In vivo tumor growth and bioluminescent imaging
PC-3-luc cells (1x106) were subcutaneously injected on either flank of six-week old male
BALB/c nude mice (Harlan Laboratories, Inc., Indianpolis, IN). When tumors were palpable,
mice were randomly divided into four groups of five mice each. Control group received vehicle
(PBS with 0.05% Tween-80, pH=7.4) and the three treatment groups received 200, 400, and 650
mg/kg body weight BLE dissolved in PBS with 0.05% Tween-80 (pH=7.4) by oral gavage daily.
In another independent experiment the control group received vehicle (PBS with 0.05% Tween80, pH=7.4) and the treatment group received 150 mg/kg body weight HC (dissolved in PBS
with 0.05% Tween-80 (pH=7.4)) by oral gavage daily. Tumor growth was monitored by
measuring the luciferase activity in live mice by bioluminescent imaging in real-time using the
IVIS in vivo imaging system (PerkinElmer, Inc., Hopkinton, MA) with the Live Imaging
software. Briefly, mice anesthetized with isoflurane were intraperitoneally injected 25-30 mg/ml
luciferin and imaged with a CCD camera. An integration of 20 s with four binnings of 100 pixels
was used for image acquisition. The relative photon quantitation at the tumor site of the mice
from vehicle- or BLE-treated or HC-treated groups was quantitated twice a week for six weeks.
All animal experiments were performed in compliance with institutional IACUC guidelines.
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4.3.14 Immunofluorescence and immunohistochemical staining
Paraffin-embedded tumor sections from vehicle and BLE-treated groups were processed
and immunostained with apoptotic markers, cleaved caspase-3 and cleaved PARP, the
proliferation marker, Ki67 and hematoxylin and eosin (H&E). Images were captured using
fluorescence microscopy. Microscopic evaluation was performed by a pathologist in a blinded
manner. Organs and tumors collected from HC- or vehicle-fed mice after 6 weeks of treatment
were formalin-fixed or frozen immediately post-euthanasia. The tumor and organ sections were
cut (5 µm) and stained with hematoxylin and eosin (H&E), cleaved caspase-3 and cleaved
PARP. A pathologist performed blind-mannered microscopic evaluation of all the sections.
Complete blood count was performed on blood samples collected from vehicle- and HC-fed
C47BL6/J mice (3 per group) after consecutive oral administration of vehicle and HC (150
mg/kg bw) for 3 days.
4.3.15 Determination of half-maximal lethal dose (LD50) and acute in vivo toxicity
C47BL6/J mice were fed with very high doses (5g/kg and 2 g/kg bw) of BLE or HC and
followed by observation of their health conditions. BLE or HC were fed to mice at various doses
to determine the dose at which 50% of the mice in the BLE- or HC-fed group are alive (LD50).
4.3.16 Statistical analysis
All the experiments were repeated at least 3 times. Values from quantitative experiments
are expressed as the mean ± standard deviation (SD) and were calculated using Microsoft-Excel
software. The Student’s t-test and a two-way analysis of variance (ANOVA) were performed to
determine the differences between the control and treatment groups. P-values <0.05 were
considered as statistically significant.
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4.4
4.4.1

Results
BLE induces apoptosis and inhibits proliferation of tumor growth in vivo
Betel leaves have been shown to exhibit antiproliferative, antimicrobial, and

immunomodulatory properties. Considering the disease-fighting potential of BLE, we first
examined its in vivo efficacy to inhibit human prostate tumor xenografts implanted
subcutaneously in athymic nude mice. We used a stable PC-3 cell line that expresses luciferase
(PC-3-luc), which enables real-time visualization and non-invasive monitoring of prostate cancer
growth longitudinally in mice. In an experiment to determine the half-maximal lethal dose
(LD50), we found that 700 mg/kg bw BLE was not well-tolerated. Animals showed evident signs
of discomfort and were thus euthanized at day 6. Next, we performed a dose-dependent study
comprising five mice in each of four groups that were fed with vehicle (PBS) and 200, 400, or
650 mg/kg bw BLE daily by oral-gavage for six weeks. Treatment responses were monitored
twice a week by bioluminescent imaging (Figure 4.1A). Our data show that BLE-treated groups
display inhibition of tumor growth significantly over six weeks in contrast to vehicle-treated
control animals (Figure 4.1A, B). Relative photon quantitation revealed that 400 mg/kg bw BLE
showed a ~61% inhibition in tumor volume at a confidence level of p<0.05 (n=5 Figure 4.1A), as
measured at week 6 compared to vehicle-treated controls. Body weights were recorded twice a
week to assess general health and well-being of animals during treatment. Mice in the BLE
treatment groups exhibited normal weight gain with no signs of discomfort during the treatment
regimen. All animals in the control group were euthanized by day 42 post-inoculation due to
tumor overburden, in compliance with IACUC guidelines. At the end of week six, the excised
tumors (Figure 4.1E) were weighed post-euthanasia, and a ~59% reduction in tumor weight was
recorded in a subset of mice from 400 mg/kg bw BLE-treated group compared to controls.
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Though the 650 mg/kg bw BLE-fed group showed significant inhibition of tumor growth, mice
could not tolerate the dose beyond four weeks of treatment (Figure 4.1Ai). These mice showed
loss of appetite and weight (Figure 4.1C) and were euthanized at week four.

Figure 4.1 Dietary feeding of BLE showed inhibition of human prostate tumor xenograft
growth in nude mice.
Male nude mice were subcutaneously injected with 106 PC-3-luc cells. (Ai) Bioluminescent
images indicating progression of tumor growth of various dose groups over 6 weeks. (Aii)
Graphical representation of photon quantitation from vehicle-treated mice and varying doses of
BLE-treated mice for 6 weeks. (B) Tumor growth monitored by vernier calipers and presented as
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tumor volume in cubic millimeter, over a period of 6 weeks. (C) Graphical representation of
body weight of vehicle-treated mice and varying doses of BLE-treated mice. (D) Survival graphs
of BLE dose-dependent treatment and controls over 9 weeks. (Ei) Photographic images of
excised tumors and (Eii) Graphical representation of tumor weight. The data points and the error
bars represent average values and standard deviations, respectively, of all the animals in each
group (*P < 0.05 compared with controls using two-sample t-test).
The longevity of surviving mice in 400 mg/kg bw fed treatment group was monitored
based on general health and well-being of the mice after BLE feeding was suspended at week 6.
Kaplan Meir analysis revealed that this treatment group exhibited 60% survival until nine weeks
(Figure 4.1D). Furthermore, biochemical analysis of serum markers (alanine transaminase,
aspartate transaminase, alkaline phosphate, lactic acid dehydrogenase, creatinine kinase, and urea
nitrogen) was compared between the vehicle- and BLE-fed groups and was found to be within
the normal range (Figure 4.2). The remarkable efficacy of BLE in inhibiting in vivo tumor
growth encouraged us to determine the composition of this leaf extract to gain insights into its
active principles.

Figure 4.2 Organ-associated toxicity was not observed in BLE-fed group.
(A) Urea nitrogen levels in BLE-fed group were comparable to that of vehicle-fed group. (B)
The lactate dehydrogenase (LDH) and creatinine kinase levels in both the groups did not show
any abnormal differences. (C) The biomarkers of liver, alanine aminotransferase (ALT), alkaline
phosphatase (ALP), and aspartate aminotransferase (AST) were comparable for both the groups.
(P<0.06 compared to controls using two-sample t-test).
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Paraffin-embedded tumor tissue sections from vehicle and BLE-fed mice were processed
and immunostained for the cell proliferation marker, Ki67 (MIB-1) to evaluate in vivo inhibition
of tumor growth. Our data showed a decrease in Ki67 expression in tumor sections from BLEfed mice suggesting reduction in cell cycle activity upon BLE treatment (Figure 4.3Ai). H&E
staining of tumor sections from BLE-fed mice revealed large pale pink cytoplasmic areas (Figure
4.3Aii) indicating clearing of tumor cells. Also, tumor sections from BLE-fed groups showed an
increase in cleaved caspase-3 and cleaved PARP expression (Figure 4.3Bi-Bii) compared to
tumor sections from control vehicle-fed groups, implying induction of apoptosis upon BLE
treatment.

Figure 4.3 BLE induces apoptosis
(Ai) Ki67 immunostaining, (Aii) hematoxylin and eosin staining and immunofluorescent staining
for apoptotic markers, (Bi) cleaved caspase-3 and (Bii) cleaved poly (ADP ribose) polymerase of
tumor sections from vehicle- and BLE-fed mice.
4.4.2

Identification and quantitation of bioactive constituents of BLE using column
chromatography
The non-toxic in vivo attributes of BLE were also confirmed in vitro, wherein the IC50 of

BLE was found to be ~14 fold higher in normal prostate epithelial RWPE-1 cells (IC50=447
µg/ml, Figure 4.4) compared to human prostate cancer PC-3 cells (IC50=32 µg/ml, Figure
4.5C,D). Given the wide therapeutic window, we next aimed to identify and isolate the bioactive
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constituent/s responsible for the in vivo efficacy of BLE. Thus, we first fractionated BLE using
classical column chromatography by employing a gradient method to ensure absolute separation
with a reduced analysis time.

Figure 4.4 Antiproliferative assay of BLE in normal prostate epithelial cells.
Plot of percentage cell survival vs concentration to measure the half-maximal growth inhibitory
concentration (IC50) of BLE against normal prostate epithelial, RWPE-1 cells. (P<0.06 compared
with controls using two-sample t-test)
A series of solvent systems with a gradual increase in polarity were used to elute BLE
along the silica gel column, and the separated constituents were collected as fractions (Figure
4.5A). 100% hexane was initially passed through the column to elute non-polar constituents of
BLE. Ethyl acetate was then introduced into the mobile phase to enhance polarity along with
dichloromethane, and elution of moderately polar constituents was thus achieved. Finally,
increasing concentrations of methanol (from 0.5% up to 30%) in combination with
dichloromethane were used to elute highly polar components (Figure 4.5A). Based on this
separation scheme, BLE constituents were resolved into 15 fractions followed by subjection to
analytical TLC. Fractions with comparable retention factor (Rf) values were pooled together to
finally obtain 10 fractions, F1-F10 (Figure 4.5B), which were tested for their antiproliferative
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activity using an MTT assay in PC-3 cells. All fractions were concentrated under reduced
pressure and lyophilized. While processing the first fraction, F1, no visible material was
observed in the flask and thus this fraction could not be collected.

Figure 4.5 Fractionation of BLE using column chromatography.
(A) Ten fractions of BLE were obtained from classical chromatography using a gradient method.
Fifteen fractions eluted were pooled to obtain 10 fractions based on comparable Rf values. H =
hexane, E = ethyl acetate, D = dichloromethane and M = methanol. (B) TLC of 15 fractions
using 70:30 hexane/ethyl acetate (1–3), 10:90 ethyl acetate/dichloromethane (4–7), 5:95
methanol/dichloromethane (8–12) and 15:85 methanol/dichloromethane (13–15) solvent
systems. Fractions with comparable Rf values were pooled together to obtain 10 fractions. (C)
Plot of percentage cell survival versus gradient concentration of different fractions. MTT assay
was performed on fractions F2–F10 and compared with the parent BLE. (D) Bar graphical
representation of IC50 of each fraction, parent BLE and the standards HC and EU. Data points
and error bars represent average values and standard deviations, respectively, of three
independent experiments (P<0.05 compared with controls using two-sample t-test).
The half maximal inhibitory concentrations (IC50) of nine fractions thus obtained are
shown in Figure 4.5C-D. The least polar fraction, F2, was identified to be the most active with an
IC50 of 10 µg/ml and showed a 3-fold better activity than the parent extract. The difference in the
activity of various BLE fractions could be attributed to the presence of constituents varying in
their polarity, which we attempted to investigate next.
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Several studies on piper betel leaves have reported that BLE is rich in phenols including
hydroxychavicol (HC), eugenol (EU), chavibetol (CHV), and allylpyrocatechol (APC)
(Chakraborty, 2011; Kaur et al., 2009; Rathee et al., 2006). Chemically these compounds
comprise monocyclic aromatic rings with phenolic and allyl moieties (Paranjpe et al., 2013).
Preliminary analysis of BLE fractions by TLC using HC and EU as standards (Figure 4.6A)
revealed that F2 consisted of both EU and HC. However, TLC cannot rule out that the bands
corresponding to EU and HC in F2 could be compounds with similar polarity including their
positional isomers like chavibetol (CHV), isoeugenol (IEU), and allylpyrocatechol (APC)
(Rathee et al., 2006), respectively (Figure 4.6B). While EU was not seen in the later fractions,
bands corresponding to HC were identified in F3 and F8-F10.
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Figure 4.6 Qualitative analysis of HC and EU.
(A) TLC analysis was performed for each fraction and compared with the standards HC and EU.
Comparable bands revealed that F2 contained both HC and EU. This was confirmed by cospotting the fraction with each standard. (B) Chemical structures of polyphenols, EU with its
positional isomers, isoeugenol and CHV, and HC with its positional isomer, APC. (C) LCUV/MS comparison of HC in F2–F10. HC (m/z = 149) was detected in negative ion mode and
was compared with the pure standard.
Further, co-spotting F2 with HC and EU confirmed the presence of bands corresponding
to these pure standards. The next step was to examine the presence of HC and EU in all the
fractions using UV detector equipped high performance liquid chromatography (HPLC-UV)
coupled with tandem mass spectrometry (MS), an analytical technique with higher sensitivity
and better separation efficiency. The HPLC-UV/MS analysis of F2-F10 in negative ion mode
(scan, m/z 100-500) revealed the presence of HC (m/z=149) in all the BLE fractions. However,
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the abundance of HC in F2 was much higher compared to the rest of the fractions (Figure 4.6C).
A linear decrease in its abundance was observed in the subsequent fractions and, interestingly,
F10 was more concentrated in HC compared to F9. The rationale behind the ‘bleed-over’ of HC
into later fractions could be attributed to the strength of intermolecular hydrogen bonds between
the stationary silica and HC. With an increase in the polarity of the solvent system, the hydrogen
bond breakage perhaps results in the spill-over of some residual amounts into the later fractions,
as detected in HPLC. Seemingly, the final fraction with the highest polarity perhaps completely
solubilized the residue and thus HC was detectable in F10 as well. In addition, other phenolic
compounds like chavicol (m/z=133), phenylalanine (m/z=164), hydroxychavicol acetate
(m/z=191), piperol A (m/z=341), and piperol B (m/z=355) were also detected in the BLE
fractions. However, the molecular ion peak at m/z=163 could not be confirmed as either EU or
CHV. Given that the TLC and HPLC/MS data suggested the presence of HC and EU (Figure
4.6A,C) in F2, we next aimed at identifying the contribution of these individual phytochemicals
towards F2’s activity.
4.4.3

Subfractionation of F2 and nuclear magnetic resonance and mass spectrometric
characterization of F2 subfractions
Bioactivity-guided fractionation of BLE suggested that F2 (IC50=10 µg/ml) is ~3-fold

more active than BLE (IC50=32 µg/ml) in human prostate cancer PC-3 cells. We also tested the
activity of F2 in other prostate cancer cell lines, namely, DU145 and 22Rv1. The IC50 values of
F2 in DU145 and 22Rv1 were found to be 100 and 39 µg/ml, respectively (Figure 4.7A,B).
While the IC50 of F2 in DU145 was 1.25 fold lower than that of BLE, 22Rv1 showed only
slightly lower IC50 of F2 compared to BLE (data not shown). Our results showed that F2’s
antiproliferative activity is in the following order: PC-3>22Rv1>DU145. PC-3 and DU145 cells
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are androgen-receptor negative and harbor non-functional p53, whereas 22Rv1 cells are
androgen-receptor positive and harbor wild-type p53. These data suggest that the
antiproliferative activity was independent of androgen receptor or p53 status in the cell lines
studied. Having compared the activity of F2 against different prostate cancer cell lines, our next
step was to determine the bioactive constituents accountable for F2’s activity.

Figure 4.7 Antiproliferative efficacy and subfractionation of F2.
(A) Plot of cell survival versus concentration of F2 for different prostate cell lines. MTT assay
was done on additional prostate cell lines, 22Rv1 and DU145, to compare the efficacy of F2. (B)
Bar graph represents IC50 of F2 for different prostate cancer cell lines DU145, 22Rv1 and PC-3.
(C) Preparative TLC was done to further separate the constituents of F2. The mobile phase was a
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binary mixture of 70:30 hexane/ethyl acetate. Six bands were obtained, which were scraped,
reconstituted in dichloromethane, filtered and concentrated. (D) Plot of cell survival versus
concentration of F2 sub-fractions for PC-3 cells using MTT assay (*P<0.09 compared with
controls using two-sample t-test). (E) Bar graph that compares the IC50 of F2 sub-fractions.
Standards HC and EU were also tested for comparison. (F) Plot of cell survival versus
concentration of F2 sub-fractions without F2-1. F2-1 (which demonstrated highest IC50) was
removed from F2 and the remaining fraction (WF2-1) was tested using PC-3 cells. WF2-1 stands
for F2 without F2-1 (*P<0.09 compared with controls using two-sample t-test). (G) Bar graph
represents the IC50 of F2 sub-fractions including WF2-1. Standards HC and EU were also tested
for comparison.
The constituents of F2 were separated using preparative TLC by loading 100 mg of F2
onto the silica gel plate, followed by placing it in a 70:30 hexane/ethyl acetate system. The mostactive fraction, F2, was resolved into 6 bands (Figure 4.7C), which were collected as subfractions (as mentioned in Materials and Methods section), and MTT assay was performed to
determine their individual efficacies compared to the parent F2. The IC50 values for sub-fractions
ranged between 16-251 µg/ml, with F2-2 through F2-6 showing similar potency as F2 (Figure
4.7D,E). F2-1 however remained an exception and was found to be least active with an IC50 of
251 µg/ml (Figure 4.7E). The residual bands after initial loading of the sample onto the TLC
plate could be due to various plant constituents like tannins and lignins, which did not move with
the solvent system. The next step involved elucidation of chemical structure of the sub-fraction
component/s.
Nuclear magnetic resonance (NMR) spectroscopy and tandem mass spectrometry (MSMS) were employed for structural elucidation of F2 sub-fraction component/s (data not shown).
In addition, structure confirmation was also done by appropriate spectral comparisons to the
information available in literature (data not shown). For F2-1 the molecular ion peak
corresponded to either EU acetate or CHV acetate, as both isomers show a molecular ion peak at
207 (MW=206). The F2-2 peaks in the NMR spectra corresponds to HC diacetate, and its
molecular ion peak appears accurately at 235 (MW=234). The presence of molecular fragments
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of HC acetate and HC were detected in the mass spectrum. F2-3 was identified to be HC
diacetate. Two bands of the same constituent could be due to the presence of either ionized or
other non-specific forms of intra- and intermolecular interactions. F2-4 could not be identified,
mostly due to the low amounts available; therefore, it remains an unknown in this study. Our
ongoing efforts are focused on a scale-up purification to identify F2-4. Also, spectral
characterization and comparison to the standard identified F2-5 as HC, with a molecular ion peak
at 149 (MW=150). Furthermore, the spectrum did not show a triplet peak, thus ruling out the
possibility of its positional isomer APC. The structure of F2-6 is still unidentified and will be a
subject of future studies.

Having analyzed the distinct activity of each sub-fraction, we found that the IC50 of F2-1
was quite high (251 µg/ml) compared to other sub-fractions. To correlate its contribution to F2’s
efficacy, all sub-fractions excluding F2-1 were combined and tested in PC-3 cells (Figure 4.7F).
The resultant IC50 value of this mixture was 6 µg/ml (Figure 4.7G), which was comparable to
F2’s activity as a whole, thus revealing that F2-1 was not vital for F2’s activity. However, as the
NMR and MS data suggested an ambiguity regarding the identity of F2-1 (data not shown),
coupled with our initial observations of EU’s presence in F2 (Figure 4.6A), it was important to
confirm the identity of F2-1.

To gain deeper insights into F2-1’s identity, 13C NMR analysis was performed (data not
shown), which revealed that F2-1 was CHV acetate. Comparing the initial TLC data (Figure
4.6A) and the corresponding IC50 values (Figure 5C,D) of all BLE fractions, we rationalized that
HC seemed to play a major role in imparting BLE’s in vitro and in vivo efficacy.
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4.4.4

Determining the contribution of HC to BLE’s antiproliferative activity
The HPLC analysis of BLE fractions revealed traces of HC in F4-F10 (Figure 4.6C).

Comparing the efficacy of F2 with that of F4-F10 fractions (Figure 4.5C,D), we reasoned that
HC could be majorly responsible for F2’s efficacy. To confirm this further, the low-abundance
HC fractions, i.e., F4-F10, were combined and tested in comparison with F2, which had the
highest abundance of HC. The resultant efficacy of F4-F10 mixture (25.11 µg/ml) was lower
than that of F2 (10 µg/ml) (Figure 4.8A,B), thus supporting a major role of HC in F2’s efficacy.
Though the contributions of other phytochemicals cannot be discounted as they might be
offering synergy, HC appears to be majorly responsible for F2’s activity. Thus, our data suggest
that HC might be the major contributor to BLE’s antiproliferative efficacy among all the other
constituents.

Figure 4.8 Comparison between F2 and combined fractions F4-F10.

161
(A) Line plot of cell survival versus gradient concentrations for F2, F4–F10 and BLE (P<0.05
compared with controls using two-sample t-test). (B) Bar graphical representation of the IC50
values of F2, F4–F10 and BLE. (C) HPLC-MS analysis for identification and quantitation of HC
in BLE.
Next, to determine the presence of HC in BLE, HPLC-UV, and HPLC-MS analyses were
employed simultaneously in the negative ion mode using ACN: H2O (1.5% acetic acid) solvent
system. 1 mg/ml of BLE dissolved in pure methanol was injected into the system and the tandem
mass spectrum thus obtained was scanned for a m/z range of 100 to 500. A significant peak was
detected with an m/z of 149, matching that of HC as previously described (Figure 4.8C).
Quantitation of HC was carried out by calibration of a standard curve with known concentrations
of pure HC, followed by calculating the abundance of HC in BLE. This analysis indicated that
HC was present at ~26.59% in BLE. Interestingly, F2 contained ~25.25% of HC, thus implying
that ~95% of the total HC content of BLE was reconstituted in F2. Further, when tested for its
antiproliferative activity, F2 was found to be 3-fold more active than BLE, suggesting the
usefulness of HC isolation from betel leaves to evaluate it as a single agent for prostate cancer
management.

4.4.5

HC inhibits proliferation and perturbs the cell cycle progression of human prostate
cancer cells
The long latency time of prostate cancer offers a “wide window” of opportunity for

chemopreventive intervention by dietary agents. Thus, we first asked if HC inhibited the growth
of various androgen-independent prostate cancer cells in a concentration gradient dependent
manner. Our data showed that HC significantly inhibited cellular proliferation of all prostate
cancer cells with IC50 values in the range of 30-320 µM (Figure 4.9Ai-Aii). The order of
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sensitivity was 22Rv1>C4-2>PC-3>DU145, with C4-2 being the most sensitive and DU145 the
least. DU145 cells were found to be least sensitive against HC treatment likely due to the
expression of MDR (multidrug resistance) phenotype and p-glycoprotein (Pgp) in hormoneindependent cancer cells like PC-3 and DU145, which are widely known for inducing drug
resistance. The IC50 of HC in normal prostate epithelial RWPE cells was found to be 398 µM
(Figure 4.9B), which was ~4-13 fold higher than for cancer cells suggesting that HC specifically
targets cancer cells while sparing normal cells. HC exhibited similar antiproliferative activity in
other cancer cells like MiaPaCa-2, Panc-1, MDA-MB 231 and HeLa (Figure 4.9C) with IC50
values of 76, 224, 126 and 71 µM respectively.

The resistant cell line against HC (as observed in Figure 4.9Ai, i.e., highest IC50), PC-3
was selected to further understand HC’s mechanisms of action. A trypan blue assay performed to
quantitate cell viability upon HC treatment, showed reduced cell viability of PC-3 cells in a timedependent manner (Figure 4.9Di). We next performed a clonogenic or colony formation assay
that determines the capacity of a cell to proliferate indefinitely upon drug removal to form a
colony (Figure 4.9Dii). While control cells proliferated profusely to produce several colonies,
only a fraction of treated cells restored their ability to form colonies (Figure 4.9Dii) upon
treatment with 100 µM HC on the relative clonogenicity. Representative micrographs of colonies
in control and HC-treated cells (Figure 4.9Dii, top right) when counted, quantitated to a ~4-fold
reduction in number and size of surviving colonies upon HC treatment.
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Figure 4.9 HC inhibits proliferation and perturbs the cell cycle progression of human
prostate cancer cells.
(Ai) Determination of IC50 of HC. PC-3 cells were treated with HC at increasing concentrations
(1–250 µM) for 48 h. The percentage cell proliferation was measured by MTT assay. (Aii) HC
shows enhanced inhibition of proliferation in various prostate cancer cells. Bar-graphical
representation of IC50 values (mentioned above) of HC tested in C4-2, DU145, 22Rv1, and PC-3
cells. Cells were treated for 48 h with increasing gradient concentrations of HC. The percentage
of cell proliferation was measured by MTT assay. (B) HC does not effect the proliferation of
normal cells. The normal prostate epithelial, RWPE, cells were treated with increasing
concentrations of HC and the percent cell proliferation was determined by MTT assay. (C) HC
shows inhibits the proliferation of various cancer cells. Bar-graphical representation of IC50
values (mentioned above) of HC tested in MiaPaCa-2, Panc1, MDA-MB 231, and HeLa cells.
Cells were treated for 48 h with increasing gradient concentrations of HC. The percentage of cell
proliferation was measured by MTT assay. (Di) HC effects the cell viability of PC-3 cells. Bar
graphical representation of percent cell viability of PC-3 cells treated with HC as demonstrated
by trypan blue assay, (*, P<0.05, compared with controls). (Dii) HC inhibits the clonogenic
capacity of prostate cancer cells. Bar-graphical representation and photograph of crystal violet-
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stained surviving colonies from control and HC-treated groups. (E) HC perturbs the cell cycle
progression of prostate cancer cells. (Ei) Cell cycle distribution of PC-3 cells in a threedimensional disposition as determined by flow cytometry at different time points upon treatment
with 100 µM HC. (Eii) Bar-graphical representation of the percent G2-M, S, G1 and Sub-G1
populations at different time points. Values and error bars shown in the graphs represent mean
and SD respectively. (*, P<0.05, compared with controls).
We next asked if HC-mediated growth suppression was due to its cell-cycle intervention.
To this end, we evaluated the effect of HC exposure on cell-cycle kinetics of PC-3 cells over
time. Figure 4.9Ei shows time-course of HC-treatment in a three-dimensional format. HC caused
cells to accumulate in the G1 phase as early as 6 h until 24 h, followed by an increase in Sub-G1
population, indicating the possible onset of apoptosis.
4.4.6

HC induces ROS-dependent mitochondrially-mediated intrinsic apoptosis,

DNA

damage and autophagy
HC has been previously reported to generate reactive oxygen species (ROS) and exhibit
prooxidant property in epithelial cancer cells (Chang et al., 2002; Lee-Chen et al., 1996), and
hence to test if HC could induce ROS in prostate cancer cells, we stained PC-3 cells with
DCFDA and DHE and analyzed them flow cytometrically as well as observed microscopically
(Figure 4.10A-C). DCFDA is cell permeable and it is cleaved intracellularly by non-specific
cellular esterases. DCFDA reacts with peroxides to yield the fluorescent product, DCF, which is
a direct measure of the peroxides generated. The DCF fluorescence was measured at 485 nm
(excitation) and 535 nm (emission). HC-treated cells exhibited a significant increase in DCF
staining compared to controls (Figure 4.10Ai) as well as an increase in mean fluorescence (right
shift) at 6 and 9 h compared to the controls (Figure 4.10Aii). However at 12, 18 and 24 h, the
intensity was similar to that of controls suggesting that the induction of peroxides by HC was
within 12 h of treatment.
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Another ROS probe, DHE, which reacts with superoxides was used to further confirm the
generation of ROS due to HC. DHE converts to ethidium bromide upon oxidation and appears in
the nucleus as red fluorescence. Microscopical examination of HC-treated PC-3 cells revealed
the generation of superoxides by HC (Figure 4.10Bi). Flow cytometric data also suggested the
increase in red fluorescence (right shift, Figure 4.10Bii), read at 580 nm emission wavelength.
There was a slight increase in the mean fluorescence intensity from 6 to 18 h and a significant
increase at 24 h post-treatment.

Figure 4.10 HC induces reactive oxygen species in prostate cancer cells.
(Ai) Fluorescent micrographs of DCDA stained-control and HC-treated cells (blue – nucleus;
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green-DCFDA). (Aii) Flow cytometric evaluation of DCFDA stained-control and HC-treated
cells at various timepoints. (Bi) Fluorescent micrographs of DHE stained-control and HC-treated
cells (blue – nucleus; red-DHE). (Bii) Flow cytometric evaluation of DHE stained-control and
HC-treated cells at various timepoints. (C) Source of HC-induced ROS. Mean fluorescent
intensity quantitation of ROS produced by ROS in the presence and absence of specific
inhibitiors, rotenone (mitochondrial electron transport chain) and apocynin (NOX). (D) Growth
inhibition by HC is ROS-dependent. Cells were treated for 48 h with 100 µM HC in the presence
and absence of ROS scavenger, tiron. The percentage of cell proliferation was measured by MTT
assay. Values and error bars shown in the graphs represent mean and SD respectively (*, P<0.05,
compared with controls).
It is well known that mitochondria and NADPH oxidase (NOX) are the major
endogenous sources of ROS generation in cancer cells (Lee et al., 2006; Sauer et al., 2001). To
this end, we raised a question to delineate the source of ROS generation upon HC treatment.
Employing specific inhibitors of these sources, we examined the change in mean fluorescence
intensity of DCFDA upon treating with apocynin (NOX inhibitor) and rotenone (mitochondrial
complex I inhibitor) (Karna et al., 2010). Interestingly, we observed that simultaneous treatment
of PC-3 cells with both inhibitors (Apo+Rot) significantly ablated endogenous ROS levels.
However, despite this quenching upon HC treatment, there was a slight increase in ROS levels
(Figure 4.10C) suggesting a mitochondrial and NOX independent induction of oxidative stress.
This could most likely be attributed to the presence of catechol group in HC, known for
imparting prooxidant property (Mira et al., 2002; Paranjpe et al., 2013). We then asked if the cell
death observed upon treatment with HC was dependent on its ROS-generation activity. To this
effect, the cell survival of HC-treated PC-3 cells was measured in the presence and absence of
tiron, a ROS scavenger (Karna et al., 2010). There was a significant increase in cell survival
(50%) in cells pre-treated with tiron, followed by HC as compared to only HC-treated cells
(Figure 4.10D), thus indicating the involvement of HC-induced ROS in triggering cellular death.
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Having identified that HC-induced cell death is ROS-dependent, we next evaluated if the
it is via apoptosis. Our data showed that treatment of PC-3 cells with HC resulted in increased
expression of cleaved caspase-3, further supported by increase in cleaved PARP expression at 18
h of HC treatment (Figure 4.11A-B) suggesting that HC induces apoptosis. Immunofluorescence
micrographs of cells treated with HC also show the enhanced expression of apoptotic markers,
cleaved caspase-3 and cleaved PARP (Figure 4.11Aii and 4.11Bii) compared to their controls.
Furthermore, the pro-apoptotic role of ROS was confirmed by evaluating the cleaved PARP
expression in tiron pre-treated (2 h) PC-3 cells that were then subjected to HC treatment.
Immunoblot analysis of these lysates demonstrated an increased cleaved PARP expression in
case of 12, 18 and 24 h samples as compared to their complementary tiron-treated samples, thus
indicating that the HC-induced ROS were involved in triggering apoptosis in PC-3 cells.
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Figure 4.11 HC induced apoptosis is ROS dependent.
Immunoblot and fluorescent microscopic analysis of control and HC-treated cell lysates for
apoptotic markers, (Ai-Aii) cleaved caspase-3 and (Bi-Bii) cleaved PARP, respectively. Cleaved
PARP expression was analyzed in the presence and absence of tiron (blue – nucleus; green –
cleaved caspase-3 and cleaved PARP). (C) HC disrupts the mitochondrial membrane potential in
prostate cancer cells. Flow cytometric evaluation of control and HC-treated cells stained with JC1, a cationic dye. (Di) Immunoblot analysis of mitochondrial proteins, p-Bcl-2, and total Bcl-2.
β-actin was loading control. (Dii) HC induces release of cytochrome c from mitochondria.
Control and HC-treated PC-3 cells were triple stained with MitoTracker (red), which co-localizes
in the mitochondria, anti-cytochrome c antibody (green) and Hoechst dye, which stains the
nucleus (blue). Overlay of the three stains illustrates the release of cytochrome c from the
mitochondria in the HC-treated cells.
It is a well-known fact that the release of cytochrome c into the cytosol due to disruption
of mitochondrial membrane triggers intrinsic apoptosis (Tait and Green, 2010). Considering our
observation that HC induces mitochondrial ROS, evaluating any possible disturbances in the
mitochondrial membrane potential seemed to provide a plausible reason for HC-induced
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apoptosis in cancer cells. To this effect, we further confirmed intrinsic apoptosis by measuring
the collapse of mitochondrial transmembrane potential (Ψm) (Figure 4.11C) and examining
release of mitochondrial cytochrome c into the cytosol (Figure 4.11D). JC-1, a cationic-dye,
characterized by membrane potential-dependent mitochondrial accumulation (Cossarizza et al.,
1993), was used to stain cells treated with HC for 6, 9, 12, 18 and 24 h along with control cells
and an increase in JC-1 monomeric form indicative of Ψm collapse was observed (Figure
4.11C). This effect was quantitatively determined using flow-cytometry. As seen in Figure 3C,
100 µM HC-treated cells at 6 h showed a right-shift in the mean-fluorescence intensity of green
JC-1 monomers compared to controls and similar trend was observed for other timepoints as
well. Furthermore, as disruption of Ψm is known to be followed by alterations in expression of
Bcl2 members, we found that at 18 h of HC-treatment, increased the levels of phosphorylated
Bcl2 was observed, thus indicating its inactivation, while total Bcl2 levels remained unchanged
(Figure 4.11Di). In addition, cytochrome c is released into the cytosol from the mitochondria 12
h post-HC treatment, which is illustrated in Figure 4.11Dii indicating induction of intrinsic
apoptosis. The MitoTracker (red) stains the mitochondria and the anti-cytochrome c (green) in
the control cells co-localizes with the MitoTracker. However, in the HC-treated cells, the overlay
of the triple stained cells (MitoTracker (red), cytochrome c (green) and Hoechst dye (blue))
clearly shows no co-localization and cytochrome c is released from the mitochondria (Figure
4.11Dii).

Oxidative damage caused by excess ROS has been linked to DNA based modifications
like single- and double-strand breaks (Cooke et al., 2003). Based on our observations that the
growth arrest in HC-treated cells was ROS dependent, we next asked if HC-induced ROS cause
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DNA damage in PC-3 cells. To this end, we microscopically examined the HC-treated cells over
time for γ-H2AX foci that form around the DNA breakage sites. γ-H2AX is the phosphorylated
form of histone H2AX and is a sensitive marker of double-strand breaks, an early indication of
chromatin modification (Bonner et al., 2008).

Figure 4.12 HC induces ROS-dependent DNA damage.
(Ai) Immunofluorescent micrographs of control and HC-treated cells stained for γ-H2AX foci in
the presence and absence of tiron (blue-nucleus; green- γ-H2AX foci). (Aii) Quantitation of the
γ-H2AX foci in the micrographs from Ai. (B) Immunoblot analysis of γ-H2AX expression in
control and HC-treated lysates. β-actin was used as loading control. Values and error bars shown
in the graphs represent mean and SD (*, P<0.05, compared with controls).
γ-H2AX foci were found in HC-treated cells after treatment for 6, 9, 12, 18, 24 h (data
not shown) and their expression seemed to be at maximum at 18 h (Figure 4.12Ai, Aii). Clearly,
control cells lacked γ-H2AX foci indicating that the breaks were induced due to HC exposure.
Corroborating this observation, immunoblot analysis of HC- treated cell lysates also confirmed
expression of γ-H2AX, as early as 6 h, which further peaked at 18 h (Figure 4.12B) suggesting
an early and time-dependent effect on DNA damage by HC. Having identified HC-induced DNA
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damage, we next wanted to confirm if this is ROS-dependent. Hence, PC-3 cells were pre-treated
for 2 h with tiron, a ROS scavenger, followed by HC-treatment at 9, 18 and 24 h. Approximately
58% decrease in number of cells with γ-H2AX foci was observed at 18 h treatment followed by
the attenuation of ROS by tiron (Figure 4.12Ai, Aii) (P<0.05).

Given that HC induced ROS related mitochondrial damage, we were inquisitive to learn
whether HC also induced autophagy in human prostate cancer PC-3 cells. Electron microscopy,
the gold standard to identify autophagosomes in the cells (Kondo and Kondo, 2006), was
employed to demonstrate the effects of HC on PC-3 cells. Transmission electron microscopy was
used to observe the ultrastructures present in control and 100 µM HC-treated cells. Large doublemembranous cytoplasmic vacuoles resembling autophagosomes with intracellular organelles
entrapped within them were observed in HC-treated cells (Figure 4.13A, indicated by black
arrows). The induction of autophagy by HC was further demonstrated by the immunoblot
analysis of HC-treated cell lysates for classic autophagy markers, beclin-1 and LC3-IIb (Figure
4.13Bi-ii). Increased expression of beclin-1 was observed at 12 h treatment and the expression of
converted form of LC3-II was observed to increase over time starting as early as 6 h (4.13Bi).
This was further supported by the microscopic observations of cells stained for acidic vesicular
organelles (AVOs), another characteristic feature of autophagy. Cells treated with HC were
visualized using fluorescent microscopy upon staining with acridine orange (AO), a
lysomotropic agent. AO, a weak base can cross the biological membrane in an uncharged state
and exhibits green fluorescence. Its protonated form is found in the acidic compartments of cells
and has a red fluorescence. As seen in Figure 4.13C, the control cells showed green fluorescence
indicating the lack of acidic vacuoles and on the other hand, HC-treated cells showed red
fluorescence signifying the presence of AVOs thus suggesting induction of autophagy. We also

172
evaluated the AO fluorescence flow cytometrically and it was observed that there was a
significant right shift in cells treated with HC compared to the control as early as 6 h (Figure
4.13D). However, at 12 h, the HC-treated cells resembled control cells, as there was no shift in
the fluorescence intensity.

Figure 4.13 HC induces autophagy in prostate cancer cells.
(A) Representative transmission electron micrographs showing the ultrastructures of control and
HC-treated PC-3 cells. The double-membranous cytoplasmic vacuoles resembling
autophagosomes in HC-treated cells are highlighted by black arrows. Immunoblot analysis of
(Bi) beclin-1 and LC3-IIb in control and HC-treated cells (Bii) LC3-IIb expression in control and
HC-treated cells that were pre-treated with tiron. β-actin was loading control. (C)
Immunofluroscent micrographs of control and HC-treated cells stained with AO (blue – nucleus;
green – unprotonated AO; red – AVOs). (D) Flow cytometric evaluation of AVOs formation
upon treatment with HC at various time points.
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Furthermore, to determine if the autophagy induced by HC was ROS-dependent, we
performed immunoblot analysis of tiron-pretreated cell lysates. The reduced expression of LC3IIb in 12, 18 and 24 h HC-treated samples suggested that ROS were required to induce
autophagy (Figure 4.13Bii). However, there was minimal expression of LC3-IIb in the control,
which was further observed to decrease in tiron-treated control (Figure 4.13Bii).
4.4.7

Oral HC feeding significantly inhibits PC-3 tumor-growth
Having identified significant in vitro anti-proliferative and pro-apoptotic activity of HC,

we were curious to examine the in vivo efficacy of HC to inhibit subcutaneous human prostate
tumor xenografts implanted in athymic nude mice. A PC-3 cell-line stably-expressing luciferase
(PC3-luc), which allowed real-time visualization and non-invasive observation of prostate cancer
growth was employed in this study. 150 mg/kg bw HC and vehicle (PBS with 0.05% Tween-80,
pH=7.4) were fed daily by oral-gavage for six weeks to the mice in treatment and control groups
respectively. Therapeutic responses were evaluated upon quantifying the relative photon counts
as revealed by non-invasive bioluminescent imaging (Figure 4.14Ai), and measuring volumes
(Figure 4.14B) of the tumors in mice from both treatment and controls groups using vernier
caliper. Approximately 72% reduction in tumor-volume (p<0.05 (n=6, Figure. 4.14Aii))
observed at week six in HC-treated mice signified time-dependent tumor growth inhibition
(Figure 4.14Ai,ii) compared to vehicle-treated group. Further, tumor-volume measurements
showed that oral feeding of HC for six weeks (42 days) decreased tumor-volume by ~75%
compared to the control group. Due to tumor over burden, complying with our institutional
IACUC guidelines, the mice in control group had to be euthanized by the end of six weeks.
Furthermore, tumors were excised upon euthanasia from control and treatment groups at the end
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point. The therapeutic response observed was further supported by ~3.3-fold difference in the
tumor weights (Figure 4.14C) from control and treatment groups.

Figure 4.14 Dietary feeding of HC showed inhibition of human prostate tumor xenograft
growth in nude mice.
Male nude mice were subcutaneously injected with 106 PC-3-luc cells. (Ai) Bioluminescent
images (one animal per group) representing tumor progression over six weeks. (Aii) Quantitation
of radiance (photons/sec/cm2/sr) measured from tumors of vehicle- and HC-fed mice. (B)
Tumor-volume (in mm3), (C) Tumor weight comparison along with photographic images of
excised tumors and (D) Body weight comparison of vehicle, and HC-fed groups. (*, P<0.05
(two-way analysis of variance, compared with controls). (E) HC induces apoptosis. Immunoblot
analysis of tumor tissue lysates from vehicle- and HC-fed groups probed for cleaved caspase-3,
and cleaved PARP. β-actin was loading control.
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In vivo apoptotic response of HC feeding in PC-3-luc tumor xenografts was evaluated for
cleaved caspase-3 and cleaved PARP expression using western blot analysis of tumor-lysates. As
expected, cleaved caspase-3 and cleaved PARP expression (Figure 4.14E) was higher in tumors
from HC-fed group compared to the control group.
Toxicity, a major burden for prostate cancer patients during chemotherapy or
radiotherapy, was barely observed in HC-fed mice, which was confirmed by histopathological
analysis of various organs posthumously obtained from treatment and control group mice. There
were no discernible differences in the appearance of intestinal, liver, spleen, lung, kidney, brain,
heart, testes, adrenal gland and pancreatic tissues from both groups (Paranjpe et al., 2013).
Comparative evaluation of serum biochemical indicators like blood urea’s nitrogen (BUN),
lactate dehydrogenase (LDH), creatinine kinase, and hepatic functional markers (ALT, AST,
ALP) revealed similar profiles for both vehicle- and HC-fed groups (data not shown).
Furthermore, complete blood analysis was performed to compare the blood collected from both
HC- and vehicle-fed mice. Evaluation of total count/percentage of various blood components
including white blood cells (WBC), red blood cells (RBC), hemoglobin (HGB), neutrophils,
lymphocytes, monocytes, basophils, eosinophils and platelets was found to be comparable with
no signs of toxicity (data not shown). In the groups fed with very high doses (5g/kg and 2 g/kg
bw) of HC, 100% of the C47BL6/J mice died concluding that HC is toxic at such high doses.
Furthermore, upon testing several doses, 560 mg/kg bw of HC resulted in the death of 50% mice
confirming the half-maximal lethal dose (LD50).

4.5

Discussion
Extensive literature suggests that fruits, vegetables, and spices impart several health

benefits and are thus regarded as potential chemopreventive agents (Chu, 2001; Cooke et al.,
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2005; Shukla and Gupta, 2005; Surh, 2003). It has been widely appreciated that fruits and
vegetables, with their complex array of phytochemicals, alter the progression of deadly
neoplasms, particularly slow-growing prostate cancers (Chan et al., 2009; Johnson et al., 2010;
Shukla and Gupta, 2005; Surh, 2003; Veluri et al., 2006). Betel leaf is traditionally used as a
mouth freshener in India and China. Consumed regularly by nearly 600 million people in Asia,
these leaves are a focus of intense research due to their wide repertoire of medicinal properties
(Bajpai et al., 2010; Kumar, 2010). This chapter reports the beneficial effects of betel leaves and
HC both in vivo and in vitro in prostate cancer models. We found that oral feeding of 400 mg/kg
bw BLE is quite effective in tumor growth inhibition with no detectable toxicity compared to
vehicle-treated controls and other doses employed in this study (Figure 4.1). This is in
concordance with a similar study where BLE significantly inhibited DMBA (7,12dimethylbenz(a)anthracene) induced skin tumors in swiss mice (Azuine et al., 1991) .
Plant extracts, as a natural blend of phytochemicals, offer immense opportunities for
discovery of active constituents, an archetype of current pharmaceutical industries. Classic
examples include isolation of Vinca alkaloids like vinblastine and vincristine from leaves of
Catharanthus roseus and taxol from the bark of yew tree (Noble, 1990). These drugs are
currently extensively used for a variety of neoplasms in the clinic (Azuine et al., 1991).
Fractionation using classical chromatography has been widely used for isolation of active
ingredients from plant extracts (Sasidharan et al., 2011). Several plant phytochemicals have
been extracted and isolated employing a bioactivity-guided approach. For example, fraction F2
obtained from the methanolic extract of Smilax spinosa, an ethnopharamceutical remedy,
displayed a higher pro-apoptotic activity than the crude extract (Seelinger et al., 2012). Also, it
has been reported that the procyanidin-rich fractions obtained from apple juice exhibit radical
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scavenging properties and have shown to be more efficacious than the apple juice extract itself
(Zessner et al., 2008). On similar lines of thought, we fractionated BLE into 10 fractions based
on their TLC profiles (Figure 4.5A,B). Further, the most active fraction was identified (Figure
4.5C,D) and its active ingredient, HC, was qualitatively and quantitatively characterized using
preparative TLC, and HPLC (Figure 4.7C and Figure 4.8C respectively).
Several studies suggest that the synergistic effect of constituent phytochemicals is
responsible for the efficacy of whole plant extracts (Jacobs et al., 2009; Wagner, 2011).
Although the concept of synergistic interrelationships between complex phytochemicals explains
the superior activity of several foods compared to their constituents, isolation of the single
constituent is favored over complex mixtures when the bulk of activity resides in a single
ingredient (Raskin et al., 2002). It is likely that such complex mixtures may contain additional
pigments and polyphenols, which may antagonize the efficacy of the active ingredient (Raskin et
al., 2002). In addition, the abundance of constituent phytochemicals in whole foods may vary
due to factors like climate, location, and physical and chemical stimuli. This is exemplified by a
recent study, which reported that the polyphenolic content of a green tea infusion varied with
cultivation and the technique of brewing, as an unstandardized infusion with a low dose of active
principles did not display the expected results in clinical trials and was thus withdrawn from
future studies (Johnson et al., 2010). On similar lines, a comparative report exists on three
different varieties of Piper betel (Bangla, Sweet, and Mysore), which suggests that the Bangla
variety exhibits the best antioxidant activity with the highest polyphenolic content. The other two
varieties with reduced polyphenol content were effective at much higher concentrations (Rathee
et al., 2006). Given that several varieties including hybrids are increasingly being cultivated all
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over the world, it is practically difficult to draw generalizations on the efficacy of these different
varieties of betel leaves that differ in their variety and geographical location.

We observed that upon fractionation of BLE, F2 constituted ~95% of BLE’s total HC
content (Figure 4.8C) and also exhibited improved efficacy as compared to the parent (Figure
4.5C,D). A study comparing the activity of betel leaf extracts made in various solvents supports
our observation, wherein the extract with highest amount of HC displayed superior antioxidant
activity. Additionally, the relevance of an optimal composition of phytochemicals for maximum
therapeutic efficacy has been widely reported in the literature supporting our observations
(Ferguson et al., 2004; Guha, 2006; Jacobs et al., 2009; Kandil et al., 2002; Miura et al., 2008;
Raskin et al., 2002; Toi et al., 2003; Veluri et al., 2006; Wagner, 2011; Zessner et al., 2008; Zhao
et al., 1999). Furthermore, HC has been shown to induce apoptosis in leukemic cells by
increasing the levels of mitochondria-derived ROS that activated the JNK pathway, thus leading
to the loss of mitochondrial membrane potential (Chakraborty, 2011). It has also been shown to
deplete cellular GSH levels, leading to oxidative stress . These mechanisms might contribute to
the low IC50 value of BLE as observed in our study. Although other BLE components like CHV
have demonstrated radical scavenging, anti-lipid peroxidation, and radio-protective properties,
our observations suggest that their contribution towards BLE’s activity is insignificant. This
could also be attributed to the diverse chemistry and biology of these compounds, as the effects
of an electron-donating moiety are likely to vary depending upon its nature and position on the
phenol ring. The presence of a hydroxyl group, an electron-donating moiety at the ortho and para
positions enhances its reducing property. For example, the methylated phenol, CHV, lacks this
free catechol, which might result in its lower antioxidant potential. This may better explain the
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enhanced activity of HC, a phenol with a free catechol group, compared to CHV(Rathee et al.,
2006).

Furthermore, several isolated compounds of plant origin, like HC in our case, have
proven to be advantageous, as they also set grounds for chemical modifications and rational drug
discovery for enhanced efficacy and superior pharmacological profiles. For example, artemesisin
(an antimalarial drug derived from the medicinal herb Artemisia annua) was chemically
modified to sodium artesunate, which displayed higher solubility and hence ease of
administration (Houghton, 1995). On similar grounds, the most active classes of anticancer
drugs, like vincas and taxanes, have all been subjected to extensive structure-activity studies to
generate superior analogs that have been reported to be effective cancer cell death traps (Fauzee
et al., 2012; Ranaivoson et al., 2012). These agents not only portend significantly greater tumor
growth inhibiting activity but also are known for their reduced toxicity as compared to their
founding molecules. More recent advances in anticancer therapeutics highlight the advent of
noscapine analogs as “kinder and gentler” microtubule modulating agents (Pannu et al., 2011)
that perhaps are relatively non-toxic compared to the classical antimicrotubule agents that impart
toxicity to normal cells.

Our enthusiasm to decipher the mechanisms via which several plant phytochemicals exert
health-promoting benefits led to the revelation of remarkably congruent yet opposite roles played
by these chemicals under different physiological conditions. Recent interest in cancer
chemopreventive research using whole foods and their active constituents, alone or in
combination with current chemotherapeutic drugs has unfolded the mysterious ways through
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which nature delivers health benefits to mankind. Plant chemicals have been known to fight
oxidative stress by quenching the free radicals responsible for mutations leading to genetic
alterations and malignant transformation of initiated cells (Quideau et al., 2011). However,
certain phytochemicals also exert prooxidant behavior and when at higher concentrations, they
tend to induce generation of reactive oxygen species in the cells (Azam et al., 2004; Quideau et
al., 2011; Sakihama et al., 2002). Literature suggests that phenolic compounds containing
catechol and pyrogallol moieties (Mira et al., 2002) induce ROS levels in cells and thus dispose
chemotherapeutic efficacy by leading to death. Given their abundance in nature, it is ideal to
isolate phenolic compounds that can exhibit pleotropic mechanisms from plant extracts and
exploit their double-edged behavior. Although there is an ongoing debate on employing whole
foods vs single active constituents for chemotherapy/chemoprevention, establishing the
mechanisms via which the whole food extracts or their constituent phytochemicals can induce
death in cancer cells is of utmost importance.
Our data demonstrates the in vitro anticancer efficacy of HC specifically in various
human prostate cancer cell lines like C4-2, DU145, 22RV1 and PC-3 (Figure 4.9Ai-Aii)
compared to normal prostate epithelial cells, RWPE-1 (Figure 4.9B). Furthermore, HC also
exhibits antiproliferative activity against a variety of cancer cell lines including MiaPaCa-2
(pancreatic), Panc-1 (pancreatic), MDA-MB-231 (breast) and HeLa (cervical). The cell cycle
arrest induced by HC in PC-3 cells (Figure 4.9Ei-Eii) further supported HC’s therapeutic
efficiency.
Literature reports suggest that cancer cells possess higher concentrations of reactive
oxygen species (ROS) compared to normal cells (Schumacker, 2006; Szatrowski and Nathan,
1991; Trachootham et al., 2009). While moderate levels of ROS are understood to facilitate cell
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proliferation and survival, an increase in these levels in cancer cells beyond a threshold lead to
cell death. As such, with a low basal level of ROS, normal cells maintain a redox balance
between generation and elimination of free radicals, and thus can tolerate a minimal increase in
this level. In contrast, cancer cells with high basal levels of ROS have reduced margin to sustain
the elevation in these levels. In such a case, an exogenous interference by ROS-modulating
agents might enhance the levels beyond toxic threshold, leading to their cell death. This
‘weakness’ of the cancer cells ensures their selective killing via ROS-mediated mechanisms
sparing the normal cells. Thus, drugs acting as prooxidants promoting the leakage of free radicals
from the mitochondria prove to be valuable anticancer therapeutics. Although plant phenolics
have been long known be antioxidants, their role in enhancing ROS levels is emerging. To the
best of our knowledge, no studies have yet shown the prooxidant behavior of HC in human
prostate cancer, PC-3 cells experimentally. Our data showed that HC induced peroxides and
superoxides in a time-dependent manner (Figure 4.10). Immunofluorescence staining suggested
that green fluorescence in case of DCFDA indicated the induction of peroxides (Figure 4.10Ai)
and red fluorescence in case of DHE signified the induction of superoxides (Figure 4.10Bi).
Flow cytometry using the above-mentioned dyes, further confirmed the time-dependent
induction of ROS by HC (Figure 4.10Aii and Bii). Further investigation revealed that these HCinduced ROS triggered cellular death in PC-3 cells (Figure 4.10D).

Excessive ROS in cells are known to induce DNA damage, apoptosis and even
autophagy, eventually leading to death (Karna et al., 2010). Insights into molecular mechanisms
reveal the death-inducing effects of HC-induced ROS in PC-3 cells where treatment with HC led
to increase in the expression of cleaved caspase-3 and cleaved PARP in the presence and absence
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of ROS inhibitor, tiron (Figure 4.11A). Apoptosis thus induced was intrinsic in nature,
suggesting a largely mitochondrially-mediated phenomenon, associated with collapse of
transmembrane potential resulting in the expulsion of apoptogenic molecules, as an upregulation
in the expression of Bcl-2 and release of cytochrome c levels into the cytosol was observed upon
treating with HC (Figure 4.11C-D). It was also observed that the HC-induced ROS caused DNA
damage, as signified by the increase in the expression of γ-H2AX foci that form around the DNA
breakage sites (Figure 4.12). Additionally, these ROS also induced autophagy in HC-treated PC3 cells (Figure 4.13). 	
  

Autophagy is a type II programmed cell death, which in some cases precedes apoptosis
(Chen et al., 2000). At a basal level, autophagy functions in maintaining the cellular homeostatis,
but when stimulated by the cellular stress conditions like oxidative stress, it becomes upregulated
rapidly. Our observations including the appearance of organelles engulfed in double-membrane
bound vesicles (Figure 4.13A), AVOs (Figure 4.13C) and overexpression of beclin-1 and LC3IIb (Figure 4.13B) revealed that HC-induced ROS triggered the induction of autophagy in PC-3
cells. Sometimes, under such ‘stressed’ conditions, autophagy functions as a double-edged
sword, contributing to cell survival by engulfing the damaged organelles. When it is unregulated,
it leads to cell death by excessive digestion and degradation of cellular components (Karna et al.,
2010). On the other hand, apoptosis, the type I programmed cell death involving the activation of
catalytic proteases, leads to rapid destruction of cellular structures. Studies have reported a
crosstalk between these ‘self-eating’ and ‘self-killing’ mechanisms, due to mutual control of the
autophagic and apoptotic proteins in the cell (Karna et al., 2010). In this context, we are currently
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investigating the HC-induced ROS-dependent interplay between autophagy and apoptosis to
impact cellular outcomes in prostate cancer cells.

Furthermore, our in vivo investigation revealed the remarkable tumor growth inhibition
efficacy of HC, also accompanied by non-toxicity (Figure 4.14). To assess the safety of HC, the
hematologic and histopathological toxicities were evaluated and there were no deviations in the
hematologic attributes in samples from treated mice compared to the controls. Using the body
surface area normalization method (Reagan-Shaw et al., 2008), we hypothesized the use of HC
as a potential chemotherapeutic or chemopreventive agent in humans, where the human
equivalent dose of 150 mg/kg in vivo dose equals ~12 mg/kg. For an average, 70 kg adult, this is
translated to an equivalent dose of <1 g HC, which can be easily supplemented as a part of daily
diet.

In conclusion, this chapter underlines the remarkable anticancer efficacy of BLE and
exceptional prooxidant role of Hydroxychavicol, an active constituent abundant in betel leaves to
confer maximum therapeutic benefits as it induces ROS in human prostate cancer cells thus
leading to their death. Our observations of this possible prooxidant role of HC are indispensible
and provide stimulus to further investigate its chemotherapeutic potential and a possible role in
chemoprevention and prostate cancer management.
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5

CONCLUSIONS

Cancer is the most dreaded modern illness with an exponential incidence in the past two
decades. With baffling questions still surrounding the causes of cancer, there is an urgent need to
address the challenges of the current prevention and treatment strategies. Several of the novel
therapeutics have proven to be either highly expensive or even a failure in the clinical setting,
while the disease has grown to be debilitating with devastating effects. A variety of factors have
been implicated in the disease pathogenesis, including mutations, environmental factors, lifestyle
choices and even diet. In this regard, The American Cancer Society published “Guidelines on
Nutrition and Physical Activity for Cancer Prevention” in 2012, which recommends a healthy
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diet emphasizing plant foods suggesting that synergistic effects are possible upon consumption
of whole plant foods.
In this dissertation, we have shown that plant-based foods display remarkable anticancer
activity while following the “golden-rule” of being well-tolerated, non-toxic, easily available and
relatively inexpensive, thus making them new age “magic bullets” in the battle against cancer.
Sweet potato greens, whole ginger and betel leaves have been shown to possess exceptional
tumor growth-inhibiting efficacies, facilitated due to the inherent synergistic interactions among
their respective constituent phytochemicals. Furthermore, our findings in the case of sweet potato
greens extract (SPGE), whole ginger extract (GE) and betel leaf extract (BLE) provide stronger
evidence of phytochemical complexity (Gundala et al., 2014; Karna et al., 2011b; Paranjpe et al.,
2013), which is an untapped resource with innumerable benefits. Though these extracts exhibited
superior efficacies in vitro, we observed a loss of anticancer activity in in vivo prostate cancer
models upon perturbing the natural balance of phytochemical content in these extracts via
fractionation processes. This disruption of the natural complex network of phytochemicals could
most likely be responsible for the discrepancies observed between in vitro and in vivo efficacies.
Firstly, we investigated the anticancer efficacy of sweet potato greens, a common dietary
component in the eastern world to signify dietary intervention to treat cancer. This attempt
revealed that F5, the most-active fraction, obtained via column fractionation of SPGE was at
least 125 fold more potent than the parent in in vitro models. However, this effect could not be
translated in the in vivo setting, where there was less than 10% difference in tumor growth
inhibiting efficacy. Further, analytical quantitation of the parent extract and most-active fraction
disclosed the presence of three major constituents, quinic acid (QA), chlorogenic acid (ChA) and
caffeic acid (CA), in varying ratios. Mechanistic evaluations revealed that both SPGE and F5
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caused cell death due to the induction of apoptosis. Our approach attempted to deconstruct the
inherent synergies among the constituent phytochemicals of SPGE and it unveiled enrichment of
components in F5, which is likely responsible for its superlative in vitro activity (Gundala et al.,
2013; Karna et al., 2011b). However, the in vivo anomaly is yet to be addressed.
Next, our attempts to acknowledge the importance of synergistic interactions among
constituent phytochemicals of a dietary agent were focused via GE, whose composition has been
well studied for years. We showed that GE exerts significant growth inhibitory and deathinducing effects in prostate cancer models while modulating the cell cycle and apoptosis
regulatory molecules. Daily oral administration of GE to human prostate tumor-bearing mice
even resulted in ~56% inhibition of tumor growth. Our in vitro study evaluating synergy among
GE’s most abundant phenolics, 6G, 8G, 10G and 6S, revealed that not only these phenolics
exhibit synergistic and additive interactions among themselves, but also show similar effects
when GE was further enriched with each of them. This observation further led to our
investigation of in vivo synergy among ginger biophenolics. It was clearly evident that 6G, 8G,
10G and 6S were not the only ones contributing towards GE’s efficacy, but the remaining
partners also exhibit synergistic and/or additive interactions to impart remarkable efficacy to GE.
Furthermore, pharmacokinetic evaluations to understand the fate of GE phenolics indicated that
6G, 8G, 10G and 6S undergo enterohepatic recirculation, and due to the phytocomplexity of
constituent entities, the bioavailability of these four active phenolics is enhanced to facilitate
better absorption, longer retention times and their controlled elimination (Brahmbhatt et al.,
2013; Gundala et al., 2014; Karna et al., 2011a).
Our investigations employing the xenohormetic betel leaf nutraceuticals unveiled a new
dimension in employing both antioxidant and prooxidant abilities of phenolic constituents to
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selectively kill the cancer cells, while sparing the normal cell population. We observed that BLE
had remarkable tumor growth inhibiting efficacy, and comprised phenolic compounds like
hydroxychavicol (HC), eugenol (EU), chavibetol (CHV), 4-hydroxycatechol, methyl eugenol,
carotenes etc. Of all these, HC was found to be the most abundant phytochemical and was
isolated from betel leaves to further understand its mechanisms of action against prostate cancer
cells. HC was found to be prooxidant in nature and perturbed cell-cycle kinetics and progression,
while reducing clonogenecity and mediating cytotoxicity by ROS-induced DNA damage leading
to the activation of several pro-apoptotic molecules. Additionally, HC elicited ROS-induced
autophagic response with an increased expression of autophagic markers like LC3-IIb and
beclin-1, which was found to be ultimately resulting in death via apoptosis. A remarkable
inhibition of prostate tumor xenografts by ~72% upon oral administration of HC was also
observed indicating the superior anticancer efficacy of betel leaf nutraceuticals (Gundala and
Aneja, 2014; Gundala, 2014; Paranjpe et al., 2013).

Furthermore, the above-mentioned dietary agents were found to be non-toxic and
inexpensive, while strongly exhibiting complex interactions among their constituent
phytochemicals, which direct the pharmacodynamic and pharmacokinetic synergies contributing
the superior tumor growth inhibiting efficacies. We believe that our studies have provided
compelling grounds for future preclinical and clinical studies to validate the potential usefulness
of such dietary agents for prostate cancer management.
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6

OVERALL SIGNIFICANCE

Due to an incomplete understanding of the various roles played by phytochemicals in
cancer, developing therapeutic regimen employing dietary agents is almost a universal failure.
There have been several trials in the past employing phytochemicals like β-carotene, αtocopherol etc., but with no evidence of health benefits (1994; Azuine et al., 1991; Azuine and
Bhide, 1992; Bhide et al., 1991b). Rather these clinical trials led to startling observations
indicating that these treatments increase the risk of disease (lung, colorectal cancers). Vitamins
and minerals like B6, folic acid, iron, Mg, Zn, Cu were also found to increase total mortality
(Surh, 2003). However, combinations of supplements in a vitamin/mineral deficient population
reduced the risk of specific cancers (Potter, 2014), thus suggesting an important role of multitargeting interventions, which also could be achieved employing whole extracts considering their
multi-ailment curing properties.

In the light of our observations employing whole food extracts and their active
counterparts, especially in the case of SPGE, it is to be understood that attempts to isolate the
active components from the parent extracts might actually lead to the loss of efficacy. Most
importantly, the wide gap that exists between in vitro and in vivo results is to be acknowledged
while determining the best agents. In vitro data obtained as a result of controlled environment
has limited potential considering the straightforward approach involved. Only a few factors can
be modulated in studying the cause and effect, thus limiting the scope of actual mechanism(s)
involved. On the other hand, in vivo system is a complex network where a multitude of factors
are constantly changing with time. Essentially, such variations have greater impact on the
metabolism of the drug administered, which are absent in the in vitro environment, thus bringing
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about the difference in efficacy. These differences were clearly observed in case of SPGE and
F5, where even though F5 was found to be ~125 fold more active than SPGE in vitro, this
difference of efficacy was not translated in vivo where the percent tumor growth inhibition
difference was <10%. It is thus implied that maximum health benefits can be obtained by
consuming the phytochemicals in their natural forms i.e., whole foods.

Furthermore, our efforts in evaluating the pharmacokinetics of whole food extracts
indicated the importance of determining the physiological modifications of constituent
phytochemicals of a whole food with respect to its in vivo efficacy. A single-day PK evaluation
suggested a possible enterohepatic recirculation mechanism of ginger components. However, a
multiple day PK can better correlate to efficacy data as the latter is obtained upon daily
administration of the extract for a period of 4-6 weeks. In the multiple PK experimental design,
mice were fed with the extract continuously for 7 days and the blood plasma concentrations of
the ginger phenolics and their respective PK parameters are analyzed and compared on day 1 and
day 7 (essentially from animals of the same groups). We observed that, after 7 days of daily oral
administration, the levels of free ginger phenolics in blood plasma on day 7 were found to be
decreased compared to those on day 1. However, upon quantitating the β-glucuronidase
treatment, the same samples were found to contain very high levels of the glucuronidated forms
of ginger phenolics. This discovery is very intriguing as it leads to speculations regarding the
elements of ginger that impart anticancer benefits. Tissue distribution studies indicated that
glucuronide of 6S was accumulating at very high concentrations within the tumor tissue.
Considering the effect being related to tumor growth inhibition, it can be speculated that,
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(a)

the glucuronides of 6S accumulating in the tumor tissues are directly
responsible for inhibition of the tumor growth

(b)

the opulent reserves of 6S glucuronides are converted into free forms of 6S
via the action of β-glucuronidase enzyme basally expressed in the tumor cells
and thus the free forms participate in the tumor growth inhibition.

With these possibilities, it is important to determine the efficacy of glucuronide forms of
constituent phenolics along with their free forms. Such an elaborate study would not only explain
the physiological mechanisms undergone by the phytochemicals in the in vivo setting, but also
unravel novel entities (active conjugated forms) that are the actual contributors.

On another note, the possibility of improving the bioavailability of constituent
phytochemcials of whole foods using other dietary agents with specific functions seems
promising in improving the efficacy. For example, UGT inhibitors like eugenol, capsaicin,
piperine, curcumin, etc., can be consumed along with the active extracts, in order to interfere
with the natural conjugation process by the UGTs, and thus resulting in prolonged circulation of
free forms of constituent phytochemicals. Also, by evaluating the effect of whole food extracts
and constituent phytochemicals on the phase I and phase II metabolizing enzymes, the safety of
these extracts to be consumed along with any therapeutic agents can be studied. These studies
will help in determining the dose limitations of extracts as well as any possible toxic interactions.
Furthermore, as a part of a two-prong approach, these active extracts can even be administered
along with therapeutic drugs to enhance the bioavailability of the latter as well as impart efficacy
via multiple pathways. This approach could also result in administering lower dose levels of the
therapeutics, thus reducing dose-related toxicity.
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Plant extracts with their affluence of phytochemicals still are the source of novel
therapeutics. Most of the current anticancer drugs, taxol, vinca alkaloids etc., were isolated and
extracted from plant extracts. For example, detailed evaluation of the unidentified compounds
observed in case of F5, derived from SPGE could lead to the discovery of novel drugs. Similarly
in ginger and betel leaves, there were several compounds, possibly isomers of gingerols,
hydroxychavicol, eugenol, cholorogenic acid etc and even dehydrated forms like shogaols.
Derivatives of known compounds are also to be investigated further for their disease-fighting
properties. Apart from the possibility of discovering novel therapeutic drugs, detailed evaluation
of dietary compositions can also lend us the advantage of designing better dosage regimen.

Overall, different kinds of agents employed in numerous studies were reported to have an
inverse impact on the disease progression, elevating risk of incidence and causing death, due to
enhanced progression of cancer, or other treatment-associated toxicities. Several reasons for the
failure of chemoprevention include, choice of test population, age, lifestyle etc. If some sort of
“poly-pill” might be worth considering suggests that a few agents that can act via multiple
pathways have shown beneficial efficacy. Targeting multiple pathways is essential as the process
of carcinogenesis is not a single step process where a single mutation or protein is responsible for
disease development and progression.. However, this idea of poly-pill or multi-targeted
approaches seem to have failed due to lack of in-depth knowledge of the capabilities of the
agents employed (like how many targets, doses at which each target is affected, time of action
etc).
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Whatever the means is, either a single agent or a whole fruit/vegetable, the following
aspects are to be considered:
(a)

There is no ideal model to study chemoprevention in vivo before human trials,
thus limiting the selection of potential agents.

(b)

Mainly the pharmacokinetics of whole food extracts are not evaluated, which
can actually direct us to novel ways of approaching the problem, especially the
dose regimen.

(c)

Very few studies have considered the possible effects of the chemopreventive
agents on the drug metabolizing agents. Physiological interferences are
ignored.

(d)

Metabolic evaluation of the phytochemical compositions is not being
employed as a part of chemotherapy or prevention, which gives rise to an
essential question, “If the metabolite or the free form is active?”
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